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Precision medicine offers the potential to transform healthcare by utilizing detailed biochemical 
insights into a patient’s disease state for therapeutic decision-making. Numerous disease specific 
biomarkers have emerged, but few are as dynamic and information-rich as those associated with 
the immune system. The immune system operates through a pathogen specific, biologically 
conserved response to coordinate detection and clearance. Immune cell associated signaling 
molecules, cytokines, modulate the immune response and their associated dynamics are ideal for 
monitoring host response. Profiling the immune response correlated to system perturbations 
provides a clinically valuable result for functional diagnostics.  
Immunoassays are a powerful tool to quantitatively measure cytokine levels in biological 
solutions. While enzyme-linked immunosorbent assays have been the gold standard technique, 
multiplexed approaches have rapidly developed in response to the need for more complex 
biological signatures to precisely describe disease states. While many of these assays demonstrate 
robust intra-assay performance, variable inter-assay and multi-center performance is a consistent 
issue. Additionally, the inherent physiological fluctuations from patient-specific, but disease 
independent sources have largely hindered the clinical implementation of these assays.  
This dissertation describes promising approaches to address the analytical and clinical challenges 
facing immune profiling guided precision medicine. Chapter 2 outlines the fundamental 
requirements for developing robust multiplexed immunoassays with silicon photonic microring 
resonator arrays. Using this basic protocol for assay development, Chapters 3 and 4 describe two 
distinct approaches toward diagnosing and monitoring infectious disease related states. Chapter 3 
focuses on designing a functional diagnostic immunoassay for latent tuberculosis infection (LTBI) 
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with the absolute assay output normalized by each subject’s basal immune response. Using this 
personalized normalization strategy, machine learning feature selection yielded promising results 
toward a diagnostic signature. Chapter 4 describes a multiplexed immune profiling approach 
incorporating rich temporal dynamics throughout the treatment of sepsis. The rapid immunoassay 
provides the cytokine trajectories of each subject throughout treatment, illustrating the dynamic 
changes accompanying immune challenge and subsequent therapeutic intervention. Chapter 5 
leverages the near-real time monitoring capabilities of the platform to characterize the differential 
binding kinetics of monomeric and dimeric therapeutic antibodies as a means of structural 
characterization. Finally, Chapter 6 discusses the future of the LTBI diagnostic signature 
development, outlining a significant expansion of the biomarker panel, informatic analysis, and 
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1.1  Evolution of Precision Medicine 
Precision medicine is a predictive, preventive, and personalized approach to healthcare.1,2 The 
evolution of this field began with a paradigm shift from viewing complex disease states as largely 
homogeneous entities to more stratified disease sub-classifications. This reclassification 
transforms an otherwise empirical treatment strategy (one treatment fits all) into stratified 
treatment options (evidenced-based treatment groups) and ultimately toward personalized care.3 
Cancer in particular has primarily embraced genomics as the basis for directing personalized 
therapeutics, but as a static representation of the system, genomic data neglects the dynamics of a 
patient’s therapeutic response.2,4 In the past, mutationally driven therapies have been a successful 
strategy with imatinib for long lasting treatment of BCR-ABL mutated chronic myeloid leukemia5, 
but this success has rarely been matched.4  In fact, developments in molecular immunology led to 
detailed analysis of the kinase domain mutations of BCR-ABL to therapeutically stratify those 
leukemia patients variably responding to early generation treatments toward newer treatment 
options.6 Recently, researchers evaluated potential predictive genomic biomarkers in major 
cancers and concluded that concurrent genetic events made exclusively genomically guided 
clinical decision-making nearly impossible due to insufficient information to prioritize genetically 
related treatments.4 To complement the richly descriptive genetic profile, functional prognostic 
and diagnostic measurements provide a current representation of the system and response to 
perturbations.2 Specifically, functional immune profiling provides a minimally-invasive strategy 
to diagnose and treat numerous diseases and has long been a standard approach in infectious 
disease.7,8  
Immunological profiling is often correlated to treatment response or more specifically, 
immunotherapy.9,10 Successful immunotherapies from immune profiling are well-represented by 
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blocking tumor necrosis factor for the treatment of rheumatoid arthritis.11 However, immune 
profiling can also reveal therapy failures demonstrated by the clinical trial of TGN1412 which 
resulted in a cytokine storm for several healthy volunteers.12,13 Both examples illustrate the 
potential for monitoring the presence and dynamics of the immune system to identify and drive 
therapeutic decisions. Despite promise, immune profiling is not without challenges including 
identifying insightful biomarkers, understanding complex immunological dynamics, and 
accounting for inherent physiological variance.3 Successfully balancing these challenges is 
necessary to the implementation of immunologically driven precision medicine.  
1.2  Immunological Biomarkers 
The immune system operates through a multi-faceted innate and adaptive response to coordinate 
pathogen identification and clearance.14 Spatially and temporally diverse interactions between cell 
types, molecular networks, and cytokines describe the comprehensive immune response and the 
potential immunological biomarker pool.15-17 Unlike the presence or absence of a pathogen, the 
immunological foreign response is a continuum and representative immune profiling yields 
dynamic responses to perturbations.8,18 Researchers have characterized the immune response by 
gene expression19, miRNAs20, and proteins21 among others, but the most successful biomarkers 
are defined by those readily detectable and well-correlated to the disease state. As small signaling 
proteins secreted by numerous immune cells, cytokines are an integral part of the immune system 
and the dynamic immune response.14  
Cytokines are central to immunomodulation by initiating chemotaxis, proliferation, and apoptosis. 
Cytokines may also be specific to an immune cell type or subset of cells and are defined by 
functional sub-classes: interleukin-1 family, interleukin-17 family, chemokines, and the α-helix 
bundle family (further divided to interleukin-2, interferon, and interleukin-10 sub-families).14 By 
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binding to a cell surface receptor, these proteins can initiate signaling cascades resulting in gene 
expression changes and further cytokine production or inhibition.18,22 Many cytokines exhibit 
redundant or dual functionality and their presence and subsequent interactions define the very 
earliest responses to a foreign pathogen.23,24 The ubiquitous nature of cytokines in immunological 
function coupled with their rich temporal dynamic response to subtle system changes positions 
cytokines as promising predictive, diagnostic, and prognostic biomarkers.  
The analytical and biological challenges of immune profiling cannot be ignored. Immune cells, 
antibodies, and cytokines are often mechanistically tied to a specific infection site or tissue, but 
can be globally measured in circulating blood and other biological fluids.17 Passive profiling 
measurements encompass various factors that influence immune biomarker levels including those 
unrelated to the immediate immune challenge.7 The resulting physiological noise may obscure an 
otherwise highly specific response to a host infection. Additionally, as a measure of rapid defense, 
cytokines and the related immune response may change dramatically on relatively short time scales 
(minutes to hours).12 Taken together, cytokines may provide detailed insight into disease onset and 
progression, but necessitate thoughtful functional assay development to prioritize critical 
biomarkers for specific disease states.  
1.3  Current Immunoassay Technology 
Several analytical immunoassay developments have led to a suite of technologies to directly 
measure cytokines and their subsequent interactions with antibodies and cell receptors. 
Historically, immunoassays have been defined by the gold standard enzyme linked immunosorbent 
assay (ELISA), capable of highly sensitive and selective analyte detection in complex media.25,26 
The era of miniaturized detection, ushered in by Feinberg and Wheeler with microspotting and  
later Ekins with ambient analyte theory, provided the basis for modern immunoassays.26,27 Those 
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developments combined with reliable monoclonal antibody generation through hybridoma 
technology28 facilitated a rapid trajectory toward robust and automated immunoassays.  
Immunoassays can be classified by the protein and cell interactions that they characterize. 
Enzyme-linked immunosorbent spot (ELISPOT) and intracellular cytokine staining by flow 
cytometry represent techniques designed to detect cytokine production at the single cell level and 
to directly connect cytokine-cell interactions.17,29 Single analyte ELISAs and related multiplexed 
approaches are bulk assays for global immune profiling from various biological fluids (i.e. blood, 
serum, urine, cell supernatant).8 The bulk immunoassays can be further sub-divided into planar 
plate or slide based- and suspension bead-based assays. Planar assays, often defined by ELISA, 
are typically single to low plex with colorimetric (single-plex) or chemiluminescent (multiplex) 
end-point readouts. The sandwich immunoassay approach often used in diagnostic ELISAs is 
described as a surface-bound capture antibody binding with an antigen followed by secondary 
antibody binding and subsequent detection.17,26 This design heavily influenced suspension bead-
based assays in which fluorescently distinct beads functionalized with unique capture antibodies 
bind antigen and secondary antibodies which are further combined with a fluorescent reporter.30 
The uniquely tagged beads provide the basis for highly multiplexed measurements, a distinct 
advantage over traditional ELISAs particularly for analyzing complex clinical samples in which a 
single biomarker is often diagnostically ambiguous.  
Recently, the inter-assay performance of a 4-plex microfluidically enabled ELISA and a 
multiplexed bead-based approach was evaluated, resulting in similar reliable intra-assay 
performance. However, the multiplexed ELISA was significantly more automated leading to faster 
time-to-results (1.25 h) with a greater assay dynamic range, suggesting better assay sensitivity. 
The bead-based approach detected significantly more distinct targets and samples per assay, but 
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suffered from decreased dynamic range and low automation, leading to longer time-to-results (5 
h).31 Both assay formats offered distinct advantages depending on the clinical need, supporting the 
use of either. Though, the conclusion of this comparison highlighted the broader issue facing 
clinical immunoassay implementation; both assays displayed a response bias that while providing 
the same relative result, did not yield consistent absolute concentration comparisons.7,30 
Immunoassay technologies are facing a clinical tipping point that demands increased 
standardization and innovative approaches to data utilization. The bias seen in the previous 
example could be explained by reagent variability, differences in readout mechanism, or 
physiological noise distinctly interfering with each system. Analytical rigor in reagent selection, 
preparation, and calibration certainly improves assay performance. However, novel functional 
assay developments and data utilization are necessary to address the physiological noise plaguing 
these otherwise promising clinical biomarker assays.  
1.4  Microring Resonator Operating Principles 
Microcavity sensors32 are a class of whispering gallery mode sensors, a reference to Lord 
Rayleigh’s description of the acoustic phenomenon. This class includes microtoroid, microsphere, 
microdisk, and microring sensor structures in which light is confined to the circumference of the 
microcavity, enhancing the effective pathlength relative to other photonic sensors.33 Sensors 
operate by coupling in propagating light from a linear waveguide at specific resonant wavelengths 
(λ), which is exceptionally sensitive to changes in the local refractive index (neff). This relationship 







where r is the radius of the sensor and m is an integer representing the azimuthal quantum number. 
Light coupling into the microcavity results in a characteristic dip in transmission and changes in 
local refractive index from surface interactions results in a shift in the resonant wavelength. 
Broadening of the spectral linewidth is related to the quality of the sensor and more directly, the 






This relationship effectively describes the photon lifetime in the microcavity and increasing the 
sampling time of the photon ultimately increases sensor sensitivity.34 The quality factor of a sensor 
depends on sensor design and fabrication, all of which are significant factors in the commercial 
utility of the sensor.  
We have employed a silicon photonic microring resonator array sensor, commercialized by 
Genalyte, Inc., for a wide variety of biosensing applications. Advantageous development decisions 
that sacrifice some quality factor have ultimately yielded a commercially viable sensor and clinical 
platform for complex sample analysis.35 The 4 x 6 mm silicon-on-insulator sensor chips are batch 
fabricated containing 128 individually addressable sensors. Each microring is 30 µm in diameter 
and fabricated adjacent to a linear waveguide with individual input and output grating couplers to 
couple light in free space. The chips are all coated in a perfluoro copolymer cladding for stability 
and the reduction of non-specific interactions with non-sensing regions with the active sensors 
exposed by photolithography. Four additional microrings are left buried under the cladding to act 
as thermal controls.  
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The instrumentation for interrogating the sensors has been extensively described36,37, but briefly 
light is coupled into the linear waveguide via the grating couplers from an external cavity diode 
laser centered at 1560 nm. The differential output is detected by a photodetector and the entire 
process is automated with an effective scan rate of 50 Hz. The sensing region from the surface of 
the sensor, characterized experimentally, is defined by the 1/e decay point of the sensitivity at 63 
nm.38 The limit of detection for this device is reported as 1.5 ± 0.7 pg/mm2.36,38   
The silicon photonic microring resonator platform has been applied to several detection schemes 
owing to its versatile surface for selective capture modification and exquisite sensitivity to changes 
in binding at the sensor surface. Additionally, the spatially arrayed individually addressable 
sensors provide a straightforward approach to multiplexing. Previous demonstrations of the 
applications of this technology include the detection of proteins39-45, RNA (miRNA46, mRNA47, 
tmRNA48), DNA49, and viruses50. Assay amplification strategies, particularly for proteins, have 
elevated the detection capabilities to equivalent or better than traditional immunoassays in 
complex biological samples.51 Additionally, this platform has coupled to liquid chromatography52 
and the near-real time binding response has been used to determine kinetic and equilibrium binding 
constants.49,53  
 Recently, Genalyte, Inc. has developed the Maverick (M24) platform in which 12 sensor chips 
are pre-assembled into a disposable array with integrated fluidics allowing for entirely software-
controlled sample introduction and reagent flow. Two samples are analyzed simultaneously in 
fluidically distinct channels of the same sensor chip, with up to 24 samples analyzed sequentially 
without user intervention.35 This significant automation advancement provides the necessary 




1.5  Development of Functional Workflows for Clinical Decision Making 
The research discussed herein describes developments for the application of multiplex 
immunoassays for functional healthcare decision-making using silicon photonic microring 
resonator arrays. Chapter 2 reviews the key tenants for developing robust multiplexed 
immunoassays with whispering gallery mode sensors. The analytical protocols described are well-
supported by related assay development recommendations, taking into consideration rigorous 
examination of the role of reagents, cross-reactivity, and matrix effects on assay performance. 
Each immunoassay described in subsequent chapters was developed utilizing the same basic 
workflow and validation.  
Chapters 3 and 4 both address infectious disease based immune profiling for diagnostic and 
prognostic decision making. Despite sharing similar fundamental assay approaches, each utilize 
unique sample types and exploit distinct advantages of the platform. Chapter 3 focuses on 
developing a diagnostic assay to identify and stratify latent tuberculosis infection (LTBI) based on 
risk of reactivation to active, infectious tuberculosis (TB). By stimulating peripheral blood 
mononuclear cells with TB-relevant, off-target, and control antigens, we aimed to reduce the 
complex observations of the transient immune response to better define the diagnosis in terms of 
robust molecular response. Additionally, each on-target stimulation response was normalized by 
the off-target and control to account for personalized immunological variations. In doing so, 
machine learning based feature selection tools revealed unique LTBI specific signatures, otherwise 
obscured prior to personalized normalization. This workflow demonstrates the utility of moving 
beyond absolute biomarker concentrations into a regime that combines a precision medicine data 
treatment with machine learning analysis tools to guide diagnostic assay development.  
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While the LTBI assay in chapter 3 did not incorporate temporal cytokine dynamics, chapter 4 
highlights the utility of this platform for making rapid and robust measurements to monitor 
dynamic clinical trajectories. Sepsis is described as an abnormal host response to a foreign 
pathogen and immunologically represented by dangerous fluctuations in cytokine response. 
Because sepsis can proceed at a rapid pace and the immune dynamics vary based on numerous 
physiological factors, temporal dynamics are necessary to understand a patient’s response to 
therapy and long-term prognosis. To that end, we monitored the trajectories of 12 biomarkers 
representing key pro- and anti-inflammatory cytokines in patient plasma throughout their stay in 
the intensive care unit. The assay was a rapid 45 minutes and required less than 150 μL of sample, 
which was well within the time intervals and sample volumes of traditional blood draws. This 
assay demonstrates promise toward utilizing complex cytokine trajectories to define patient 
prognosis and monitor treatment response.  
Finally, Chapter 5 leverages an immunoassay workflow for the characterization of monoclonal 
antibody therapies. Traditional immunoassay formats often rely on end-point measurements, but 
near real-time measurements provide intra-assay dynamics yielding kinetic and equilibrium 
binding constants. Unlike Chapters 3 and 4 both defined by primarily typical end-point results, the 
real-time association and dissociation kinetics were utilized to understand potential structural and 
functional binding changes accompanying antibody aggregation. By leveraging the multiplex 
immunoassay format, we have initially characterized the differential interactions of the monomeric 
and dimeric populations of a monoclonal antibody therapy. While there are numerous tools to 
characterize protein aggregation, very few address the functional changes to binding which 
ultimately effects therapeutic efficacy. By leveraging this multiplexed immunoassay for kinetic 
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analysis and structural characterization, we may direct pharmaceutical development and quality 
control. 
Throughout the development of each assay, the central goal has been to functionally guide 
healthcare decisions with a robust and highly adaptable platform. Guided by clinical and industrial 
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2.1 Significance Statement 
Major advances in biomolecular detection have led to vast improvements in the sensitivity and 
selectivity achievable for multi-target analysis. Whispering gallery mode (WGM) sensors are a 
rapidly developing class of analytical tools that can be configured for a variety of biomolecular 
sensing applications. To generate reliable biomarker detection assays using WGM platforms 
standardized development protocols should be established. Herein, we describe a strategy for 
developing quantitative biomarker assays on a representative WGM platform for the purpose of 
biomarker detection in complex, clinically relevant sample matrices. The method is transferable 
to analogous optical microcavity sensors and generalizable so that a variety of capture agents can 
be incorporated including antibodies and nucleic acids. 
2.2 Abstract 
Whispering gallery mode (WGM) sensors are a class of powerful analytical techniques defined by 
the measurement of changes in the local refractive index at or near the sensor surface. When 
functionalized with target-specific capture agents, analyte binding can be measured with very low 
limits of detection. There are many geometric manifestations of WGM sensors, with chip 
integrated silicon photonic devices having been first commercialized on account of robust, wafer-
scale device fabrication, facile optical interrogation, and amenability to the creation of multiplexed 
sensor arrays. Using these arrays, a number of biomolecular targets have been detected in both 
label-free and label-enhanced assay formats. For example, sub-picomolar detection limits for 
multiple cytokines were achieved using an enzymatically enhanced sandwich immunoassay that 
showed high analyte specificity suitable for detection in complex, clinical matrices. This protocol 
describes a generalizable approach for the development of quantitative, multiplexed 




Whispering gallery mode (WGM) sensors are promising for a range of (bio)chemical detection 
applications, and several recent reviews have described overall progress in this field.1-4 Rather than 
survey recent progress and specific advances in sensor geometry or analytical performance, this 
article describes a generalizable protocol for the development of quantitative, multiplexed 
biomarker assays for robust analysis of biomarkers from within complex, biologically relevant 
samples (serum, plasma, whole blood, etc.). Although alternative WGM sensors with different 
geometries and materials systems are viable platforms for detection, this protocol is written from 
the perspective of using arrays of chip-integrated silicon photonic microring resonators5—a 
platform that has been commercialized by Genalyte, Inc. Furthermore, this protocol focuses on 
enzymatically enhanced sandwich immunoassays6,7, which have been found by our lab to provide 
the highest specificity and lowest limits of detection for protein detection in complex matrices; 
however, many of the general steps are based upon or closely related to earlier examples of label-
enhanced8,9, or label-free protein biomarker detection.10,11 Similar approaches on the same 
detection platform using different capture agents have been also been applied to the detection of 
viruses12 and nucleic acid targets.13-17 
Like other WGM devices, microring resonators support optical modes that are sensitive to changes 
in the local refractive index at or near the sensor surface. By monitoring changes in the optical 
properties of resonators functionalized with target-specific capture agents, often through shifts in 
the spectral position of resonances, biomolecules can be detected with high sensitivity (Figure 
2.1).1   The general immunoassay components include a capture antibody, sample/target protein 
standard, biotinylated secondary tracer antibody, streptavidin-horseradish peroxidase (SA-HRP) 
conjugate, and chloronaphthol solution (4-CN) for enzymatic signal enhancement (Figure 2.2). 
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As with all immunoassays, performance is fundamentally related to attributes of the capture agents, 
including the affinity, avidity, specificity, and kinetics of analyte binding and unbinding. For 
silicon photonic sensors, antibodies can conveniently be covalently coupled to the sensor surface 
using standard bioconjugation methods. This chemistry can also be adapted to sensor 
functionalization with nucleic acids, including amine-terminated single-stranded DNA. After 
binding of the analyte (from the sample or standard-containing solution), the biotinylated 
secondary tracer antibody recognizes the bound antigen and provides increased specificity for the 
target protein—particularly for detection in complex matrices where non-specific binding of 
highly abundant matrix proteins can obscure target binding to the capture antibody. Binding of the 
SA-HRP conjugate to the tracer antibody provides an opportunity to tremendously enhance the 
resonance wavelength shift by the catalytic decomposition of 4-chloro-1-naphthol, which leads to 
the deposition of an insoluble product onto the sensor surface. The enzymatic signal enhancement 
is not necessary but provides a notable improvement in the limit of detection.6,9 Beyond standard 
sensor functionalization, considerable effort is devoted towards optimizing assay parameters, 
including the volume, concentration, rate and duration of delivery, and other assay reagent 
considerations. Once optimized, the assay can be rigorously calibrated, often using protein 
standard solutions, and then used for robust and reliable analyte quantitation.  
This sandwich immunoassay protocol is generally applicable for a range of protein biomarkers 
that can be specifically targeted using commercial or custom-generated antibody (or aptamer) 
capture agents. Furthermore, these approaches are amenable to single- or multiplexed protein 
detecting assays, with multiplexed assays facilitated by microspotting different capture agents at 
discrete spatial locations across the sensor array substrate (Figure 2.3). Assay optimization and 
operation are further facilitated by automated liquid handling, which significantly mitigates the 
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reproducibility issues that can plague manual plate- and bead-based assay formats. Finally, 
considerations that reduce required sample input and assay time-to-result are also important when 
considering translational application to the analysis of complex clinical samples.  
2.4 Strategic Planning 
Selection of the biomarker targets and the capture agents requires careful consideration. Once 
functionalized with a specific capture agent, the performance of the sensor is significantly 
dependent on the unique binding properties of the capture agent (e.g., affinity, avidity, and 
specificity) in addition to sensor gain. This is critical to remember when comparing limits of 
detection as a performance metric of sensors and similar assays. That is to say that limits of 
detection for specific assays are often more a result of higher affinity reagents than the performance 
of the technology itself—this is particularly important to note when critically evaluating new 
platforms that invoke irregularly high affinity interactions (e.g., biotin-avidin) for proof-of-
principle reports. Furthermore, the stability of capture agents can dictate long-term storage and 
other assay conditions. The native matrix in which a biomarker needs to be detected is also an 
important consideration, particularly if the complexity will require sample dilution. Mitigating 
matrix effects (i.e., non-specific interactions) through dilution is common, but can be non-ideal if 
the biomarker is present at low abundance. Early consideration of the target, primary and tracer 
capture agents, and potential for matrix effects can significantly reduce optimization time and 
assay failure. 
Finally, the development of a quantitative, multiplexed assay is rarely a straightforward process. 
The most robust assays require rigorous optimization regardless of the sensing platform. 
Moreover, care must be given to ensure assay reproducibility over time and perhaps even across 
multiple lots of reagents, which can have profound effects on performance. Therefore, it may be 
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necessary to iteratively repeat the basic protocols presented herein to achieve robust and reliable 
performance for the entire protein panel.  
The protocols in this article present a general method for the development and implementation of 
a multiplexed quantitative protein detection assay using WGM sensors. Three basic protocols are 
described. First, the WGM sensor is functionalized with capture probes selective for the protein 
targets. Second, the assay performance is optimized and characterized in terms of cross-reactivity, 
non-specific binding conditions, and optimal conditions. Third, the sensor array is calibrated for 
quantitative response in a matrix comparable to experimental conditions. As a specific example to 
illustrate these steps, an amplified sandwich immunoassay is described here. 
2.5 Basic Protocol 1: Functionalization of the sensor surface with antibody capture probes 
Sensor fabrication is highly dependent upon the WGM sensor geometry and materials system 
utilized; however, in all instances, the initial post-fabrication step involves the functionalization of 
the sensor surface with a target-specific capture agent(s) for an analyte(s) of interest. A common 
method to achieve this, which is compatible with silicon photonic sensor arrays, includes chemical 
modification with aminopropyltriethoxysilane (APTES), followed by reaction with a 
homobifunctional cross-linker, such as bissulfosuccinimidyl suberate (BS3), which can 
subsequently react with lysine residues and N-terminal amines on capture antibodies (Figure 2.4). 
The chemical modification and cross-linking process is applicable to many suitable WGM 
resonator materials systems. Analogous attachment schemes may be suitable provided they are 
compatible with the experimental conditions. With BS3, this protocol can also be used for the 
functionalization of other amine-containing capture agents, including commercially available 
amine-terminated nucleic acids. This protocol is also amenable to sensor functionalization using 
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robotic microarrayers, and in this way can be used to batch fabricate many identical single- or 
multiplexed detection arrays.  
Materials: 
• 3-Aminopropyltriethoxysilane (1% solution in acetone) 
• Acetone  
• Isopropanol 
• Distilled water or Milli-Q purified water 
• Acetic Acid (2 mM in distilled water) 
• Bissulfosuccinimidyl suberate (5 mM in 2 mM acetic acid—conveniently available in 2 
mg No Weigh Format from Thermo Scientific) 
• PBS buffer with BSA (10 mM with 0.5% BSA) 
• Glycerol 
• Capture antibody stock solution (at least 0.25 mg/ml, <1% sodium azide) 
• StartingBlock (PBS) buffer (Thermo Scientific) 
• DryCoat assay stabilizer (Virusys, #AG066-1) 
 
• WGM sensor/sensor array (Commercially available as 128-microring sensor arrays from 
Genalyte Inc.) 
• 20 mL scintillation vials 
• Tweezers 
• Stereoscope 




Silanizing the sensor surface 
1. Clean the sensors using appropriate organic solvents, such as acetone or isopropyl alcohol. 
When handling the sensor, use clean tweezers and be careful to avoid damaging the device. 
Be sure to give the array a final rinse in clean solvent before proceeding to the next step.  
2. Silanize chips in 1% APTES solution in acetone. Allow the chip to soak with mild agitation 
for 4 min. 
The APTES solution should be prepared fresh from stock solution stored in a desiccator 
under nitrogen. APTES will have a short shelf life if not stored correctly. 
This is easily performed in a 20 mL scintillation vial. 
3. Rinse chip for 2 min in acetone and then 2 min in isopropanol with mild agitation.  
Both steps should take place in separate 20 mL scintillation vials. 
4. Rinse the chip(s) in deionized water and dry chip under N2 gas stream until no visible 
moisture remains. 
The water rinse can be achieved with several drops of water or by dipping the chip into a 
water filled well of the 24-well plate for ~30 s 
Bioconjugation with BS3 cross-linker 
5. Prepare 5 mM BS3 cross-linker solution in 2 mM acetic acid solution.  
The BS3 solution should be prepared fresh and exposed to the sensor within 1 h. The NHS-
ester moiety readily hydrolyzes and becomes non-reactive so fresh reagents and timely use 
is critical. If using 2 mg No Weigh Format (above in Materials) dissolve an entire aliquot 
into 700 mL of 2 mM acetic acid solution. The preparation of this reagent with regard to 
pH and concentration is consistent with the commercial recommendations. The use of 
acetic acid and the length of the reaction was empirically determined for Genalyte sensors. 
27 
 
6. Place chip into a well plate and apply ~20 µL of BS3 solution onto the chip taking care to 
cover the entire sensor surface.  
When functionalizing multiple chips, complete this step with each chip in an individual well 
of a 24 well plate. Carefully add the solution on the chip surface and avoid contact with 
the plate or adding too much liquid.  
7. Allow the BS3 coated chip to sit for 3 min. Remove liquid with N2 gas stream.  
If the liquid was not contained to the surface of the chip, carefully move the chip to gas 
stream. Chips may stick to the surface of the plate.  
Spotting capture probes on chip surface 
8. Prepare 20-50 µL of  >100 μg/ml capture agent solution by diluting in 10 mM PBS and 5% 
glycerol. 
The capture concentration varies depending on optimal response. The glycerol minimizes 
capture agent drying before complete conjugation. When considering capture agents, 
always additionally include an off-target control capture, such as an isotype control 
antibody compatible with the detection assay. This should be included in every assay as a 
measure of non-specific binding.  
9. To create a multiplexed sensor array with resolution greater than that achievable by eye, 
place chip under stereoscope. Deposit capture target in 5% glycerol onto specific regions 
of the sensor array by carefully spotting liquid onto distinct sensor array clusters.  
A 2.5 µL pipet set to 0.2-0.5 µL dispense volume works well. Spot slowly. To spot multiple 
capture probes, be sure to avoid cross contamination of the capture agent spots by 
carefully spotting small and non-overlapping volumes.  
10. Transfer spotted chips to humidity chamber for one hour.  
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A humidity chamber can be easily constructed by adding a thin strip of damp clean room 
cloth over the well plate containing sensors and closing the lid. This will decrease the 
likelihood of spot evaporation before complete surface functionalization.  
11. Coat chips in DryCoat assay stabilization reagent by pipetting several drops over the 
surface and place in desiccator at 4 C until ready to use. 
To pre-block the sensors, use DryCoat with BSA to avoid non-specific protein binding. This 
can also be achieved by blocking during the experiment with StartingBlock buffer. After 
blocking, sensors are immediately ready to use and do not require DryCoat or 4 C storage 
prior to use. This step is necessary only for stable storage of functionalized sensors. The 
lifetime of the functionalized sensor is largely dependent on the stability of the probes but 
can be at least 6 months when stored in the suggested conditions. 
2.6 Basic Protocol 2: Assessing optimal conditions, cross-reactivity, and matrix effects for 
whispering gallery mode (WGM) assay optimization 
Traditional immunoassays require iterative development to assess the optimal concentration and 
protocol for each target analyte. Similarly, WGM immunoassays require this development as well 
as the evaluation of potential non-specific interactions between multiple targets. First, it is critical 
to determine the minimum concentration that will yield the maximum signal for each component 
of the assay. By minimizing reagent use, the assay becomes more cost-efficient and has minimal 
non-specific binding. A second component of assay optimization is the development of the assay 
protocol. In this example, the assay protocol, also known as the recipe, is optimized in terms of 
the flow rate and volume of each reagent (Table 2.1).  
Significant variation exists in the fluid delivery approaches used in different WGM sensor 
configurations. Examples of fluid delivery for the Genalyte M1 and M24 platforms is shown in 
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Figure 2.5, along with an example of an optical configuration to monitor a microsphere resonator 
in a polymeric chamber as described by the Vollmer group.18 While specific details may not be 
generalizable between platforms/configurations, the focus on sensor care, consistent fluid flow, 
and their impact on data quality is shared.  
Our usual approach has been to semi-optimize single-target assays before incorporating reagents 
for multiple targets. With multiplexed assays, the potential for cross-reactivity is evaluated for 
each component (primary capture and tracer antibodies). The final step of assay optimization 
consists of evaluating the effects of a complex matrix on non-specific binding and maximum 
signal. The sensors have shown robust measurements in different biological environments (e.g., 
serum, plasma, etc.), but the assay performance should be evaluated, optimized, and calibrated in 
the matrix most closely resembling the format of the final samples to be analyzed. This protocol 
was optimized for the development of a robust multiplexed immunoassay in complex matrix using 
the Genalyte silicon photonic platform.  
Materials 
• Running buffer (10 mM PBS, 0.5% BSA, Detergents such as Tween20 are optional) 
• Standard protein solutions (1-100 µg/ml stock diluted in running buffer or matrix solutions) 
• Biotinylated tracer antibodies (diluted to 0.5-4 µg/ml in running buffer) 
• Streptavidin-horseradish peroxidase conjugate (diluted to 1-6 µg/ml in running buffer) 
• Low pH Glycine solution (10 mM in Milli-Q water, pH 2.2) 
• Concentrated matrix (e.g., plasma or serum, aliquoted and stored frozen) 
• 1-step chloronapthol solution (4-CN, Thermo Scientific, containing 4-chloro-1-naphthol 
and proprietary peroxide-containing buffer) 
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• Vortex mixer 
• *96-well plates (400 mL maximum volume) 
• *Pre-cut Piercable Films for Robotics (X-Pierce, Excel Scientific) 
• *Cartridge assembly (Genalyte Inc.) 
• *Teflon sipper tubes (0.01” ID Teflon tubing) 
• *Precision torque wrench and screwdriver (1/16”) 
• *Maverick optical scanning instrumentation (Genalyte Inc.) 
Preparation of reagents for signal optimization 
1. Prepare 400 µL of standard protein solution in running buffer (10 mM PBS, 0.5% BSA). 
Gently vortex each solution prior to use.  
This should be a maximum concentration recommended by the product guide for an 
immunoassay. If this is unavailable, it is recommended to start with a concentration 
between 10-100 ng/ml. However, the saturation concentration can be highly variable and 
should be iteratively tested.  
2. Prepare 400 µL of biotinylated tracer antibody in running buffer. Gently vortex each 
solution prior to use. 
The optimal concentration of the secondary antibody will need to be determined 
empirically, but start by consulting the product guide. If this is unavailable, it is 
recommended to start with 1-4 µg/ml. Aim to achieve the maximum signal response with 
the minimum antibody concentration for that signal.  
3. Prepare 400 µL of streptavidin-horseradish peroxidase solution in running buffer. Gently 
vortex the solution prior to use. 
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This concentration should be comparable to the concentration of the biotinylated tracer 
antibody. Optimize this concentration simultaneously with the secondary antibody 
concentration. Minimize light exposure throughout solution preparation and during the 
experiment.  
4. *Transfer all reagents to a 96 well plate including 1-step chloronaphthol solution (4-CN) 
as the final step in the assay. Cover with a Pre-Cut Pierceable Film. 
The plate cover must be pre-cut for the sipper tube to access the reagents. This is achieved 
using the Pre-Cut Pierceable plate covers for 96 well plates. The 4-CN incubation should 
be followed by a short buffer rinse to remove excess reagent. Include enough running buffer 
for this step. 
Mounting WGM sensor in fluidic housing, pre-assay checks, and running the assay  
5. Assemble capture agent-functionalized WGM sensor into suitable cell for fluidic delivery. 
6. *Load a pre-functionalized chip into a base cartridge holder. 
Use tweezers and carefully align the chip with fluidic gasket and assemble cartridge using 
screwdriver and torque wrench. Tighten the screws as evenly as possible applying gentle 
pressure to the whole cartridge top to maintain even stress on the chip and gasket. Attach 
Teflon tubing to cartridge. Check flow before attaching to fluid delivery system.  
7. Load the assembled sensor into the optical mounting system. 
*Load the assay protocol into the software and register the chip. Chip registration 
performs a quick scan of each sensor and the readout determines which sensors on the 
chip are viable for the experiment. If numerous sensors fail to register or the entire chip 
fails to register, this may indicate the chip alignment is off or the chip is damaged.  
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8. Before starting the assay, check the flow quality across the sensor by performing a pre-
scan buffer rinse step for approximately 5 minutes.  
Watch the fluid lines for visual confirmation of flow and reduction in bubbles. At this point, 
no data is generated (“pre-scan”), but bubbles may be seen in the tubing. Watching the 
progress of a bubble flowing in the tubing lines is a good indication of fluid flow. It is 
critical that the flow is established before scanning to avoid poor reagent interactions with 
the sensor. If there are many bubbles present in the fluid lines or the lines are dry, manually 
purge the lines with buffer or water via syringe. 
9. Deliver reagents sequentially to the pre-functionalized sensor surface. 
Recipes can vary based upon the specifics of an individual assay. The initial running buffer 
rinse steps may be used to establish the baseline and confirm fluid flow. If there are 
significant bubbles or limited flow, there will be significant deviation in the sensor 
response in the first 1-2 minutes. If this occurs, stop the assay and re-purge the device. 
Once the recipe proceeds to the analyte step, the assay should not be restarted. Running 
buffer rinse steps typically range from 1-5 minutes, Sample from 5-20 minutes, and 
remaining reagents from 5-20 minutes in sequential steps. Flow rates can range from 10-
40 µL/min. A final rinse of the fluid lines should be 10-30 minutes of water. For biological 
samples, include a 10% bleach rinse (~10 min) prior to the water rinse. For a sandwich 
immunoassay with enzymatic signal amplification an example recipe is shown in Table 1.  
* Prepare assay recipe by defining each step of the assay, duration, and flow rate in a CSV 
file. All sensor rings must be assigned as a probe sensor or control sensor.  
10. *Start recipe and optical monitoring of resonance wavelength shift. Once the recipe is 
completed, rinse fluid lines completely. 
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11. Examine results and iteratively adjust reagent concentrations, flow rates, and flow 
durations to optimize the magnitude of sensor response for a given analyte concentration.  
Assessing cross-reactivity for multiplexed assays 
12. Once multiple, individual sandwich assays are independently optimized, multiple capture 
antibodies can be spotted at distinct spatial locations across the array.  
13. Separately prepare the analyte and secondary antibody reagents for each target. 
The analytes and secondary antibodies will be introduced to the chip one at a time.  
14. Transfer the reagents, buffer, and a 10 mM glycine rinse to a 96 well plate or other fluid 
containment system.  
This cross-reactivity assay requires that each analyte and secondary antibody is 
introduced one at a time. Between each target introduction, the low pH glycine rinse (~2 
min) acts to disrupt the analyte-capture interaction to regenerate the surface. Assessment 
of cross-reactivity is performed by sequentially flowing buffer, analyte, buffer, tracer 
antibody, buffer, glycine, buffer, repeat.  
15. Sequentially deliver each standard protein and tracer antibody across the array one-at-a-
time.  
Each analyte and secondary antibody should elicit a response only at the sensor 
functionalized with the target-specific capture agent. The low pH glycine rinse will disrupt 
the binding between the capture agent and target protein causing the target and tracer to 
be removed from the sensor between every analyte-specific sequence of the recipe. 
16. Review resonant wavelength shifts for each individual assay across the entire multiplexed 
capture antibody array and check for cross-reactive responses.  
34 
 
A cross-reactive response is determined as a signal response from n sensor functionalized 
with a capture with the addition of an unrelated target protein and secondary tracer. If the 
off-target response is observed for only one step and disappears with a buffer rinse than it 
may be weakly interacting and removed with a longer buffer rinse step during the actual 
assay. If cross-reactive responses are observed, try a lower analyte concentration that 
more closely mimics concentrations expected in the sample matrix. Sometimes cross-
reactivity is observed at artificially high concentrations used for initial assay trials, but 
this can be irrelevant for assays performed at lower concentrations, such as those seen in 
real biological matrices. 
Assessing matrix effects 
17. Using the optimized concentrations, prepare 400 µL analyte solutions containing each 
analyte at a concentration at or near saturation. The solutions should be prepared with 
varying concentrations of desired sample matrix (serum, plasma, etc.) ranging from 100% 
serum to 100% running buffer.  
By spiking solutions with a high concentration of analyte, a small amount of natively 
present analyte will not significantly change the sensor response. This will provide a direct 
observation of the matrix effects. However, when assessing the possible interactions of a 
complex matrix with the assay, review the matrix composition. For example, commercially 
available, pooled human serum or plasma may contain detectable levels of the target 
analyte, which can contribute a specific background signal during matrix evaluation.  
18. Complete steps 5-10 of this protocol using an optimized assay recipe. Review the data for 
any non-specific binding and changes in the magnitude of the signal. Perform some 
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experiments to explore matrix effects at lower concentrations more similar to what would 
be expected in the native biological matrix. 
Use these data to assess necessary dilutions for future calibration and sample treatment. 
If the signal is greatly affected at a certain percentage of complex matrix then the 
calibration and samples should be appropriately diluted to mitigate signal loss.  
2.7 Basic Protocol 3: Calibrating the optimized multiplexed assay in complex matrix for 
analyte quantitation 
For high quality, quantitative measurements, assay calibration is critical. Described below are the 
necessary steps to calibrate the response of a fully optimized multiplexed immunoassay. There are 
two main approaches to preparing calibrant solutions: serial dilution and random concentration. 
Serial dilutions are favored because it minimizes pipetting errors and involves a more linear 
standard preparation process. However, the concentration profiles of standard solutions generally 
do not represent the complex matrix of a real world sample, which can lead to a masked effect 
related to high or low protein concentration. Random concentration solutions may represent more 
realistic solution concentrations, but require that each solution is prepared individually. This 
preparation is more tedious to mitigate potential dilution and pipetting errors. Together, the two 
approaches can be used to complement each other in fully characterizing assays.  
Using the data collected from the calibration experiment, a calibration curve can be constructed 
and critical metrics, including limit of detection (LOD) and limit of quantitation (LOQ), can be 
determined. Using this information, the assay is now ready for experimental sample analysis. 
Example data and the resulting calibration curve with delineated LOD and LOQ are shown in 
Figure 2.6.   
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All materials in this step are identical to those described in the previous two basic protocols. 
Preparing multiplexed calibration solutions 
1. Prepare 400 µL multiplexed analyte solutions in the complex matrix, varying the 
concentration from zero to the pre-determined maximum (signal saturation). Include a 
minimum concentration near or just below the expected limit of detection for each analyte 
for full characterization.  
The matrix composition and concentration range should be pre-determined from the 
optimization process (Basic Protocol 2). The solution preparation can be completed via 
serial dilution or by preparing each analyte solution with random concentrations of each 
analyte. Both calibration approaches are recommended to fully characterize the signal 
response.  
Use fresh (or recently thawed) recombinant protein standards and keep all samples and 
matrix on ice or at 4 C throughout preparation.  
2. Prepare multiplexed biotinylated tracer antibody solutions for the entire calibration curve 
analysis. The antibodies should be diluted in running buffer.  
Keep tracer solution on ice or at 4 C throughout preparation and use. Prepare solutions 
fresh for the experiment unless otherwise tested.  
3. Prepare the streptavidin-HRP solution for the entire calibration curve.  
Keep solution on ice or at 4 C throughout use and limit exposure to light. The concentration 
of this solution may need to increase to compensate for the increased concentration of total 
detected analyte. If the maximum signal is lower than expected, increase the concentration 
until comparable maximum signal from the optimization is achieved.  
4. Prepare sensor and solutions for assays.  
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Leave the prepared solutions on ice or at 4 C for as long as possible before their use in the 
assay.  
Collecting and pre-analyzing data 
5. Analyze all calibration samples including a blank (no analyte, only matrix) using the steps 
outlined in Basic Protocol 2, steps 5-10.  
6. Once the data collection is complete, check that all data has been saved and itemize by 
target.  
*Data will be output in a folder organized by sensor number.  
7. Import the data into any data processing program that suits the following analysis steps. 
Most analysis programs or statistical programming languages would provide the 
necessary tools for data processing. 
Data analysis 
8. If baseline controls were used then subtract the signal from this response. 
*On-chip thermal controls may be used to correct for thermal fluctuations.  
9. Plot the sensor response as a function of time. 
10. Average the data of redundantly spotted sensors (technical replicates).  
*Redundantly spotted sensors in the array can be considered as technical replicates, 
allowing for data averaging. 
11. Using the averaged data, calculate the net shift during the enzymatic amplification step for 
the assay readout. 
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Calculate this by choosing a consistent time point during the amplification step and 
subtracting that signal from the signal of a time point prior to the amplification (i.e., buffer 
step prior to amplification). Use the same time points for the analysis of all samples.  








𝑝 + 𝐴2 
where A1 is the initial value (Δpm), A2 is the final value (Δpm), x is the analyte 
concentration (pM), x0 is the center value (inflection point, pM), and p is the power 
parameter affecting the slope of the linear portion of the fit surrounding the inflection point.  
Using this data, the limit of detection and limit of quantitation can be determined for each 
target. Both metrics are necessary for quantitative sample analysis.  
2.8 Reagents and Solutions 
Milli-Q water, or equivalently pure water, is used in all recipes and protocol steps. All buffers are 
filtered with sterilized, low protein binding disposable filters. All protein and antibody solutions 
should be prepared fresh and maintained at as high of concentrations as possible for storage. Long-
term storage at diluted concentrations should be thoroughly tested. Consideration must also be 
given to the presence of carrier proteins or antimicrobial compounds within commercially 






Background Information. Whispering gallery mode (WGM) resonators function by detecting 
changes in the local refractive index.1  Figure 1 shows the operating principles for microring 
resonators wherein light is coupled onto the chip via a grating coupler and propagates down the 
linear waveguide via total internal reflectance.5 For other WGM sensor geometries, light is 
commonly coupled in via an extruded fiber optic or prism. The waveguide is directly adjacent to 






where λ is the wavelength of light, r is the microring radius, m is an integer, and neff is the effective 
refractive index sampled by the microcavity. Resonances are measured by monitoring dips in 
transmittance through the waveguide past the resonator as the probe wavelength is swept through 
a suitable spectral range.5  
WGM immunoassays are an alternative to the traditional plate- or more recent bead-based protein 
assays. The gold standard plate-based enzyme-linked immunosorbent assays (ELISAs) are labor 
intensive and typically single-plex. Most bead-based assays have multiplexing capabilities, but 
numerous manual steps can introduce significant error. When validating WGM-based 
immunoassays, parallel analysis using ELISA or other existing immunoassay platform is strongly 
encouraged to robustly validate and correlate the results. For multiplexed assays, this is extremely 
cumbersome; however, side-by-side validation of all targets across a subset of biological samples 
can instill confidence in the approach. 
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Standard protein assay validation. A key step in the development of the protein assay is the 
validation of the selective detection of a single protein target. This is typically accomplished with 
a standard protein as a positive control prior to sample analysis. This protein can be obtained 
commercially or produced in house, and is typically recombinantly expressed or isolated from 
natural sources (e.g., prostate-specific antigen purified from human plasma or seminal fluid is 
available from Meridian Life Science). When using antibodies as the capture and tracer agents, 
consult product information from the vendor regarding recommended pre-screened antibody pairs 
and compatible protein standards. To further verify the quality and binding characteristics of 
antibody pairs, validation with ELISA or a related immunoassay platform is advised. However, 
certain proteins will not have available positive standards. An alternative method to validate an 
antibody pair is to create or identify reference cell populations with specific expression of the 
target protein. We did this for a number of phosphorylated protein targets, considering an antibody 
pair as suitable for a specific target when the signal was significantly above the off-target control 
response, the assay showed a concentration-dependent response and statistically insignificant 
signal for negative control experiments, and independent Western blots indicated an appropriate 
band using the same antibody clone(s).19  
Monitoring all assay steps for a comprehensive view of performance. In the assay described 
herein, signal quantitation is achieved by utilizing the enzymatically enhanced signal from the 
tertiary conversion of 4-CN. However, assay optimization is greatly aided by the ability to monitor 
(in real-time, ideally) the shift in resonance wavelength during each assay step. For example, by 
separately monitoring primary capture and tracer antibody binding steps a great deal of information 
can be gleaned, including knowledge of antibody and antigen cross-reactive responses. In one 
recent example, we were able to utilize primary and tracer binding data to rule out antibody cross-
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reactivity and reveal that the commercially available protein standard solution, which had been 
obtained from natural sources, had a minor contaminant that was another biomarker from within 
our multiplexed assay.20 Real-time analytical capabilities can also provide insight into the kinetics 
of antigen-antibody interactions, which are important to keep in mind as fast dissociation rates of 
the capture antibody-antigen complex will complicate detection with the tracer antibody and may 
lead to a reduction in rinsing times. 
2.10 Troubleshooting 
Low primary capture or tracer antibody binding response. Choosing the antibody pair or any 
capture target is crucial to the success of the assay. The performance of the assay is dependent on 
the sensitivity and selectivity of the capture and tracer agents. Focus on pre-validated monoclonal 
antibody pairs whenever available when selecting antibody pairs. When initially testing an 
antibody pair, there are a number of reasons for lack of signal. However, if an antibody or protein 
standard is in question, perform a secondary validation such as an ELISA. The best side-by-side 
comparison is an ELISA developed as consistently as possible (i.e. similar buffers, reagent 
preparation). If this is unsuccessful, replace the antibody pair or protein as needed. Importantly, 
do not implicitly trust vendor information on antibody compatibility—especially for antibody 
sandwich pairs. Many times vendors will not describe the targeted epitope, making it difficult to a 
priori establish whether two separate antibodies will work together. Also, be wary of lot-to-lot 
variation of antibodies, which can have profound effects on long-term assay stability and 
reproducibility.  
Non-specific binding. Non-specific binding can present as a high signal when the target analyte 
is not present in the solution and also as high signals for control (off-target) sensors. The primary 
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ways to investigate and mitigate this issue is through thorough optimization and by pre-blocking 
sensor surfaces. Minimize the concentration of secondary antibodies that may non-specifically 
bind to the surface or other targets. Complex matrix composition is often responsible for non-
specific binding, but be weary of significantly diluting the sample beyond the detection limit. It 
may also be advantageous to modify the recipe by increasing the length of buffer rinses between 
steps to clean the surface of weakly bound biomolecules. One of the main advantages of the multi-
step sandwich immunoassay described herein is that the quantitative measurement is made in the 
absence of biological matrix--after tertiary reagent addition and multiple rinses with buffer. In this 
way, the signal used for quantitation does not contain any non-specific binding response; however, 
cross-reactive responses from primary capture or tracer antibodies is not corrected for using this 
(or any other) approach. 
Signal Response and Flow. Consistent fluid flow is necessary to deliver reagents to the sensor 
surface. An issue with fluid flow will manifest as signal drift or a spread in responses for 
multiplexed assays (i.e., sensor spread, which is when redundant sensors drift apart to give a large 
deviation in response), or no signal response. For general assays, visually establish fluid flow and 
lack of air bubbles prior to the introduction of the assay reagents. Inconsistent fluid flow is a 
common source of error and Table 2.2 outlines specific flow-related issues and the related 
solutions. 
2.11 Anticipated Results  
With manually functionalized arrays, Basic Protocol 1 provides the necessary information to 
generate consistent multiplexed chips. Basic Protocol 2 provides a general method to rigorously 
test immunoassays for cross-reactivity, non-specific binding interactions, and matrix effects. This 
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protocol is broadly applicable for the development of clinical assays with numerous WGM sensors. 
Once a calibration curve with clinically relevant LODs has been obtained, the assay can be used 
for clinical evaluation of biological fluids. 
2.12 Time Considerations 
Functionalization of the sensor arrays depends on the batch size and number of targets. The chips 
can be stored at 4 C or used immediately. The time considerations for Basic Protocol 2 depend on 
the number of targets and matrix type. Each target will require multiple experiments for 
optimization and matrix evaluation and an additional experiment for cross-reactivity. Assuming 
two targets and a 60 min assay time, Basic Protocol 2 requires at least one full day. Finally, the 
assay calibration depends on assay length and the number of data points collected. Assuming two 
targets, 60 min assay, and 8 data points, Basic Protocol 3 requires approximately 6 hours. The 














Table 2.1 Example optimized sandwich immunoassay with enzymatic signal amplification 
Description Duration (min)* 
Running buffer 2 
Sample 20 
Running buffer 2 
Secondary antibody 10 
Running buffer 2 
SA-HRP conjugate 10 
Running buffer 3 
4-CN solution 15 
Running buffer 7 














Table 2.2 Common problems and solutions to fluid flow related errors 
Problem Solution 
Air bubbles 
Manually purge the entire flow path 
with buffer 
Seal/fluid junction leak 
Adjust connection, reinforce with 
Teflon tape, or replace connection 
Clog in cartridge top* or 
microfluidic component 
Remove component, sonicate if 
possible, manually purge with 
multiple solvents, and reassemble 
Clog in tubing 
Replace tubing (do not force 
through pumps) or separate from 
set up and thoroughly purge with 
multiple solvents 
Broken seal between 
cartridge top and chip* 
Remove cartridge top, dry, 
carefully reassemble* 
Reduced or loss of signal 
after initial troubleshooting 
Run a reliable test assay 
(Instrument calibration) 
Those problems or solutions marked with an asterisk* are specifically related to the example 


















Figure 2.1 Operating principles for microring resonator sensors. (A) A scanning electron 
microscope (SEM) image shows a 30 μm active microring with an adjacent linear waveguide. (B) 
Light is coupled onto the chip via a grating coupler and propagates down the linear waveguide via 
total internal reflectance. Under resonance conditions, light couples into the adjacent microring, 
resulting in a narrow dip in the transmittance past the microring, which is measured by a 
photodetector after coupled off-chip by a second grating coupler. (C) Shifts in the resonant 
wavelength occur due to changes in the refractive index near the surface of the ring. The schematic 
example depicts a target protein binding to a capture antibody, resulting in a shift of the resonance 
to a longer wavelength. This figure was adapted with permission from Wade et.al., ACS Cent. Sci. 





Figure 2.2 Enzymatically-enhanced assay scheme with the signal response for the example 
system. The assay consists of (1) chip functionalization and protein blocking steps, (2) analyte 
capture from sample, (3) binding of biotinylated tracer antibody, (4) binding of SA-HRP conjugate 
to biotinylated tracer, and (5) enzymatic signal enhancement via oxidation of 4-CN to the insoluble 






Figure 2.3 Schematic representation of the microring arrays on the sensor chip functionalized, in 
clusters of four microrings, with 16 different capture probes in two fluidic channels. The white 



















Figure 2.4 (A) Structure of the silanization agent 3-Aminopropyltriethoxysilane (APTES) and (B) 






















Figure 2.5 Examples of fluid delivery: Genalyte M1 cartridge assembly for a single chip array (A-
B), Genalyte M24 cartridge assembly for 12 arrays with integrated fluidics (C), and an optical 
configuration to monitor a microsphere resonator in a polymeric chamber as described by the 
Vollmer group (D). Panels A and B are adapted with permission from Clinical Biochemistry, 2016, 














Figure 2.6 Example calibration data and the resulting calibration curve for monocyte chemotactic 
protein 1 (MCP-1) and a control. Each data point in the calibration curve shown corresponds with 
an average of at least 23 replicates. Figure adapted with permission from Clinical Biochemistry, 
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Latent tuberculosis infection (LTBI) is estimated in nearly one third of the world’s population, and 
of those infected 10% will proceed to active tuberculosis (TB). Current diagnostics cannot 
definitively identify LTBI and provide no insight into reactivation risk, thereby defining an unmet 
diagnostic challenge of incredible global significance. We introduce a new precision medicine-
based approach to LTBI diagnostics that leverages a high throughput, multiplexed cytokine 
detection technology and powerful machine learning bioinformatics to reveal multi-marker 
signatures for LTBI diagnosis and risk stratification. This approach is enabled through an 
individualized normalization procedure that allows disease-relevant biomarker signatures to be 
revealed despite heterogeneity in basal immune response. Specifically, cytokines secreted from 
antigen-challenged peripheral blood mononuclear cells were detected using silicon photonic 
sensor arrays and multidimensional data correlation of individually-normalized immune responses 
revealed signatures predictive for LTBI status. These results demonstrate the powerful 
combination of multiplexed biomarker detection technologies, precision immune normalization, 
and feature selection algorithms for improving the positive prediction of LTBI status and 
reactivation risk from a relatively simple blood-based assay. 
3.2 Introduction 
Tuberculosis (TB) is a leading cause of mortality worldwide with an estimated 2 billion individuals 
currently infected.1,2 Latent tuberculosis infection (LTBI), an asymptomatic and quiescent disease 
state, is the most common form of TB infection accounting for approximately 90% of the total 
infected population.3 This heterogeneous population contains a majority who maintain a persistent 
lifelong asymptomatic infection and an estimated 10% who will progress to an active, highly 
infectious disease state.4,5 LTBI is treatable with prolonged antibiotic regimens, though potential 
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side effects and increased antibiotic resistance place an impetus on developing diagnostic tools to 
identify patients at the highest risk of reactivation, i.e. the population most likely to benefit from 
therapy.6 In fact, eliminating TB will require improving and expanding diagnostic testing and 
treatment of LTBI in settings where this is not routinely done. The World Health Organization has 
targeted a 75% reduction in TB deaths and 50% reduction in prevalence by 2025. These goals will 
be impossible to achieve without new diagnostically-guided approaches to disease management 
and targeted treatment of LTBI cases with the highest reactivation risk.7  
The tuberculin skin test (TST) and interferon gamma release assays (IGRAs) are commonly used 
for TB and LTBI diagnosis.8 The TST provides a qualitative measure of adaptive immune response 
to non-specific TB antigens exposed intradermally. Though a good measure of TB exposure, the 
TST cannot distinguish LTBI from memory immune response, vaccine-initiated response, and 
non-tuberculous mycobacteria exposure. Moreover, the TST only offers a 1.5% positive predictive 
value for LTBI.2 The in vitro IGRAs, such as the Quantiferon®-TB Gold In-Tube test (QFT) or 
T-SPOT®.TB test, were developed to address the TST specificity issues by quantitatively 
measuring the release of the cytokine IFN- from circulating T-cells in patient blood during 
incubation with TB-specific antigens. This single biomarker is critical for innate and adaptive 
immunity against numerous infections, and therefore it is unsurprising that despite T-cell antigen 
specificity, the IFN- signal does not provide the required differential diagnostic specificity and 
predictive value for the subset of the LTBI population at actual risk of progression to TB.9 In fact, 
IGRAs offer only modest improvements over the TST (2.5% positive predictive value for LTBI),2 
and in high TB burden populations do not show enhanced prognostic power compared to the 
TST.10 Overall, neither assay can differentiate TB patients and subjects with residual 
58 
 
immunological memory from a completely cleared or well-contained infection from those latently 
infected and at risk of TB reactivation.11,12 
While the TST and IGRA fail to clearly inform treatment strategies, both leverage the unique 
response of the immune system to TB antigens. Given the complex network of cytokines involved 
in the immune response in TB and subsequently released after T-cell antigen stimulation, we 
hypothesized that multiple-biomarker signatures may provide a more detailed, disease-specific 
glimpse into a patient’s state of infection and likely outcome.13 However, this deeper view into 
LTBI-specific immune function and memory can only be accessed via multiplexed technologies 
that provide robust and facile inflammatory biomarker profiles underlying nuanced host-pathogen 
responses. 
An enabling array-based silicon photonic microring resonator detection technology is uniquely 
positioned to provide detailed immune profiling on account of high level multiplexing, high assay 
throughput, cost effective and scalable device fabrication, and robust assay performance.14 These 
array-based sensors support resonant optical modes that are sensitive to changes in the local 
refractive index near the sensor surface. By monitoring spectral shifts in the resonance 
wavelengths of sensors functionalized with target-specific capture agents, biomolecules can be 
detected with high sensitivity and specificity (Figure 3.1).15 Many of the key analytical capabilities 
of this technology have been previous reported in the context of detecting a range of protein 
biomarkers in complex matrices with limits of detection at or below limits of conventional 
immunoassays.16,17 
Applied to the detection of cytokines, this technology uniquely supports the rapid immune 
profiling of individual samples under several TB-specific and non-specific antigen stimulation 
conditions to monitor TB-specific immune responses, identify multiple-biomarker LTBI 
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signatures, and stratify LTBI+ subjects according to reactivation risk. This extensive 
immunological characterization allows for a more nuanced approach to understanding the broader 
role of personalized immune function for LTBI status and risk stratification. TB-independent 
immunomodulatory factors enforce unavoidable individual heterogeneities within basal immune 
function thereby limiting immune-based diagnostics. Using a precision medicine approach for 
personalized response normalization reveals previously obscured diagnostic signatures for LTBI 
status and reactivation risk potential. A more thorough interrogation of both general and disease-
specific immune function gleaned through additional controls and off-target stimulation conditions 
begins to expose a more dynamic and diagnostically rich signature of an individual’s 
immunological landscape.  
The resulting high-density data streams generated by this approach are information rich, and 
advanced bioinformatic techniques are required to select those biomarker signatures correlated 
with LTBI status. Critical to bioinformatic-based decision-making are machine learning methods 
that operate by classifying diagnostically important variables particularly when a priori 
identification would not have otherwise been possible.18,19 Furthermore, this feature selection 
process aims to identify all relevant variables versus simply non-redundant features which 
provides the basis for mechanistic understanding beyond typical predictive model building. These 
informatic approaches can also be applied to the construction of an initial diagnostic signature in 
which the number of samples may be significantly smaller than the number of variables.20 Overall, 
machine learning methods provide the basis for practical yet comprehensive biomarker selection 
and LTBI diagnostic signature development.  
Herein, we present an analytical workflow towards the development of a multiplexed cytokine 
signature for LTBI detection and determination of reactivation risk. Multiplexed panels of 
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cytokines secreted from peripheral blood mononuclear cells (PBMCs) following stimulation with 
both TB relevant- and control antigens were measured from a pool of 50 subjects recruited at Mayo 
Clinic, Rochester, MN, including those with positive LTBI status and high risk of reactivation. 
The resulting cytokine levels were bioinformatically compared against established clinical 
classifiers revealing a set of biomarkers that, independent of additional clinical information, are 
promising for determining LTBI status. A richer signature was revealed through individualized 
normalization with off-target and control stimulation conditions correcting for population 
heterogeneities in basal immune function. This workflow and preliminary evidence strongly 
supports the central hypothesis that multiplexed biomarker detection, together with personalized 
immune normalization and feature selection, can reveal new diagnostic signatures to improve the 
positive prediction of LTBI diagnosis from a relatively simple blood-based assay. Patient risk 
stratification based on reactivation potential has substantial implications in terms of identifying 
LTBI positive subjects that are most likely to benefit from therapeutic intervention, and therefore 
this development suggests new biomarker-based strategies for targeted TB management. 
3.3 Results 
Immune cell stimulation and multiplexed sensor for cytokine profiling. We developed an 
experimental workflow to quantitatively measure multiplexed cytokines from stimulated PBMCs 
for the diagnosis of LTBI. The general workflow for cytokine profiling is outlined in Figure 3.2. 
PBMCs isolated from whole blood were stimulated under five different conditions: CFP-
10/ESAT-6 (TB-specific peptides), purified protein derivative (PPD—TST antigen), Candida 
albicans (off-target control), anti-CD3 antibody (pan-T-cell stimulating positive control), and cell 
media (negative control). Supernatants (35-350 μL) from the stimulated PBMCs were analyzed 
for cytokine concentrations on the microring resonator array platform by flowing across a pre-
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functionalized sensor array (Figure 3.3) loaded into a fluidically integrated cartridge of 12 
individual sensors (Figure 3.4a). The array-based, microring sensors support resonant optical 






where λ is the wavelength of light, m is an integer, r is the radius of the microring, and neff is the 
effective refractive index sampled by the resonant optical mode. By selectively functionalizing 
microring sensor elements with target-specific antibody capture agents, analyte binding-induced 
changes in neff are detected as shifts in resonance wavelength () with high sensitivity and 
specificity. A 45 min on-chip enzyme-enhanced, multiplexed sandwich immunoassay approach16  
(Figure 3.5) begins with surface functionalized capture antibodies binding target protein from 
supernatant samples. The bound analyte is then recognized by target-specific biotinylated tracer 
antibodies and then streptavidin conjugated horseradish peroxidase enzyme. Enzymatic 
conversion of soluble 4-chloronaphthol to the insoluble precipitate 4-chloronaphthon then gives a 
dramatic enhancement in resonance shift that is related to the concentration of the target in the 
supernatant solution. Concentrations of each cytokine were determined by comparing the signal 
response against a calibration curve generated for each target analyte. 
Multiplexed assay development and characterization. Commercial antibody pairs for each 
target were selected and validated for optimal performance, and the response of each calibrated 
(Table 3.1). Recombinant proteins for each target were prepared as a cocktail, diluted from 50 
ng/ml to 1.6 pg/ml (calibration range was protein dependent), and analyzed in running buffer. The 
calibration range was empirically determined to cover the saturation of the signal to below the 
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limit of detection (LOD) when including the blank measurement (running buffer only). LODs for 
each target ranged between 0.5 to 65 pg/ml and the limits of quantitation (LOQ) from 2 to 200 
pg/ml (Table 3.2). These values were calculated with the averaged calibration data (N=3 chips) 
each containing redundantly functionalized microrings. To minimize variance, the assay was 
recalibrated after running approximately one third of the samples. Calibration curves for each 
target, averaged across three calibration processes collected throughout the study and including 
different antibody lots and sensor array batches, are shown in Figure 3.6. 
Multiplexed microring measurements of cytokine secretion for each of the five different 
stimulation conditions on a representative PBMC sample is shown in Figure 3.7. To demonstrate 
assay precision, biomarker levels were determined using three different sensor chips each 
containing at least three redundantly spotted microrings per array. Results show consistent 
responses with coefficients of variation (CV) at or below 10% across multiple sensor chips, with 
redundantly spotted sensors on the same chip having CVs near 3%. For a subset of patients, the 
cytokine levels determined with the microring array were compared against multiple, single-
analyte ELISAs and found to be in good agreement for each target and across all five stimulation 
conditions (Figure 3.8). 
Clinical Sample Analysis. The research subject pool (Table 3.3) consisted of 50 individuals who 
were screened for TB and evaluated for LTBI using standard of care diagnostic tests, including 
both TST and QFT. Positive TST and QFT results were reported for 38% and 10% of the subjects, 
respectively. These results were considered along with CDC guidelines allowing for individual 
classification according to LTBI diagnoses and risk of reactivation.21-23 This process required 
careful evaluation of medical history, potential exposure to TB, and clinical assay results. The 
LTBI designations included positive LTBI per CDC recommendations (CDC+), and strict LTBI 
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diagnosis (Strict+), which required either a positive QFT and a negative TST, or a positive TST 
conversion with a negative QFT along with other risk factors for TB infection (i.e. close TB contact 
or recent immigration from a location with high TB prevalence). The designations for risk of TB 
reactivation were defined as “high-risk” or “low-risk” with risk assessment determined using the 
online TST/IGRA interpreter multidimensional prediction tool (e.g. cumulative score of TB 
reactivation ≥2%) and other relevant clinical and/or laboratory conditions, including 
immunosuppression.24 These designations were used to bin the patients as follows: 20% CDC+, 
24% Strict+, 18% low-risk, and 10% high-risk. 
Stimulated PBMC supernatants from subject samples were tested using the multiplexed microring 
detection panel, and concentrations for each biomarker determined as described above. In addition 
to the absolute target concentrations under each stimulation condition, measured target levels from 
the controls [baseline (media), a potentially immunogenic off-target (Candida), and pan-activating 
positive (anti-CD-3) supernatants] were each separately subtracted from TB-relevant stimulations 
(CFP-10/ESAT-6 and PPD) to control for different basal levels of immune function. This method 
of normalization was implemented to correct for differences in the basal immune state of each 
individual patient. A more limited version of this correction is incorporated into IGRA assays, 
where IFN- release under cell media conditions is subtracted from that of TB antigen-specific 
stimulation conditions.21  
Machine learning feature selection analysis. Analysis with Random Forest based classification 
methods have found utility in computational biomedicine due to their ability to select features from 
high dimensional data streams on the basis of relevance to clinically-defined classifications.25,26 
Boruta, a feature selection method, uses a Random Forest classification algorithm and shadow 
features, which are data that are random by design and act as a threshold above which real features 
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that are truly important emerge.20 This approach iteratively removes biomarkers that do not show 
any statistical correlation with specific LTBI related diagnoses, while retaining all features having 
any predictive value thereby avoiding premature elimination of relevant features. However, 
features that are definitively important are discriminated from those that the model cannot label as 
unimportant. For this study, important features are indexed as “predictive” while those 
provisionally important are notated as “tentative”. 
Using this method, absolute biomarker levels from stimulated PBMCs were analyzed and feature 
selection revealed several stimulation-specific biomarker signatures that correlated with LTBI 
status (CDC+ and Strict+), as well as “high” and “low” reactivation risk, as shown in Figure 3.9a. 
However, given the high density of cytokine signatures measured under multiple different TB-
relevant and control conditions, the normalization of an individual’s secreted cytokine levels using 
control stimulation levels allows for more nuanced signatures to be extracted. A separate feature 
selection using normalized cytokine levels revealed a richer set of biomarker signatures for the 
aforementioned clinical classifications, as shown in Figure 3.9b. Feature selection using Boruta 
was performed using both the absolute biomarker concentration and control-normalized 
concentrations for additional sample designations including positive TST (TST+) and positive 
QFT (QFT+) included in Figures 3.10-3.11.  
When comparing the absolute and normalized analyses for LTBI+ designations, there were 
consistencies for the predictive features described by CFP-10/ESAT-6 stimulated IL-2 for CDC+ 
and Strict+ samples. In addition, tentative features for CFP-10/ESAT-6 stimulated IP-10 and IFN-
 from the absolute analysis aligned well with similar predictive features from the normalized 
analysis. This internal consistency for a subset of CFP-10/ESAT-6 related features was expected 
considering the stimulation condition should elicit a TB-specific immunological response.13 
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Nevertheless, the personalized normalization with the off-target and control conditions revealed 
many additional predictive features for LTBI designations. Importantly, these new features were 
predominantly TB-relevant stimulation conditions, reinforcing the disease-specificity of the 
predictive features. Furthermore, CFP-10/ESAT-6 stimulated biomarkers normalized by Candida 
and CD3 stimulation response revealed unique predictive features for CDC+, Strict+, and high-
risk that would not have been otherwise identified from a less detailed stimulation assay, such as 
QFT.  
Feature selection from the precision normalized data input revealed an expected consistency 
between CDC+ and Strict+, with two additional predictive features for Strict+. The designations 
are nearly mutually inclusive, with CDC+ requiring no detectable presence of TB bacteria and a 
positive TST or QFT, and Strict+ requiring either a positive QFT and TST, or a positive TST 
conversion with a negative QFT along with additional TB infection risk factors. Interestingly, the 
Strict+ designation contained two additional biomarkers, CCL4 and IL-23, which were uniquely 
revealed only by personalized normalization and exclusive to this LTBI designation relative to all 
others (Figure 9b).  
The features correlating with high and low risk were generally consistent when using absolute or 
normalized cytokine levels, revealing IL-2, IP-10, and IFN-. Both analyses also displayed 
orthogonal features between high- and low-risk designations. Relative to the other LTBI- and TB- 
related designations, the risk categories have the fewest predictive features; however, this is likely 
due to the limited number of subjects within these two subsets of the total LTBI+ population in 
this study. Nevertheless, the orthogonal nature of biomarker features for reactivation risk 





LTBI is a persistent global health problem that is currently not well-served by the available clinical 
diagnostic methods to detect LTBI and assess potential risk for TB reactivation. Current 
immunodiagnostic tools rely upon relatively oversimplified assays of immune response to TB-
specific antigen challenge, and unsurprisingly their positive predictive value for LTBI, particularly 
in high TB burden regions, are suboptimal. Given the complex networks of cytokines that regulate 
both innate and adaptive immune responses in TB, a deeper understanding of the immunological 
profile of latent infection and disease reactivation might be gleaned through a multiple-biomarker 
diagnostic approach. To date, very little work has been done to develop a robust integrated 
diagnostic workflow for the identification of key biomarkers for personalized reactivation risk 
assessment.9 Recent studies have identified potential alternative biomarkers for discriminating 
active TB from LTBI, but this is often completed with traditional protein detection methods 
following (QFT) assays, which offer limited stimulation and sample conditions.27,28 Additionally, 
there has been little success in stratifying patients according to reactivation potential, in part due 
to the limited capacity to profile panels of biomarkers from multiple stimulation conditions with 
sufficient throughput to access a more comprehensive immunological profile. 
To this end, we developed a multiplexed cytokine detection assay based upon high density arrays 
of silicon photonic microring resonators. Attributes of this technology include its intrinsic 
scalability and amenability to multiplexing, both of which are products of the robust and well-
established semiconductor fabrication methods. Using this platform, we developed and validated 
a 7-plex cytokine detection panel applied to LTBI. The microring resonator assay exhibited good 
dynamic range, limits of detection, and reproducibility, and correlated well with single-plex 
ELISA assays. This proof-of-concept study demonstrated that this diagnostic technology 
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accurately detected and quantified concentrations of seven cytokines secreted from patient-derived 
PBMCs after stimulation with TB-relevant and control antigens and, when combined with a 
powerful feature selection approach, revealed individually-normalized immune signatures that 
correlated to LTBI status and risk of reactivation. 
Using a Boruta feature selection method, absolute and normalized cytokine levels were found to 
be predictive for LTBI-relevant clinical designations under proper stimulation conditions. Of 
highest potential diagnostic relevance, IFN-, IP-10, and IL-2 correlated with Strict+, CDC+, and 
high-risk LTBI designations. IFN- has been the sole biomarker for TB diagnostics since the 
introduction of the IGRAs.29,30 IP-10 (chemokine ligand CXCL10) is secreted by antigen 
presenting cells upon stimulation with cytokines such as IFN-, TNF-α, and IL-2, and displays 
similar dynamics to IFN- but is often found at higher concentrations.31-33 IP-10 has also been 
shown to correlate strongly with LTBI risk34 and to significantly improve sensitivity for active TB 
when combined with IFN-ɣ detection.35,36 An increased detection rate for TB has been observed 
when measuring a combination of cytokines, particularly IP-10 and IFN-, likely due to otherwise 
missing a false negative outcome due to occasional down-regulation of a single cytokine.37,38 A 
recent small study reported IFN-, IP-10, and IL-13 ratios of TB-antigen to mitogen levels in 
plasma of the QFT platform to discriminate LTBI from TB.39 IL-2 secreted from the stimulation 
of CD4 T-cells40 has shown similar promise for discriminating LTBI from active TB41 and 
diagnosing active TB in pediatric applications.41,42 
The central aim of this study was to determine whether a personalized approach to immunological 
normalization could help reveal new multi-biomarker signatures for LTBI diagnosis and 
stratification of reactivation risk. By employing a precision medicine approach to correct for 
inevitable immunological heterogeneities between individuals, we hoped to reveal a more dynamic 
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and diagnostically rich signature of the immunological landscape. Furthermore, by identifying 
additional relevant features using machine learning methods, we would eventually hope to 
elucidate immunological changes that accompany reactivation.  
The potential for increased immunological nuance via normalized biomarker secretion was first 
observed by the increased number of predictive features revealed through the Boruta feature 
selection for the normalized concentration analysis relative to the absolute concentration analysis. 
Upon closer examination of the TST+ predictive features, the absolute analysis reveals more 
predictive and tentative features, but half of them are unrelated to the TB-specific stimulations. 
Given the high false positive rate associated with the TST,2 the presence of some non-specific 
predictive features is perhaps expected. However, the normalized analysis reveals a similar number 
of relevant features that are all TB-related, with half normalized by non-traditional stimulation 
controls (anti-CD3 and Candida). The QFT+ results also benefitted from the normalized feature 
selection with an additional two predictive features revealed. While neither predictive feature was 
related to IFN- secretion, the dynamics of IP-10 are known to be similar to IFN-, but at much 
higher biomarker concentrations.  
The CDC+ and Strict+ designations, which are important LTBI+ diagnoses, revealed predictive 
features for the absolute concentration analysis for only IL-2, while IP-10 and IFN- related 
features were either found to be tentative or entirely unimportant. A more detailed signature was 
exposed with the normalized analysis, defining LTBI-relevant stimulations of IFN-, IL-2, and IP-
10 normalized by the negative and positive controls. The Strict+ designation included an additional 
two features related to IL-23 and CCL4. CCL4 is a chemoattractant to activated T-helper cells and 
macrophages,43 and increased levels have been correlated with TB+ contacts, suggesting it may be 
better correlated with exposure or latency rather than active TB.44,45  
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When assessing risk stratification, the low-risk designation reveals distinctly orthogonal predictive 
features from the high-risk designation, including media-normalized LTBI-relevant stimulation of 
IFN- secretion—a biomarker/stimulation condition not observed with the absolute analysis. The 
low-risk category also reveals a normalized predictive feature for IFN- that originates from non-
TB-related stimulation conditions; however, the low-risk designation can be characterized by 
patients with more tenuous LTBI diagnoses that may be correlated with a more heterogeneous 
immunological profile.4,11 The high-risk designation, additionally defined by risk factors beyond 
an LTBI+ status, was uniquely characterized by the IP-10 and IL-2 TB-relevant stimulation 
normalized by the Candida stimulated response. This is noteworthy because the mechanism for 
reactivation, while not well-defined, is thought to be affected by overall immune response. 
Therefore, immune response to a non-TB, fungal pathogen might provide insights into overall 
immune fitness that is somehow linked to risk of reactivation. The interplay between general 
immune response and reactivation risk is best illustrated by two characterized mechanisms for 
reactivation: co-infection with HIV and therapeutic neutralization of tumor necrosis factor. Both 
reactivation mechanisms result from compromised immune function and advantageous 
proliferation of TB.3,5 By assessing and normalizing to the personalized immune response using 
control and off-target antigens, a better glimpse into general immune response may be gleaned and 
integrated into a more comprehensive reactivation risk assessment.  
In conclusion, we developed and validated a multiplexed immunodiagnostic approach toward 
diagnosis of LTBI and stratification of reactivation risk that relies entirely upon secreted biomarker 
signatures from a simple in vitro assay. Multiplexed cytokine detection from within patient-derived 
samples of TB-related antigen exposure was performed using a silicon photonic platform that 
showed robust analytical performance. Machine learning, feature selection approaches were used 
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to reduce this data-dense sensor output to identify specific biomarker signatures correlative with 
LTBI status and reactivation risk. The biomarkers IFN-, IP-10, and IL-2 appear as particularly 
promising markers for assessing LTBI status and TB reactivation risk when considered in light of 
comprehensive stimulation conditions and precision normalization for heterogeneities in basal 
immune response. Taking advantage of the multiplexing capacity, scalability, and high throughput 
capabilities of this technology, this original biomarker panel will be expanded and applied to a 
larger research subject cohort. Moreover, the initial group of biomarkers will serve as the basis for 
building and evaluating a composite cytokine-based, multi-marker signature predictive for LTBI 
diagnosis and reactivation. More generally, the initial success of this overall approach suggests 
that the integration of data-rich biosensing technologies with powerful feature selection 
informatics may lead to new opportunities in inflammatory-based precision disease diagnostics. 
3.5 Materials and Methods 
Instrumentation. Maverick (M24 and M1) optical scanning instrumentation and sensor array 
chips were purchased from Genalyte. The sensor array chip fabrication and optical scanning 
instrumentation have been previously described.14,46 Sensor arrays were batch fabricated to each 
contain 128 individually-addressable active sensing microrings, and four on-chip controls for 
thermal drift.  
The optical properties of capture agent-modified sensors are responsive to biomolecular binding-
induced changes in the local refractive index, as described above. A detailed description of the 
instrumental method for determination of resonant wavelength shifts was been previously 
reported.14 Resonance wavelength shifts are monitored in real-time and reported in units of 
Δpicometers (Δpm). The magnitudes of resonance shifts quantitatively correlate with the 
concentrations of analytes in solution. 
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Reagents. All reagents were purchased from Sigma-Aldrich, unless otherwise specified. 
Bis[sulfosuccinimidyl] suberate (BS3), streptavidin–horseradish peroxidase (SA–HRP) conjugate, 
1-step chloronaphthol solution, and StartingBlock (PBS) Blocking Buffer were purchased from 
Thermo Scientific. 3-Aminopropyltriethoxysilane (APTES) was purchased from Gelest and 
DryCoat assay stabilizer with blocking protein was from Virusys. Antibodies were purchased from 
commercial vendors listed in Table 3.1. The anti-IL-2 tracer antibodies were biotinylated using 
EZ-link NHS-PEG4-Biotin (Thermo Scientific) per manufacturer instructions.  
Sensor Functionalization. Microring array sensor chips from Genalyte were first rinsed in 
acetone for 2 min to remove a protective coating. The chips were then silanized in a 1% APTES 
solution in acetone for 4 min followed by 2 min rinses in acetone and isopropyl alcohol, and then 
briefly rinsed with deionized water and dried under nitrogen. A 2 mM acetic acid solution 
containing 5 mM BS3 crosslinking reagent was then microspotted onto the chip. Antibody 
solutions of 0.25 mg/ml in 10 mM PBS and 5% glycerol were spatially arrayed onto clusters of 
four microring sensors. Each capture probe was redundantly spotted at different locations across 
the array for a total of 8 sensors per target in each fluidic channel (2-channels per chip) and then 
incubated in a humidity chamber for 1 h (Figure 3.3). Chips were then coated in DryCoat and 
transferred to a desiccator at 4 °C for storage.  
Antibody Selection and Validation. Antibody validation, assay optimization, and cross-reactivity 
screening were performed in batches using lower-plexity, manually-spotted sensor arrays. Final 
assays of the entire biomarker panel were performed on arrays functionalized using a robotic 
microarrayer. All hand-spotted chips were analyzed with a Maverick M1 optical scanning 
instrument that utilizes a single sensor array cartridge (Figure 3.4a). and partially integrated fluidic 
delivery. Fully automated analysis of microspotted sensor arrays within a 12-chip, disposable 
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cartridge with integrated fluidic delivery channels (Figure 3.4b) was performed using a Maverick 
M24 instrument.  
Antibody pairs against biomarkers were selected per vendor guidelines with the goal of non-
overlapping epitope targeting. Each antibody pair was validated with recombinant target proteins 
and the entire assay protocol optimized to maximize signal while minimizing reagent consumption. 
Each sandwich pair was confirmed to not cross-react with other antigens in the panel or other non-
specific reagents (i.e. no off-target binding during capture and tracer steps of the assay). Matrix 
contributions were found to be minor in negative control experiments. Furthermore, since analyses 
were based only upon resonance shift from the tertiary signal enhancement step, which first 
required two high affinity and specificity antibody recognition events, contributions from non-
specific matrix adsorption did not influence quantitation. For each protein target, assay 
performance was directly compared with enzyme linked immunosorbent assays (ELISAs) and 
found to be in good agreement. Seven cytokine targets (IFN-, IL-2, IP-10, TNF-, IL-23, CCL3, 
and CCL4) were selected because of their role in the immunological response to TB and potential 
to selectively identify LTBI.13,47 ELISAs having the same antibody pairs as in the microring assay 
were developed in house for each target except for IL-2 (kit purchased from BD Biosciences). 
During method development and validation, the assay for IL-23 had a higher LOD than the other 
targets and this biomarker was often not detected in patient samples as indicated by the assay 
reproducibility and ELISA comparison studies. Furthermore, the informatic analysis described 
below revealed limited predictive utility for this marker.  
Immunoassay procedure. For the Maverick (M24) instrument, 12 chips were pre-assembled into 
a disposable plastic AutoArray with integrated fluidics allowing software-controlled reagent flow. 
Two samples were run simultaneously and up to 24 samples analyzed sequentially without 
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intervention (2 channels/samples per chip). The Maverick (M1) instrument was used exclusively 
for antibody validation. For both instruments, the reagents in the assay were diluted in running 
buffer (PBS-B: 10 mM PBS, 0.5% BSA), loaded into a 96-well plate, and delivered to the sensor 
surface under software control.  
The assay consisted of the following steps: (1) PBS-B rinse (2 min), (2) sample (9 min), (3) PBS-
B rinse (2 min), (4) biotinylated tracer antibody (9 min), (5) PBS-B rinse (2 min), (6) SA-HRP (9 
min), (7) PBS-B rinse (2 min), (8) 4-cholornaphthol (8 min), (9) PBS-B rinse (2.5 min). Buffer 
rinse steps were completed with a 40 μL/min flow rate and all other steps were at 30 μL/min. The 
total assay time was 45.5 min, with two assays performed simultaneously.  
Differences in resonance wavelength measured in buffer before and after the enzymatic signal 
enhancement step were used to quantify target levels in the supernatants of stimulated subject 
samples. Responses measured for a series of standards were fit to a logistic function to generate a 
calibration curve used for cytokine quantitation from supernatant samples. More details regarding 
microring sensor data processing and calibration can be found in Table 3.4.  
Processing of Microring Sensor Data. Microring resonance wavelength shifts were processed 
using Origin 9.1 (OriginLab) as well as a custom program for semi-automated data analysis. The 
difference (net shift) in resonance wavelength measured in buffer before (t=23 min) and after (t=46 
min) the enzymatic signal enhancement step was used to quantify target levels in the supernatants 
of stimulated patient samples. For each target, the presented data represents averaged responses 
from at least three replicate measurements on a single chip. For calibration, sensor responses 
(averaged net shift in units of Δpm) were measured as a function of recombinant target 









𝑝 + 𝐴2 
where A1 is the initial value (Δpm), A2 is the final value (Δpm), x is the analyte concentration 
(pg/ml), x0 is the center value (inflection point, Δpg/ml), and p is the power parameter affecting 
the slope of the linear portion of the fit surrounding the inflection point (Table 3.4). The LOD was 
determined as the averaged signal of the blank plus three times the value of the standard deviation. 
The LOQ was determined the averaged signal of the blank measurement plus ten times the standard 
deviation. 
 Clinical Sample Collection and Stimulation. The study, which was part of a prospective and 
single-center study for LTBI immunodiagnostics, as previously described,48 was approved by the 
Mayo Clinic Institutional Review Board and Olmsted County Public Health Services. All study 
participants signed an informed written consent and were enrolled between October 2015 and 
March 2016. Study subjects included unexposed individuals and subjects with various risk for TB 
infection, including untreated LTBI patients and patients with prior LTBI therapy at low risk of 
reactivation. Risk factors for TB infection, TB progression, and/or TB reactivation were extracted 
through a validated questionnaire and review of medical records. LTBI diagnosis was made per 
CDC criteria and based on TB risk factors, and by prior TST and QuantiFERON®-TB (QFT) 
results.21-23 The “Online TST/IGRA calculator” was also used to estimate the cumulative risk of 
TB reactivation in all subjects.24 
Blood samples were simultaneously obtained for QFT testing (Mayo Clinic Infectious Disease 
Serology Laboratory) and multiplexed cytokine immune reactivity profiling. PBMCs were 
separated by Ficoll gradient centrifugation within 2 hours of blood sampling, and pellets frozen 
with 10% DMSO in liquid nitrogen until immune profiling in batches. Thawed PBMC pellets 
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(viability ≥85%) were stimulated for 40-48 hours with either TB-relevant antigens, including a 
mix of CFP-10/ESAT-6 peptides or purified protein derivative (PPD), or positive and negative 
controls, which included purified Candida albicans antigen (MyBioSource), anti-CD3 antibodies 
(Mabtech), or cell culture media, as previously described.48 Supernatants from stimulated PBMCs 
were stored at -80 C and shipped on dry ice for cytokine concentration measurements by 
individual ELISA and multiplexed microring resonator assays. 
Samples were thawed and vortexed prior to loading into the 96-well plate for microring assays and 
ELISA testing. Each sample was analyzed undiluted and after a 10-fold dilution in running buffer. 
ELISAs were performed to compare against microring-determined cytokine sample 
concentrations. QFTs was performed as recommended by the manufacturer (Qiagen GmbH). A 
cut-off level of IFN- ≥0.35 IU/ml and >50% above nil defined a QFT(+) test. Research laboratory 
personnel were blinded to the results of QFT. 
Feature Selection. A Boruta feature selection model20 was utilized to identify the biomarker 
features associated with LTBI diagnosis. This approach uses a Random Forest classification 
algorithm to iteratively remove features found statistically to be less relevant than random probes, 
known as shadow features. Relevant features are identified as those that have correlations to LTBI 
diagnosis bins that are statistically robust compared with shadow features. The Boruta approach 








Table 3.1 Antibodies and recombinant proteins for protein targets 
Target Role Source* Catalog Number 
IFN-ɣ 
Capture Mabtech 3420-3-250 
Antigen Mabtech BMS303 
Tracer Mabtech 3420-6-250 
IL-2 
Capture BD Biosciences 555051 







Capture BD Biosciences 555046 
Antigen BD Biosciences 551130 
Tracer BD Biosciences 555048 
IL-23 
Capture Mabtech 3450-3-250 
Antigen Mabtech 3457-10 
Tracer Mabtech 3457-6-250 
TNF-α 
Capture BioLegend 502802 
Antigen BioLegend 570102 
Tracer BioLegend 502904 
CCL3 
Capture R&D Systems AF-270-NA 
Antigen R&D Systems 270-LD-010 
Tracer R&D Systems BAF270 
CCL4 
Capture R&D Systems MAB271 
Antigen R&D Systems 271-BME-010 
Tracer R&D Systems BAF271 
*Full Source Information: 
Mabtech, Nacka Strand, Sweden 
BD Biosciences, San Jose, CA 
eBioscience, San Diego, CA 
BioLegend, San Diego, CA 





Table 3.2 Limit of detection and limit of quantitation determined from the protein standard 
curve 
Target LOD (pg/ml) LOQ (pg/ml) 
CCL3 0.5 1.7 
CCL4 2.2 8.1 
IFN-g 4.4 16.7 
IL-2 4.5 16.5 
IP-10 6.0 24.1 
IL-23 66.0 200.4 























Table 3.3 Demographic and clinical characteristics of study subjects 





N (%) 50 (100) 35 (70) 19 (38) 10 (20) 10 (20) 12 (24) 5 (10) 9 (18) 
Female, N (%) 33 (66) 23 (46) 11 (33) 6 (18) 6 (18) 8 (24) 3 (9) 6 (18) 
Male, N (%) 17 (34) 12 (24) 8 (47) 4 (24) 4 (24) 4 (24) 2 (12) 3 (18) 
HCW (%) 26 (52) 30 (60) 10 (38) 5 (19) 5 (19) 6 (23) 2 (8) 5 (19) 
Age (Mean 
years ± SD) 
57 ± 17 61 ± 15 58 ± 18 43 ± 16 43 ± 16 46 ± 17 42 ± 20 48 ± 16 
Group: N (number), HCW (health care worker). Clinical classifications: TST+ = tuberculin skin test positive, 
QFT+ = QuantiFERON®-TB test positive, CDC+ = positive LTBI according to CDC recommendations, 
Strict+ = strict LTBI diagnosis, High Risk = LTBI positive with a high risk of reactivation, Low Risk = LTBI 
















Table 3.4 Logistic fit parameters for the standard curve of each protein target 





x0 (pg/ml) p 
CCL3 0.823 0.999 Value 136.88 9345.70 127.41 0.75 
   SE 30.10 221.57 12.69 0.03 
CCL4 0.527 0.999 Value 197.52 9740.15 406.93 0.83 
   SE 22.11 254.85 36.61 0.03 
IFN-ɣ 0.838 0.999 Value 142.51 9380.10 1226.77 0.77 
   SE 16.33 372.88 165.52 0.03 
IL-2 1.151 0.999 Value 152.93 9315.14 1095.28 0.82 
   SE 20.59 364.48 145.45 0.04 
IP-10 0.565 0.998 Value 162.96 10848.26 1458.26 0.88 
   SE 14.68 657.33 296.60 0.05 
IL-23 1.484 0.998 Value 270.33 8193.03 8191.59 0.96 
   SE 19.48 437.27 1409.34 0.06 
TNF-α 1.211 0.999 Value 143.18 9629.61 1982.81 0.83 
   SE 16.20 543.24 423.63 0.05 




















Figure 3.1 Operating principles for the microring resonator sensors. (a) The microring sensor 
detects changes in the local refractive index by coupling light from an external cavity diode laser 
into a linear waveguide via grating couplers. Light propagates down the linear waveguide via total 
internal reflection and couples into the microring when the resonance condition resulting in a dip 
in transmission past the microring. (b) The resonant wavelength shifts due to changes in refractive 
index near the surface of the ring depicted by a protein binding to a target-specific antibody. This 
binding can be monitored as a function of relative shift over time with the response proportional 







Figure 3.2 Multiplexed cytokine detection scheme toward LTBI diagnosis. (A) Patient PBMCs 
were stimulated with TB specific antigens (CFP-10/ESAT-6 or PPD) and the supernatant collected 
for analysis. (B) Supernatants were then flowed across a sensor array functionalized with target-
specific capture probes. Twelve chips containing 24 distinct fluidic channels are contained in a 
single-use AutoArray. (C) Resonance wavelength shifts observed from an enzymatically enhanced 
immunoassay correspond to concentrations of each target. Error bars represent ±SD (n≥3 technical 
replicates). (D) Resonance wavelength shifts can be converted to concentrations and analyzed 




Figure 3.3 Sensor array capture spotting map. The 4 x 6 mm silicon photonic chip contains 132 
active rings and 4 thermal controls. Active rings are arranged in clusters of 4, and the chips contains 
32 clusters of rings. The chip schematic shows the layout for antibody spotting using a robotic 











Figure 3.4 Maverick instrument cartridge set up.  (a) For the Maverick (M1) instrument used 
exclusively for antibody validation, single chips were loaded into a base cartridge holder, topped 
with a 0.007″ laser cut Mylar gasket, and a Teflon cartridge top. Solutions were delivered to the 
cartridge assembly via a 0.01″ ID Teflon tubing screwed directly into the cartridge top. (b) For the 
Maverick (M24) instrument, 12 chips were pre-assembled into a disposable plastic fluidic 
integrated AutoArray.  The fluidic gasket aligns two fluid channels and two fluidic tubes per chip 
for a total of 24 experiments per AutoArray.  The fluidic tubes are automatically bent 90 degrees 
to align with a 96-well reagent plate and the reagent uptake is fully programmed and executed by 
the instrument software.  Two samples (or 1 sensor array chip) are run simultaneously and up to 









Figure 3.5 Enzymatically-enhanced sandwich immunoassay scheme. Multiplexed protein 
detection in PBMC supernatant is a 48-minute assay consisting of multiple binding steps and 
enzymatic signal enhancement. The assay consists of (1) chip functionalization and protein 
blocking, (2) analyte capture from post-stimulated PBMC supernatant, (3) binding of biotinylated 
tracer antibody, (4) binding of SA-HRP conjugate to biotinylated tracer, and (5) enzymatic signal 
enhancement via oxidation of 4CN to the insoluble product, 4-chloronaphthon. The data trace from 
protein binding (black), off-target (blue), and control in 10 mM PBS-B buffer. Error bars represent 









Figure 3.6 Calibration of the multiplexed sensor array. Serial dilutions of recombinant protein 
standards for seven cytokine targets were used to assess the performance across approximately 
five orders of magnitude in 10 mM PBS-B buffer. The net shift from the enzymatic amplification 
was used as the readout. The signal is an average of three separate calibration curves collected 
throughout the patient sample analysis time. Error bars represent ±SD (n3). The data was fit to a 









Figure 3.7 Chip array reproducibility using supernatant from stimulated patient PBMCs. The 
supernatant from PBMCs stimulated with five different conditions was measured. Each 
measurement represents results from three different chips with n≥3 functionalized sensors for each 
target. The error bars represent ±SD. CVs for all targets are ≤10%. IL-23 is not shown due to 
consistently low measured concentration. 
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Figure 3.8 Validation of microring resonator (MRR) results with ELISA. Each protein target was 
analyzed from stimulated PBMC supernatant with ELISA and the MRR and the quantitative results 
compared.  Error bars represent ± SD (n=3 for ELISA and n≥3 for MRR).  IL-23 and IL-2 are not 









Figure 3.9 Feature selection results from post-stimulated PBMC supernatant for the absolute 
biomarker concentrations (a) and the control and off-target normalized biomarker concentrations 
(b). The dark blue shaded features represent those determined predictive, the light blue shaded 
features represent those determined tentatively predictive (promising but inconclusive), and the 
unshaded (white box) features represent those determined as unimportant for the classification of 
LTBI and risk of reactivation.  The clinical classifications are described as: CDC+ = positive LTBI 
according to CDC recommendations, Strict+ = strict LTBI diagnosis, High Risk = LTBI positive 




Figure 3.10 Feature selection results from absolute biomarker concentrations from post-stimulated 
PBMC supernatant. The dark blue shaded features represent those determined predictive, the light 
blue shaded features represent those determined tentatively predictive (promising but 
inconclusive), and the unshaded (white box) features represent those determined as unimportant 
for the classification of LTBI and risk of reactivation. The clinical classifications are described as: 
LTBI- = negative for LTBI, TST+ = tuberculin skin test positive, QFT+ = QuantiFERON-TB test 
positive, CDC+ = positive LTBI according to CDC recommendations, Strict+ = strict LTBI 
diagnosis, High Risk = LTBI positive with a high risk of reactivation, Low Risk = LTBI positive 





Figure 3.11 Feature selection results from control and off-target normalized biomarker 
concentrations from post-stimulated PBMC supernatant. The dark blue shaded features represent 
those determined predictive, the light blue shaded features represent those determined tentatively 
predictive (promising but inconclusive), and the unshaded (white box) features represent those 
determined as unimportant for the classification of LTBI and risk of reactivation.  The clinical 
classifications are described as: LTBI- = negative for LTBI, TST+ = tuberculin skin test positive, 
QFT+ = QuantiFERON-TB test positive, CDC+ = positive LTBI according to CDC 
recommendations, Strict+ = strict LTBI diagnosis, High Risk = LTBI positive with a high risk of 
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Sepsis, a life-threatening syndrome defined by significant physiological and biochemical 
dysregulation in response to infection, is a leading cause of death and critical illness worldwide. 
Current strategies for prognosis and treatment rely on nonspecific physiological abnormalities, but 
diagnostics based on more specific cellular mechanisms might provide an opportunity for directed 
intervention. Because of the complex pathophysiology of the immunological response to sepsis, 
gold-standard biomarkers to characterize primary pathogens and sepsis progression are lacking. 
We introduce a multiplexed, temporally resolved approach to characterizing the immune response 
in septic patients. This approach is enabled by rapid quantification of plasma proteins using a 
multiplexed silicon photonic microring resonator chip array. Measurements were collected over 
the course of treatment in the intensive care unit, and results were assessed by bacterial gram status, 
survival, and sepsis severity. The results demonstrate intriguing temporal dynamics in systemic 
inflammatory biomarker levels that might provide utility in characterizing sepsis outcome and 
potentially therapeutic response.  
4.2 Introduction 
Sepsis is a life-threatening condition that is among the most common causes of death for patients 
in the intensive care units, with mortality rates near those for myocardial infarctions.1,2 Sepsis 
mortality has decreased with improved treatment strategies, but an aging populous will lead to an 
overall increase in total number of sepsis related deaths in the United States.2-4 Sepsis treatment 
places a significant financial burden on the healthcare system, with an estimated $20 billion in 
spending for sepsis-related hospital care in the United States.5  
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Sepsis is defined as life-threatening organ dysfunction caused by an abnormal host response to an 
infection. A subset of those with sepsis proceed to septic shock which, characterized by profound 
circulatory, cellular, and metabolic abnormalities, significantly increases mortality.6,7  Though the 
definitions for sepsis and septic shock currently rely on clinical evaluations, including the 
Sequential Organ Failure Assessment (SOFA), the underlying mechanisms for this clinical 
presentation may be more insightful for diagnosis and treatment.8  Central to aberrant pathogen 
response is inflammatory dysregulation, which unabated leads to multi-organfailure.9  
Considerable effort has been directed towards methods for rapid pathogen identification and the 
identification of diagnostic biomarkers, but a gold standard has yet to emerge.1,10   
At this time, blood culture methods provide some of the most actionable information for clinicians; 
however, the time to result often exceeds 8 h. Additionally, many times additional genomic 
characterization, via PCR or sequencing, is needed to definitively identify the pathogen in a way 
that informs treatment.11,12 More importantly, nearly 50% of blood cultures from septic patients 
return as culture-negative.13  Because of the lengthy assay time and potentially inconclusive nature 
of blood cultures, clinicians often resort to broad spectrum antibiotics, which can lead to 
unintended side effects, inadequate elimination of the pathogen, and increased antibiotic 
resistance.14 As such, novel diagnostics are critical to characterizing bacterial sepsis and directing 
treatment.  
There is a continually growing literature characterizing the predictive value of biomarkers for 
diagnosing sepsis and monitoring progression.15,16  Many of the well-studied biomarkers are 
immunological proteins triggered by the host immune response in sepsis.7,17-19 Procalcitonin 
(PCT), a prohormone for calcitonin, is produced in response to bacterial infections and strongly 
correlates with infection severity.  One of the few clinical biomarkers demonstrated to have utility 
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for sepsis, PCT provides insight into early infection and response to pathogen targeted treatment.1  
However, as a single biomarker, PCT provides limited insight into sepsis severity and prognosis. 
Additional biomarkers describing the pro- and anti-inflammatory response have been studied, but 
the consensus on clinical utility is restricted due to the significant heterogeneity of the 
inflammatory response over time, particularly when considering additional comorbidities.18  To 
better understand the critical trends for predicting prognosis and treatment response, a more data 
rich and personalized approach to biomarker monitoring is required.   
Current technologies employed for protein biomarker measurements are the gold standard enzyme 
linked immunosorbent assay (ELISA) and bead-based multiplexed protein detection methods, 
such as Luminex. Both assays provide quantitative protein analysis in complex matrixes, but 
necessitate long incubation times and numerous manual steps. Furthermore, ELISA typically 
measures only a single biomarker at a time. Despite these challenges, much of the current sepsis 
biomarker literature is completed using these sensitive protein detection tools which are at present, 
difficult to integrate at clinical time course requirements.16,18    
As an alternative to the existing protein detection techniques, our group has developed a silicon 
photonic microring resonator platform that leverages robust and cost-effective semiconductor 
fabrication to create sensitive and multiplexable biomolecular sensor arrays.20  Microring 
resonators are chip-integrated optical microcavities that support the propagation of optical modes 
that are extremely sensitive to the local refractive index environment. Specifically, photons of a 
particular wavelength propagate in the microring cavity under a tightly held resonance condition 
described by:  
𝑚𝜆 = 2𝜋𝑟𝑛𝑒𝑓𝑓 
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where m is a non-zero integer, λ is the wavelength of light, r is the radius of the resonator, and neff 
is the effective refractive index sampled by the optical mode. The resonance shifts at specific 
wavelengths are monitored for individual sensors. When functionalized with target-specific 
capture agents, binding can be monitored with high sensitivity and specificity.21  This technology 
has been applied to detect several different classes of biomarkers in physiologically complex 
samples.22,23  Many of the key developments, including enhancement strategies have been 
previously reported including the ability to detect a range of biologically relevant proteins at or 
below the detection limits of commercial immunoassays.24,25 
To monitor the temporal dynamics of a broad range of cytokines, we have developed a 12-plex 
cytokine assay capable of analyzing plasma samples in 45 min. By employing a robust and rapid 
assay design, we can temporally monitor multiple key cytokines within the clinical timeframe of 
traditional physiological tests. The 12 protein markers, representing immunologically relevant 
markers for sepsis onset and progression (Table 4.1), are  tumor necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), 
interleukin-18 (IL-18), interleukin-1 receptor antagonist (IL-1Ra), monocyte chemoattractant 
protein-1 (MCP-1), procalcitonin (PCT), soluble tumor necrosis factor receptor-1 (sTNFR1), 
granulocyte colony stimulating factor (G-CSF), and interferon-γ (IFN-γ).  We demonstrate the 
ability to sensitively quantify all 12 biomarkers from time course blood draws of 17 subjects who 
were admitted to the ICU for bacterial sepsis. The biomarker concentrations at various time points 
were evaluated for potential to discriminate subject pools based on bacterial gram status, survival, 
and sepsis severity. While unique biomarker relationships were uncovered, the richer temporal 
data provided insight into the role of biomarker dynamics for sepsis diagnostics. Simultaneously 
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evaluating multiple biomarkers and their dynamics over time demonstrates the potential of 
immunological trajectory as a tool for improved prognosis and treatment evaluation.  
4.3 Results and Discussion 
Few of the existing biomarker detection technologies can address the numerous challenges 
presented with sepsis. Understanding the dynamic immunological state accompanying sepsis 
requires rapid multi-protein monitoring over the duration of the pro-and anti-inflammatory 
responses. This multiplexed temporal dynamic profile may yield a more personalized, actionable 
information for diagnosing and treating sepsis. Because no single biomarker to date has yielded 
gold-standard results for sepsis diagnoses, multiplex biomarker characterization has been the focus 
for novel sepsis related measurements.1 Here, we describe a robust multiplex technology with 
integrated liquid handling and high-throughput complex sample processing. With this 12-plex 
assay, we can analyze two samples every 45 minutes which is well within the interval times of 
clinical sample collection for the duration of each subject’s ICU stay. The results of the 12-plex 
immunological protein screening are rich subject specific temporal dynamics correlated with 
sepsis severity, gram status, and survival.  
Multiplex assay overview. To profile the broad immunological response of sepsis, twelve 
biomarkers were selected representing pro- and anti-inflammatory response as well as additional 
key proteins in sepsis diagnosis (Table 4.1). Once integrated into a 12-plex array, the sensors were 
calibrated and evaluated for matrix effects. The robust response at 10% plasma allowed for plasma 
sample analysis with less than 20 μL of plasma. The enzyme-amplified multiplexed sandwich 
assay approach began with pre-functionalized chips containing identically arrayed fluidic channels 
containing 13 different capture antibodies including 1 control (n=4 sensors per capture antibody, 
per channel). The analyte is then flowed over the surface for capture followed by recognition by 
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biotinylated tracer antibodies. The addition of streptavidin conjugated horseradish peroxidase (SA-
HRP) leads to enzymatic enhancement by the oxidation of 4-chlornaphthol (4-CN) to 4-
chloronaphthon, an insoluble product, which when deposited on the microring surface elicits a 
significant resonance shift related to the solution biomarker concentration (Figure 4.1).  
Calibration and plasma analysis. The complete assay was calibrated by analyzing a cocktail of 
recombinant proteins diluted in running buffer (10 mM PBS, 0.5% BSA) from 0.24 pg/ml-800 
ng/ml (range was protein dependent). Using the enzymatically amplified signal from multiple 
concentrations for quantification, calibration curves (Figure 4.2) were constructed using a logistic 
function (n=4 sensors per target/concentration). Limits of detection (LOD) and quantification 
(LOQ) were calculated using the average of three calibration curves (n=3 chips per concentration) 
for each marker and range from 2.0-1074.5 pg/ml and 8.9-3407.3 pg/ml respectively (Table 4.2). 
For subject plasma analysis, samples were diluted 10x in running buffer and concentrations for 
each target were determined using the enhanced signal response (n≥3 sensors per target) and 
averaged calibration.  
Clinical sample analysis. The research subject pool consisted of 17 individuals who were 
admitted to the ICU with bacterial sepsis. Subjects were diagnosed with sepsis and treated 
according to traditional clinical recommendations. When clinical tests requiring a blood draw were 
ordered throughout the duration of the ICU stay, plasma from each time point was collected and 
analyzed using the 12-plex biomarker panel. Using the quantitative biomarker levels, clinical 
evaluation, and additional clinical assay results, subjects were divided into designations describing 
sepsis severity, bacterial gram status and survival. Sepsis severity was documented for each subject 
as either “severe sepsis and septic shock,” the most severe sepsis diagnosis category, or “shock” 
and “septicemia” binned together as a less severe sepsis diagnosis. Bacterial gram status was 
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described as either a gram-positive or gram-negative bacterial infection based on clinical 
evaluation and blood culture results. Survival was determined based on the subject outcome at the 
end of the ICU stay regardless of duration. Statistical evaluation of the significance of each 
biomarker for each designation was completed for the first three time points of each subject’s ICU 
stay regardless of time interval. Time 1 represents “time zero” or the first time point for each 
subject upon admission to the ICU. Time 2 is an average of 10.3 h (3.7-21.6 h) after time zero and 
time 3 is an average of 20.8 h (7.7-45.8 h) after time zero. While ranges of time for each time point 
vary significantly, they represent the first 8-48 h which is typically at or before positive culture 
results are available and within a critical timeframe for clinical decision making for sepsis.14   
Discriminating bacterial gram status. Despite fundamental differences in gram-positive and 
gram-negative bacterial pathogens and the apparent differences in host response, gram status for 
bacterial sepsis has been correlated to numerous immunological biomarkers with little literature 
consensus.26-28 Current clinical recommendations are also similar for both pathogen types despite 
the potential to characterize pathogen gram status as largely different disease states.29 To further 
differentiate immunological host response for pathogen gram status, we observed good 
discrimination (p=0.027) between gram-positive and gram-negative subjects at time point 3 for 
IL-18 concentrations (Table 4.3). In particular, IL-18 levels are elevated in gram-positive 
infections, a relationship that has been previously demonstrated.30  IL-18 is a pro-inflammatory 
cytokine related to Th1 and can induce cell-mediated immunity in response to microbial products 
including lipopolysaccharide.  IL-18 plays a unique role in pathogen response as well as more 
generally inducing IFN-ɣ and related pro-inflammatory release.31 Furthermore, this distinction 
would not have been evident in the first two time points, demonstrating the utility of temporal 
biomarker monitoring.   
105 
 
Discriminating survival status. Rapidly predicting the potential outcome of a septic patient has 
tremendous clinical potential, particularly if the correlated biomarker response can be mitigated 
with therapeutic intervention.32  All of the biomarkers identified as relevant to discriminating 
survival outcome have been good predictors of mortality with sepsis in the literature.33,34  Table 
4.4 describes the biomarkers relevant for discriminating survival over the first three time points.  
Each time point reveals at least one additional marker discriminating survival, highlighting the 
critical nature of multiplex biomarker and temporal dynamic profiling. For the first time point, IL-
10 is the only marker with relevance to survival (p=0.047) and as a significant anti-inflammatory 
cytokine, its persistent elevated release is a key risk factor for both sepsis severity and death.35  
Increased IL-10, as seen in time points 1 and 2 for the non-survivors, may lead to profound 
immunosuppression due to its primary role in minimizing production of critical pro-inflammatory 
cytokines.10  The second time point also shows an increase in biomarkers discriminating survival 
with the addition of IL-8 (p=0.032), PCT (p=0.032), and sTNFR1 (p=0.032).  IL-8, a chemokine 
that attracts neutrophils to sites of inflammation, has been correlated to poor outcome when its 
initial levels are elevated in septic patient samples, similar to what is observed in this study.34,36 
Although elevated IL-8 only discriminates survival at time point 2, increased PCT and sTNFR1 
discriminates survival at time points 2 and 3.  PCT  has long been an established biomarker for 
diagnosing and monitoring sepsis as it is ubiquitously involved in response to bacterial 
infections.1,32,37  Like IL-10, sTNFR1 plays a central role in the anti-inflammatory response, which 
has been demonstrated more so than pro-inflammatory signaling as predictive for mortality in 
sepsis patients.36,38,39 Unsurprisingly, IL-1Ra (p=0.047) a potent IL-1 receptor antagonist, appears 
relevant at time point 3, joining sTNFR1 as critical anti-inflammatory markers elevated in the non-
survivor sepsis cohort.  Time point 3 also reveals IL-6 (p=0.021), an interleukin associated with 
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both pro- and anti-inflammatory response mechanisms that has been associated with severe sepsis 
and a high risk of mortality at increased levels.40,41     
The biomarker relationship to survival over time exemplifies the complex cytokine dynamics and 
difficulty in identifying both which markers to target and the ideal measurement point. To further 
illustrate the temporal dynamics of those biomarkers correlated to discriminating survival, Figure 
4.3 shows two subjects with the same bacterial gram status and sepsis severity, but different 
survival outcomes. Trajectory differences in IL-1Ra, sTNFR1, PCT, and IL-6 are evident with 
sustained elevated levels or persistent increases over the first 13 h for the non-survivor (Figure 
4.3b).   
Discriminating sepsis severity. Although bacterial sepsis is generally defined as a series of 
dysregulated physiological responses to an uncontained bacterial infection, only a subset of those 
with sepsis proceed to severe sepsis with septic shock defined by profound cellular and metabolic 
aberrations and increased mortality.8,42  Early and robust discrimination of these populations may 
provide distinct immunological profiles to better understand each sepsis state and potential 
treatment strategies.  There are multiple clinical metrics to define the state of sepsis, often 
incorporated into hospital records using International Classification of Diseases.42  Using this 
information and accompanying descriptions from the hospitalization records, subjects were 
divided into “severe sepsis plus septic shock” and “sepsis” bins, the latter defined by both “shock” 
and “septicemia” in hospitalization records.  Table 4.5 describes those biomarkers discriminating 
subjects based on the sepsis severity bins previously defined. Unlike survival, sepsis severity is 
discriminated by several makers in the first two time points and the number of relevant biomarkers 
drops dramatically for time point 3. Multiple time points include relevant elevated levels of IL-
1Ra (p=0.10, 0.047), sTNFR1 (p=0.048, 0.005, 0.010), IL-6 (p=0.005, 0.020), and IL-8 (p=0.015, 
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0.027) defining severe sepsis plus septic shock which has significant overlap with non-survivors 
who shared the same relevant trends. Elevated PCT levels at time points 2 and 3 (p=0.001, 0.002) 
are also relevant for discriminating sepsis severity as well as survival which may be biologically 
related to a persistently uncontrolled bacterial infection. Three additional biomarkers uniquely 
discriminate subjects by sepsis severity: IFN-ɣ (p=0.029) and MCP-1 (p=0.003) at time point 1 
and G-CSF (p=0.048) at time point 2. Elevated levels of both G-CSF and MCP-1 have been 
identified as good predictors of early mortality and well-correlated to organ dysfunction and 
increased sepsis severity.33,34   
Novel to this study are the temporal dynamics of the multiplex biomarker measurements, which 
affords a clearer personalized profile of the immunological response to changes in diagnoses and 
treatment. Figure 4.4 compares two subjects, with consistent bacterial gram status and survival 
outcome, who were initially defined as severe sepsis plus septic shock (time points 1 and 2) and 
after successful treatment were updated to septicemia (hospital record update indicated by vertical 
dashed line). Both subjects show significant decreases in IL-6, sTNFR1, IL-1Ra, G-CSF, and 
MCP-1 over the first three-time points illustrating a potentially successful treatment response. 
Despite the similarities, there are clear and unsurprising differences in subject biomarker profiles 
likely resulting from the heterogenous nature of the individual immunological response in sepsis. 
Establishing causes of patient heterogeneities could potentially be revealed with a larger patient 
pool. 
4.4 Experimental Methods and Materials 
Instrumentation. Concentration dependent measurements were achieved by monitoring 
resonance wavelength shifts using the Maverick (M24) instrument (Genalyte, Inc., San Diego, 
CA) in which 12 sensor array chips were pre-assembled into a disposable plastic array with 
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integrated fluidics. The system includes automated reagent flow and multi-sample analysis with 
two samples running simultaneously (2 fluid channels per chip) and a total of 24 samples per array. 
Sensor array fabrication has been previously described20. Briefly, 4 mm x 6 mm arrays are batch 
fabricated containing 128 individually addressable microrings and an additional four on-chip 
controls for thermal drift correction. The resonance shifts are monitored in near real-time and 
reported in Δ picometers (Δpm). The resonance shifts are directly correlated to the concentration 
of analyte in solution and can be calibrated for concentration determination. The instrumental 
details and methodology for determining the resonance wavelength shifts has been previously 
described in further detail.43 
Reagents. Dulbecco’s phosphate buffered saline was purchased from Sigma-Aldrich (St. Louis, 
MO). Zeba Spin desalting columns (cat. num. 89882), EZ-link NHS-PEG4-Biotin (cat. 
num.21329), 3-aminopropyltriethoxysilane (APTES) (cat. num. 80370), bis[sulfosuccinimidyl] 
suberate (BS3, cat. num. 21585), high sensitivity streptavidin-horseradish peroxidase conjugate 
(SA-HRP, cat. num. 21130), 1-step chloronaphthol solution (1-step CN, cat. num. 34012), and 
StartingBlock (PBS) blocking buffer (cat. num. 37538) were purchased from Thermo Fisher 
Scientific (Rockford, IL). DryCoat assay stabilizer (cat. num. AG066-1) and DryCoat assay 
stabilizer with blocking protein (cat. num. AG044-1) were purchased from Virusys (Taneytown, 
MD). Glycerol (cat. num. BP229-1) was purchased from Fisher BioReagents. Recombinant 
biomarker antigen standards, capture, and tracer antibodies used for the biomarker panel were 
obtained from various companies listed in Table 4.6. All tracer antibodies were purchased as 
biotinylated conjugates except for PCT which was biotinylated using EZ-link NHS-PEG4-Biotin 
(Thermo Fisher Scientific) per manufacturer instructions. 
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Antibody selection and validation. Antibody selection was completed per vendor guidelines with 
emphasis on non-overlapping epitopes (Table 4.6). Cross-reactivity screening was performed for 
each antibody pair using validated recombinant proteins. Notably, the signal used for 
quantification is measured exclusively from the secondary binding step, therefore resonance shifts 
from non-specific adsorption do not contribute to the signal. Additional assay optimization and 
matrix effects was completed to determine optimal dilutions and reagent consumption conditions 
for maximum signal. Each sandwich pair was determined to have minimal cross-reactivity with 
minor signal enhancement on the off-target controls at extreme protein concentrations. Matrix 
effects were negligent at 10x dilution. Therefore, each calibration was completed in buffer and 
each subject sample was analyzed after 10x dilution. Twelve proteins (TNF-a, IFN-g, IL-1b, IL-
6, IL-8, IL-10, IL-18, MCP-1, IL-1Ra, sTNFR1, PCT, and G-CSF) were selected for the panel due 
to their role in the immunological response to sepsis (Table 4.1).  
Sensor functionalization. Sensors used for subject sample analysis and calibration were 
functionalized by Genalyte using a robotic microspotter. The sensor chips were prepared by 
washing with acetone (2 min) to remove a protective photoresist layer, followed by silanization 
with 5% (v/v) APTES in acetone (4 min), and additional acetone (2 min) and isopropanol (2 min) 
rinses. The chips were rinsed with deionized water and dried under nitrogen. A 2 mM acetic acid 
solution containing a 5 mM BS3 crosslinking reagent was exposed to the chip for 3 min followed 
by drying with nitrogen. Chips were then functionalized with 13 different capture antibodies 
(including control) at 0.25 mg/ml containing 5% (v/v) glycerol each arrayed on a specific sensor 
clusters (Figure 4.5) and incubated at rt for 1 h. Each cluster was again microspotted with DryCoat 
containing BSA, incubated for approximately 1 h, assembled into the fluidic cartridge, and stored 
at 4 °C in a desiccator.  
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Immunoassay Procedure. The 12-chip cartridge for the M24 system consists of integrated inlet 
fluidics to draw reagent from a 96-well plate over distinct channels of each individual chip. The 
cartridge design enables continuous analysis of 24 samples without intervention facilitating high 
throughput sample analysis. Each sensor array analysis (2 samples) was completed in 45.5 min. 
Importantly, these samples are fluidically isolated, preventing sample cross-contamination. The 
running buffer for the entire assay was 0.5% BSA in 10 mM PBS. The assay consisted of the 
following steps (duration, flow rate): 1) running buffer (3 min, 30 μL/min); 2) subject samples (2 
min, 40 μL/min, 4.5 min, 20 μL/min); 3) running buffer (1 min, 40 μL/min); 4) biotinylated 
detection antibodies (10 min, 30 μL/min); 5) running buffer (1 min, 40 μL/min); 6) SA-HRP 
conjugate (10 min, 30 μL/min); 7) running buffer (2 min, 40 μL/min); 8) 4-CN (9 min, 30 μL/min); 
9) running buffer (3 min, 40 μL/min).  Each biotinylated tracer was diluted to 2 μg/ml and the SA-
HRP conjugate was diluted to 6 μg/ml. Subject samples were diluted 10x in running buffer prior 
to analysis. 
Patients selection and sample collection. Ethical review of this study was completed and signed 
informed consent was obtained for each participant. Subjects were recruited for this study after 
admission to the ICU with suspected sepsis at Carle Foundation Hospital in Urbana, IL. A total of 
17 subjects were enrolled and included in the data analysis. The enrolled subjects range from 28-
82 years old and are described by survival, gram-positive or negative infection, and sepsis severity. 
Subjects required continual monitoring including regular blood draws for clinical testing therefore 
sample collection had no impact on the standard or timing of care. Blood samples were collected 
for this study throughout the entire ICU stay for each participant. The blood samples were collected 
in lithium heparin-coated collection tubes and centrifuged at 4500 g (6 min, 4°C) to obtain blood 
plasma. Additional plasma after traditional clinical testing were stored at -80°C and transferred to 
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the University of Illinois for multiplex biomarker analysis. Additional time correlated clinical 
information including physiological measurements (e.g. basal temperature, white blood cell 
counts, etc.) and continued diagnosis updates were collected as well.  
Biomarker data analysis. Data analysis was performed using OriginPro 2016 (OriginLab 
Corporation, Northampton, MA). Resonance wavelength differences before and after enzymatic 
signal enhancement were used to quantify each target. To calibrate this measurement, responses 








𝑝 + 𝐴2 
where A1 is the initial value (Δpm), A2 is the final value (Δpm), x is the analyte concentration 
(pg/ml), x0 is the center value (inflection point, Δpg/ml), and p is the power parameter affecting 
the slope of the linear portion of the fit surrounding the inflection point. The resulting fit 
parameters for the average of three different calibration experiments are shown in Table 4.7. The 
LOD was determined as the averaged signal of the blank plus three times the value of the standard 
deviation and the LOQ was determined the averaged signal of the blank measurement plus ten 
times the standard deviation (Table 4.2). The calibration curves represent the average of at least 4 
on-chip technical replicates per concentration of each biomarker. Subject samples were diluted 
10x so the resulting measurement was converted to a concentration and multiplied by 10 to 
determine the final plasma concentration. All resulting concentrations below the calculated LOD 
for a biomarker was treated as zero for additional analyses.  
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Clinical data analysis. Time points for each sample were determined by designating the first 
blood draw in the ICU as time zero. All admission and additional diagnoses were normalized to 
each subject’s time zero. For the statistical analysis, time points 1-3 represent the first three 
samples collected for each patient regardless of the time interval. At each time point, subject 
biomarker data are described by gram-positive (n=8, 47%) or gram-negative (n=9, 53%) infection 
and survivor (n=14, 82%) or non-survivor (n=3, 18%). Additionally, subjects were described by 
admission diagnoses of severe sepsis plus septic shock (n=6, 35%) and shock or sepsis (n=11, 
65%) for time points 1-2 with a shift in diagnoses at time point 3 moving two subjects from severe 
sepsis plus septic shock (n=4, 24%) to shock or sepsis (n=13, 76%). Sepsis severity was assigned 
as a binary determination based on clinical criteria at admission to the ICU and any additional 
sepsis related diagnoses. Severe sepsis plus septic shock was deemed the most severe septic 
diagnosis while all other designations (“shock” and “septicemia”) were considered together as 
“sepsis”. Gram-positive and gram-negative designations were assigned by a clinician based on 
clinical data including positive blood cultures. Concentrations for each biomarker at each time 
point were categorized by each of the previously described clinical designations and assessed using 
Mann-Whitney U-test (statistical significant results evaluated at p=0.05).  
4.5 Conclusions 
Sepsis elicits a complex and often personalized immunological response, necessitating advanced 
diagnostic tools to characterize progression. There has been increased consensus for simultaneous 
monitoring of multiple immune biomarkers over time to illustrate disease trajectory, but few 
protein detection techniques can overcome this clinical challenge. Using a silicon photonic 
microring resonator platform for 12-plex protein measurements provides a rapid and robust assay 
for high-throughput sample measurement. This 45-minute assay provides results from subject 
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plasma within the traditional clinical assay timeframe. This initial study provides promising time 
dependent biomarker relationships to sepsis related classification and prognosis provide clinical 
support for continued sepsis trajectory characterization. Using this 12-plex microring chip-array 
would provide a cost-effective and clinically tractable tool to make these otherwise difficult 


















Table 4.1 Target proteins and general immunological role 











 PCT Correlated to bacterial infection 














Table 4.2 Limits of detection and quantitation calculated from averaged calibrations 
Target LOD (pg/ml) LOQ (pg/ml) 
TNF-α 9.2 33.9 
IFN-γ 20.5 100.6 
IL-1β 13.4 53.0 
IL-6 2.0 8.9 
IL-8 4.3 20.3 
IL-18 22.7 91.0 
MCP-1 8.0 29.3 
IL-1Ra 1074.5 3407.3 
sTNFR1 5.6 23.2 
IL-10 21.2 89.8 
PCT 179.0 618.8 














Table 4.3 Plasma cytokine concentrations: gram-positive versus gram-negative infection 
 Gram positive (n=8) Gram negative (n=9)  
Target Time 1 Time 1  p* 
IL-18 
3560.3 (142.0-64270.3) 647.0 (0-321429.9) 0.139 
Time 2     Time 2   p* 
3560.3 (393.6-103033.0) 818.2 (0-2021250.0) 0.114 
Time 3     Time 3 p* 
2798.0 (0-556797.7) 735.9 (100.7-505614.9) 0.027+ 
Values are expressed in pg/ml and as mean (range); *Mann-Whitney rank sum test; +P<0.05, 
gram positive versus gram negative; Interleukin-18: IL-18; Time 1: time zero, Time 2: 10.3 h (3.7-
















Table 4.4 Plasma cytokine concentrations: survivors versus non-survivors 
  Survivors (n=14) Non-survivors (n=3)   
Target Time 1 Time 1  p* 
IL-1Ra 142696.0 (0-544142.3) 331474.4 (17604.4-546848.4) 0.197 
IL-6 116146.9 (0-1383830.0) 30610.7 (15726.5-40907.9) 0.244 
IL-8 2177.8 (0-15983.3) 11798.9 (548.2-34294.0) 0.197 
IL-10 2466.3 (0-10897.7) 13931.1 (1467.7-28961.1) 0.047+ 
PCT 4931.9 (0-16569.0) 12904.8 (0-38714.4) 0.985 
sTNFR1 30218.0 (2945.3-115254.4) 45070.6 (23507.9-86816.2) 0.509 
Target Time 2     Time 2   p* 
IL-1Ra 94165.6 (0-397902.8) 229413.6 (149366.9-341567.0) 0.068 
IL-6 29248.9 (571.9-242765.5) 20238580.0 (22232.0-60652600.0) 0.068 
IL-8 668.4 (0-4588.7) 13534.3 (555.1-37295.6) 0.032+ 
IL-10 1856.9 (0-11709.1) 19240.9 (2920.8-47783.8) 0.032+ 
PCT 7809.2 (0-52879.2) 23899.5 (14221.9-36270.4) 0.032+ 
sTNFR1 24611.9 (6036.0-49469.4) 44471.0 (25675.6-57857.0) 0.032+ 
Target Time 3     Time 3 p* 
IL-1Ra 62989.2 (0-341078.1) 209502.4 (116112.6-339309.6) 0.047+ 
IL-6 8488.6 (45.6-40907.9) 292616.7 (18595.2-797190.8) 0.021+ 
IL-8 489.8 (0-2742.9) 4283.2 (459.6-11380.3) 0.091 
IL-10 2973.4 (0-16479.0) 6061.2 (916.2-16252.7) 0.156 
PCT 7077.6 (0-41517.3) 31756.6 (13600.7-60664.8) 0.021+ 
sTNFR1 21421.9 (4301.1-36054.1) 48196.2 (34479.4-59347.4) 0.012+ 
Values are expressed in pg/ml and as mean (range). *Mann-Whitney rank sum test; +P<0.05, 
survivors versus non-survivors; Interluekin-1 receptor antagonist: IL-1Ra; Interleukin-6: IL-6; 
Interleukin-8: IL-8; Interleukin-10: IL-10; Procalcitonin: PCT; soluble tumor necrosis factor 









Table 4.5 Plasma cytokine concentrations: severe sepsis plus septic shock versus sepsis 
 Severe Sepsis + Septic Shock (n=6
#) Sepsis (n=11#)  
Target Time 1       Time 1      p* 
G-CSF 109812.3 (3629.9-230000.0) 42660.1 (0-321429.9) 0.180 
IFN-ɣ 688.9 (0-2178.0) 1161.6 (0-12303.2) 0.029+ 
IL-1Ra 382179.9 (17604.4-546848.4) 63553.4 (0-520818.2) 0.010+ 
IL-6 258214.9 (15726.5-1383830.0) 15327.3 (0-104078.6) 0.005+ 
IL-8 9604.8 (538.8-34294.0) 750.6 (0-2876.6) 0.015+ 
MCP-1 95245.8 (5405.1-261177.2) 5227.2 (0-21146.0) 0.003+ 
PCT 12719.2 (0-38714.4) 2858.7 (0-15091.8) 0.117 
sTNFR1 52294.2 (23507.9-115254.4) 22227.1 (2945.3-45007.7) 0.048+ 
Target Time 2       Time 2      p* 
G-CSF 504148.9 (1714.0-2021250.0) 40371.7 (0-225417.6) 0.048+ 
IFN-ɣ 264.5 (0-1071.2) 1102.1 (0-10933.5) 0.571 
IL-1Ra 175692.3 (62618.5-341567.0) 86582.3 (0-397902.8) 0.047+ 
IL-6 10136414.7 (4150.7-60652600.0) 27885.2 (571.9-242765.5) 0.020+ 
IL-8 7169.0 (277.3-37295.6) 631.5 (0-4588.7) 0.027+ 
MCP-1 21359.2 (909.6-106440.3) 5345.2 (189.0-19028.0) 0.350 
PCT 25145.4 (6949.0-52879.2) 2741.4 (0-11302.7) 0.001+ 
sTNFR1 41364.6 (25539.9-57857.0) 20890.2 (6036.0-40796.6) 0.005+ 
Target Time 3       Time 3      p* 
G-CSF 155141.5 (6063.3-505614.9) 75236.4 (0-556797.7) 0.296 
IFN-ɣ 194.9 (0-779.5) 1268.2 (0-15327.8) 1.000 
IL-1Ra 160542.6 (13663.0-339309.6) 66783.5 (0-341078.1) 0.201 
IL-6 219658.0 (782.0-797190.8) 9081.4 (45.6-40907.9) 0.163 
IL-8 3245.3 (131.6-11380.3) 517.3 (0-2742.9) 0.245 
MCP-1 9981.0 (388.4-34408.4) 3365.9 (94.8-17905.1) 0.703 
PCT 34196.8 (13600.7-60664.8) 4428.4 (0-16468.8) 0.002+ 
sTNFR1 42902.7 (27022.3-59347.4) 20991.1 (4301.1-36054.1) 0.010+ 
Values are expressed in pg/ml and as mean (range). *Mann-Whitney rank sum test; +P<0.05, 
severe sepsis plus septic shock versus sepsis; #Subject numbers for time point three are n=4 for 
severe sepsis plus septic shock and n=13 for sepsis; Granulocyte colony stimulating factor: G-
CSF; Interferon gamma: IFN-ɣ; Interluekin-1 receptor antagonist: IL-1Ra; Interleukin-6: IL-6; 
Interleukin-8: IL-8; Monocyte chemoattractant protein-1: MCP-1; Procalcitonin: PCT; soluble 
tumor necrosis factor receptor-1: sTNFR1; Time 1: time zero; Time 2: 10.3 h (3.7-21.6 h); Time 










Table 4.6 Antibodies and recombinant protein for protein targets 




Capture BioLegend 502802 
Antigen BioLegend 570102 
Tracer BioLegend 502904 
IFN-γ 
Capture Mabtech 3420-3-250 
Antigen Mabtech BMS303 
Tracer Mabtech 3420-6-250 
IL-1β 
Capture eBioscience 16-7018-85 
Antigen eBioscience 14-8018 
Tracer eBioscience 13-7016-85 
IL-6 
Capture eBioscience 16-7069 
Antigen eBioscience 14-8069 
Tracer eBioscience 13-7068 
IL-8 
Capture BD Biosciences 554716 
Antigen BD Biosciences 554609 
Tracer BD Biosciences 554718 
IL-18 
Capture R&D Systems D044-3 
Antigen R&D Systems B001-5 
Tracer R&D Systems D045-6 
MCP-1 
Capture eBioscience 14-7099 
Antigen eBioscience 14-8398 
Tracer eBioscience 13-7096 
IL-1RA 
Capture R&D Systems MAB280 
Antigen BioLegend 714406 
Tracer R&D Systems BAF280 
Tracer BioLegend 509501 
sTNFR1 
Capture R&D Systems MAB625 
Antigen R&D Systems 636-R1 
Tracer R&D Systems BAF225 
IL-10 
Capture eBioscience 16-7108 
Antigen eBioscience 14-8109 
Tracer eBioscience 13-7109 
PCT 
Capture abbexa abx019247 
Antigen abbexa abx060206 
Tracer abbexa abx019248 
G-CSF 
Capture R&D Systems MAB214 
Antigen BioLegend 713402 




Table 4.7 Logistic fit parameters for the standard curve of each protein target 
Target Reduced χ2 Adj. R2   A1 (Δpm) A2 (Δpm) x0 (pg/ml) p 
TNF-α 
23.73 0.988 Value 155.7 8408.7 1336.5 0.86 
    SE 17.8 642.4 418.6 0.08 
IFN-γ 
1.69 0.998 Value 408.2 10846.1 1753.3 0.79 
    SE 18.8 315.0 201.8 0.04 
IL-1β 
18.26 0.998 Value 161.4 9419.6 3950.8 0.84 
    SE 9.1 228.4 443.8 0.04 
IL-6 
5.39 0.989 Value 133.6 11155.1 927.7 0.72 
    SE 48.3 707.5 327.5 0.07 
IL-8 
1.26 0.999 Value 149.0 9926.9 1873.2 0.76 
    SE 25.2 307.2 221.0 0.05 
IL-18 
20.94 0.984 Value 148.8 10065.0 2463.3 0.83 
    SE 12.1 185.9 168.2 0.03 
MCP-1 
13.18 0.998 Value 174.6 9657.3 2191.1 0.84 
    SE 18.4 269.3 312.8 0.04 
IL-1RA 
3.53 0.998 Value 222.1 8822.5 36030.4 1.09 
    SE 13.6 230.0 3389.0 0.07 
sTNFR1 
46.48 0.997 Value 177.5 10869.9 2611.0 0.79 
    SE 28.4 475.9 601.2 0.08 
IL-10 
22.04 0.968 Value 95.7 11885.4 2417.4 0.72 
    SE 64.2 395.8 447.1 0.05 
PCT 
4.18 0.999 Value 500.3 8954.1 1590.2 1.09 
    SE 57.6 170.3 116.5 0.09 
G-CSF 
11.25 0.994 Value 157.0 10023.5 2120.5 0.85 
















































Figure 4.1 Representative protein data for the enzymatically-enhanced sandwich immunoassay. 
The inset illustrates the stepwise capture of primary antigen from the sample followed by 
subsequent binding of the biotinylated secondary tracer and streptavidin conjugated horseradish 
peroxidase (SA-HRP). The SA-HRP catalyzes the oxidation of 4-chloronaphthol converting it to 






























































Figure 4.2 Calibration of the multiplexed sensor array. Serial dilutions of recombinant protein 
standards for twelve cytokine targets were used to assess the performance across approximately 
eight orders of magnitude in 10 mM PBS/0.5% BSA buffer. The net shift from the enzymatic 
amplification was used as the readout. The signal is an average of three separate calibration curves 
collected throughout the sample analysis time. Error bars represent ±SD (n=4). The data was fit to 







































































Figure 4.3 Representative survival related biomarker trajectories (n=3 time points) for two 
subjects. Subjects were both characterized by the same bacterial gram status and sepsis severity, 











































































Figure 4.4 Representative sepsis severity related biomarker trajectories (n=3 time points) for two 
subjects who transitioned from severe sepsis and septic shock to sepsis within the first three time 
points (transition time represented by horizontal dotted black line). Subjects were both 
characterized by the same bacterial gram status and survival outcome. Subjects’ diagnosis was 
changed (a) 8.8 h after time zero and (b) 13.8 h after time zero.  
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Figure 4.5 Sensor array antibody capture spotting map. The 4 x 6 mm silicon photonic chip 
contains 132 active rings and 4 thermal controls. Active rings are arranged in clusters of 4, and the 
chips contains 32 clusters of rings. The chip schematic shows the layout for antibody spotting 
using a robotic microspotter. The fluidic path across the chip is also highlighted by the dashed 
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5.1 Abstract  
There has been a significant increase in the development of biological-based therapeutic agents. 
The most pervasive class of biological therapeutics is humanized monoclonal antibodies (mAb), 
which can treat a variety of disorders via selective inhibition or stimulation of biological targets. 
Antibody-based therapeutics present an analytical challenge to validate the purity and efficacy 
compared to traditional small molecules. The chemical structure is insufficient for 
characterization; properties that affect binding, affinity, and specificity must be determined. 
Critical parameters defining the efficacy of a mAb therapy include degree of aggregation and 
epitope specificity. Currently available analytical methods are cumbersome and difficult to 
integrate into the development pipeline. Herein, we present a workflow coupling size exclusion 
chromatography (SEC) with our multiplexed microring resonator detection platform to evaluate 
the functional binding characteristics of therapeutic monoclonal antibodies. Sensor arrays feature 
a combination of capture probes targeting the IgG constant regions, Fab fragment, and κ light 
chain. From the fractions of discrete monomer and dimer populations, we can assess the affinity 
reagent-specific responses in a single multiplexed kinetic titration. We have evaluated the binding 
characteristics of the monomer and dimer populations of a therapeutic mAb to elucidate the dimer 
structures and, by extension, the effect of dimerization on target recognition. This combined 
method will be a powerful addition to the product development and quality assurance pipelines 
that support the emerging field of biological therapeutics. 
5.2 Introduction 
Monoclonal antibody therapies (mAb), a class of biologics, have seen an unprecedented rise in 
development and clinical implementation in the last 20 years.1,2 Recent revenue from over 30 
different therapies totaled nearly $20 billion and growing with hundreds of new therapies in 
134 
 
clinical trials.3 Unlike traditional small molecule therapies (150-600 Da), mAb are large (~150 
kDa), complex biological structures composed of mouse derived complementarity determining 
regions grafted onto a recombinant human immunoglobulin backbone.4  The resulting functional 
form of the hybrid protein depends on higher order structural features including secondary protein 
structures (i.e. alpha-helices, beta-sheets) and the binding complex, all of which are affected by 
additional post-translational modifications and mutations.5,6  Production and storage conditions 
can significantly affect the higher order structural features leading to changes in epitope specificity 
and protein aggregation.7  Aggregation of particular concern because the monomeric structure is 
often the functional form and any higher order aggregate often reduces the therapeutic efficiency.8 
The chemical structure alone is insufficient to characterize the impact of aggregate derived 
structural changes.  New analytical tools must be integrated into the drug development pipeline to 
understand the functional relationship between structural changes from aggregation and 
therapeutic efficacy. 
Protein aggregation arises from system stresses (i.e. pH changes, freeze-thaw cycles) and often 
results in changes in target recognition.7 Currently, multiple techniques are employed to 
characterize mAb aggregates9-11, but few provide the necessary throughput and functional output 
to meet industrial quality assurance needs.  Mass spectrometry (MS) has made significant advances 
in identifying detailed structural components of mAbs, differentiating isomers and elucidating 
aggregation mechanisms.12,13 Specifically, hydrogen/deuterium exchange MS and hydroxyl 
radical labeling have revealed subtle structural differences between the monomeric and dimeric 
forms of mAbs.14,15 Additional aggregate characterization is performed using analytical 
ultracentrifugation and dynamic light scattering.16  While each of these analytical tools provide a 
unique contribution to mAb and aggregate characterization, each is laborious making them 
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difficult to integrate into an industrial workflow.  Moreover, few techniques directly address the 
functional binding changes accompanying aggregation.  
To better understand the structural nature of the predominant aggregate pathway, dimerization, 
and the related changes in binding efficiency, we have developed a hybrid method coupling size 
exclusion chromatography (SEC)7 and multiplexed silicon photonic microring resonator arrays.  
Silicon photonic microring resonators, a refractive index based sensor, detects subtle changes in 
binding at the sensor surface as shifts in resonance wavelength of the microring resonator. This 
response is directly correlated to the analyte concentration in solution and results in accurate 
characterization of kinetic and equilibrium binding. We have selected capture antibodies targeting 
specific regions of the IgG structure including the constant heavy CH1, CH2, CH3 regions, Fab 
(antigen binding fragment), and κ light chain. By arraying the capture antibodies onto a 
multiplexed sensor chip and flowing dimer and monomer mAb over the sensor surface, we can 
probe the specific binding interactions of the monomeric and dimeric structures of a mAb (Figure 
5.1). The resulting binding interactions will allow us to elucidate subtle structure-binding 
relationships that arise with dimerization.  
We present the monomeric and initial dimeric characterization of a therapeutic mAb species using 
a workflow combining SEC and multiplexed microring resonator arrays. By monitoring the 
association and dissociation of each species through single concentration analysis or multi-
concentration kinetic titrations, we can determine the kinetic and equilibrium binding constants 
and compare those to evaluate differential binding interactions and the related structural features 
of the dimer population. This integrated SEC-multiplexed affinity measurement would 
significantly streamline the detailed characterization of mAbs and integrate well into 
pharmaceutical characterization processes. 
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5.3 Materials and Methods 
Reagents and Materials. Reagents were purchased from Sigma-Aldrich, unless otherwise 
specified. Bis[sulfosuccinimidyl] suberate (BS3) and StartingBlock (PBS) Blocking Buffer were 
purchased from Thermo Scientific. 3-Aminopropyltriethoxysilane (APTES) was purchased from 
Gelest and DryCoat assay stabilizer with blocking protein was from Virusys. Antibodies were 
purchased from commercial vendors listed in Table 5.1. The therapeutic mAb was provided by 
Eli Lilly and Company.  
All analyses were completed in running buffer (20 mM Tris HCl pH 7.4, 0.1 M NaCl, 0.5 mM 
EDTA, and 0.01% NaN3).  
Instrumentation. The sensor chips and optical scanning instrumentation, Maverick (M1), were 
purchased from Genalyte, Inc. (San Diego, CA). The sensor array and instrumentation have been 
previously described.17,18  Sensor chips are batch fabricated each containing 128-individually 
addressable active sensing microrings (30 μm diameter) and four thermal controls. Each sensor 
has an adjacent linear waveguide with input and output diffraction grating couplers to enable 
independent interrogation and monitoring. The sensors are responsive to changes in the local 






where λ is the wavelength of light, m is an integer, r is the radius of the microring, and neff is the 
effective refractive index sampled by the resonant optical mode. By selectively modifying the 
microring surface with target specific agents, target binding events induce changes in the local 
refractive index which are detected as shifts in the wavelength. The shift is directly proportional 
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to material bound at the surface with binding shifting the resonance to longer wavelengths and 
depletion shifting the resonance to shorter wavelengths.17 Resonance wavelength shifts monitored 
in real-time are reported in units of Δpm (picometers) and the magnitudes of the shifts 
quantitatively correlate with the concentration of analytes in solution. 
All experiments were completed with the same instrumental device preparation. The sensor chip 
was loaded into a custom cell with microfluidic flow channels defined by a laser cut Mylar gasket 
(0.007 in), previously described in detail.19 The reagents in the assay were diluted in running 
buffer, loaded into a 96-well plate, and delivered to the sensor surface under software control.   
Sensor Functionalization. Microring resonator sensor chips (Genalyte) were functionalized with 
antibodies targeting specific human IgG subunits. Chips were rinsed in acetone (2 min) to remove 
the photoresist protective coating followed by silanization in 1% APTES in acetone (4 min). Chips 
were then rinsed for 2 min each with acetone and isopropyl alcohol, and then briefly rinsed with 
deionized water (~15 s) and dried under nitrogen. A 2 mM acetic acid solution containing 5 mM 
BS3 crosslinking reagent was then microspotted onto the chip. Freshly prepared (from frozen 
aliquot) antibody solutions diluted to 0.25 mg/ml in 10 mM PBS and 5% glycerol (v/v) were 
spatially arrayed by hand under a stereoscope, taking care to avoid any overlap in spotted solution. 
Chips were incubated in a humidity chamber for 1 h followed by coating in DryCoat and 
transferred to a desiccator at 4 °C for storage. 
Monomer and dimer isolation by size exclusion chromatography. Stock therapeutic antibody 
diluted to 5 mg/ml was injected onto a Superdex 200 10/300 column (GE Healthcare, Pittsburgh, 
PA). The column was operated at a flow rate of 50 μL/min. Absorbance was monitored at 280 nm 
for both the monomer and dimer. Fractions were automatically collected every 15 s in a 96-well 
plate at 4 °C. The following proteins standards were used with the associated known hydrodynamic 
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radius: Thyroglobulin (17 nm), Ferritin (12.2 nm), Bovine Liver Catalase (10.4 nm), and Bovine 
Serum Albumin (7.1 nm). Fractions for each species were pooled and the concentration determined 
using a Nanodrop UV-Vis.  
Single Concentration Monomer and Dimer Experiments. Purified monomer or dimer solutions 
were diluted to matched target concentrations in running buffer (400 μL total) and transferred to a 
96-well plate. The assay consisted of the following steps: (1) Buffer rinse (5 min), (2) Therapeutic 
Antibody (10 min), (3) Buffer rinse (5 min). All assay steps were completed at flow rate of 30 
μL/min. Each experiment was completed using a freshly functionalized sensor chip with four 
capture antibodies (Ab6 was omitted due to initially poor performance).  
Monomer Kinetic Screening Experiments. To determine the binding kinetics for the monomer 
with each capture antibody, monomer antibody was flowed over the multiplexed chip surface with 
increasing concentrations for 10 min followed by 10 min rinses with running buffer during which 
desorption of the monomer was observed.20  All assay steps were completed at flow rate of 30 
μL/min. Each experiment was completed using a freshly functionalized sensor chip with five 
capture antibodies 
Data analysis. Microring resonance wavelength shift data was recorded as a function of time and 
corrected for any thermal drift or bulk shifts using on-chip controls rings (exposed to solution but 
otherwise unfunctionalized). The signal from the control rings was averaged and subtracted from 
each individual active sensor ring. Kinetic data was divided into association (antibody binding) 
and dissociation (post-sample buffer rinse) steps and fitted using integrated rate equations for 1:1 
Langmuir binding, previously described in greater detail.21,22  All data analysis was completed 
using Origin 9.1 (OriginLab) as well as a custom program for semi-automated data analysis.  
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5.4 Results and Discussion 
General workflow and kinetic analysis. To characterize the monomeric therapeutic antibody, 
which will be termed “monomer”, kinetic titrations were performed. The workflow illustrated in 
Figure 5.2, proceeds with concentrated monomer isolated from size exclusion chromatography 
(SEC) (Figure 5.2a), serially diluted from 900 nM to 0.4 nM, and flowed over the same multiplex 
array pre-functionalized with five different capture antibodies (Figure 5.2b). The five capture 
antibodies targeted different regions of the IgG structure outlined in Table 5.1.  All capture agents 
demonstrated concentration dependent responses in which larger shifts in resonance wavelength 
correlated to flowing increased monomer concentrations across the sensor array. Each set of traces 
represents the averaged response from all sensors for each capture antibody (n≥4 sensors per 
capture antibody). Upon terminating the monomer flow and initiating a buffer rinse, dissociation 
of the monomer is seen with decreasing resonance wavelengths. Figure 5.2c illustrates the 
association and dissociation of the monomer at 15.6 nM which corresponds to the highlighted 
region in Figure 5.2b. The thick lines corresponding to the color of each capture antibody trace 
represent the association and dissociation functions. By fitting the binding and dissociation, the 
association and dissociation rate constants (ka and kd respectively) can be determined assuming a 
1:1 binding model.20,21  Both ka and kd were determined by fitting the real-time resonance 
wavelength shifts from association to: 
𝛥𝑝𝑚(𝑡) = 𝛥𝑝𝑚𝑚𝑎𝑥𝜃(1 − 𝑒
𝛾𝑡) 
where 𝜃 is the fractional total occupancy and 𝛾 is equal to: 
𝛾 = 𝑘𝑎𝐶 + 𝑘𝑑 
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Therefore, ka and kd were determined by plotting 𝛾 as a function of the therapeutic antibody 
concentration as shown in Figure 5.2d. The 𝛾-plots follow a linear relationship to extract ka from 
the slope and kd from the intercept of the linear fit. The kd can also be determined directly from 
dissociation, which is advantageous when the kd is sufficiently small yielding potentially 
inaccurate intercept values from the 𝛾-plots.20 Therefore, the real-time resonance wavelength shifts 
corresponding to dissociation were directly fit with the following exponential decay function: 
𝛥𝑝𝑚(𝑡) = 𝛥𝑝𝑚𝑚𝑎𝑥𝑒
𝑘𝑑𝑡 
For the determination of extremely slow rates of dissociation necessitating long measurements of 
slowly changing response, non-ideal sensor performance can complicate this requiring a lower 
bound cutoff for the dissociation rate. We have previously established the slope noise as 0.02 
Δpm/min19 so a reasonable lower bound for a measurable rate would be ~0.05 Δpm/min. 
Washburn, et. al. establishes that with a 50 pm loading of antibodies, this results in a 2 x 10-5 s-1.23  
While this cutoff is not directly applicable to the behavior of all capture antibodies (antibody 
loading ≠ 50 pm shift with all capture antibodies), this is a good first approximation of dissociation 
limits. Therefore, dissociation rate values below 2 x 10-5 s-1 will be denoted as such and require 
further verification. In cases in which the kd determined from the intercept of the 𝛾-plots is not too 
small, both the intercept and the direct fit of the dissociation yield similar results. The resulting ka 
and kd values were used to calculate the equilibrium dissociation constant, KD (ka/kd), yielding two 
values for KD (resulting from the 𝛾-plot determined kd and the directly fitted kd).  
Kinetic screening analysis for the monomer. To sufficiently characterize the binding of each 
capture antibody in a single assay, a large monomer concentration range (0.4-900 nM) was 
screened. Despite the numerous concentrations, capture antibodies were stable over the length of 
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the experiment, consistent with similar past experiments.19,23 The individual traces for each capture 
antibody are highlighted in Figure 5.3. The traces illustrate the concentration range corresponding 
to the linear range of the associated 𝛾-plot, shown in Figure 5.4.  Capture antibodies Ab3 and Ab6 
show low binding activity until much higher concentrations of the monomer, while Ab5, Ab7, and 
Ab8 display binding at much lower monomer concentrations. The resulting 𝛾 plots display good 
linearity for each plot with at least five points for each linear fit. The ka and kd were extracted from 
the linear equation and the directly measured kd extracted from the dissociation and were used to 
calculate KD values, which are compiled in Table 5.2 (experiment type: Kinetic). In some cases, 
poor performance of an antibody prohibited accurate fitting to the model and therefore, did not 
allow for determination of kinetic or equilibrium binding constants. This is seen with Ab8 in which 
the kd and subsequent KD could not be reliably determined from the 𝛾 plot values, but kd was 
determined directly from dissociation and used for a second KD calculation. The kinetic titration 
was duplicated for each capture antibody. There was insufficient quality data for the kinetic 
analysis of Ab3 and Ab7. The remaining three capture antibodies yielded similar ka and directly 
fitted kd values. The kd values determined from the 𝛾 plots were more inconsistent when comparing 
the duplicate kinetic experiments for all three capture antibodies. The resulting KD values for the 
independently determined ka and kd values were relatively reproducible for the three capture 
antibodies.  
Single concentration monomer and dimer analysis. The dimeric therapeutic antibody, termed 
“dimer”, was characterized through single concentration analysis in which kinetic screening 
experiments were completed by matching monomer and dimer concentrations (11-140 nM) and 
completing single analyses per sensor chip. The experiment proceeds similarly to the kinetic 
titration in which SEC isolated dimer was flowed over the surface followed by a buffer rinse to 
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initiate dissociation. Each experiment was completed on a newly functionalized sensor chip, each 
modified with four capture antibodies (Ab6 was initially omitted due to poor performance at tested 
concentrations). The resulting binding traces for each capture antibody at all tested concentrations 
were plotted (Figure 5.5a) and fit using the previously described parameters. Using the resulting 
data, 𝛾-plots were generated for three of the capture Abs for the dimer, shown in Figure 5.5b-d. 
Capture Ab3 did not yield a linear relationship due to low binding at the tested concentrations. The 
single concentration monomer experiments yielded sufficiently linear data for all four capture 
antibodies. The resulting kinetic and equilibrium constants are shown in Table 5.2 for the 
monomer (experiment type: Single) and Table 5.3 for the dimer. Due to the length of the buffer 
rinse after association, only dimer interactions with Ab8 yielded a reliable direct kd value for all 
dimer analyses. Overall, the interactions of the dimer and capture antibody yielded similar 
association and dissociation rates as well as calculated KD.  
Comparing kinetic titration and single concentration experiments. When evaluating the single 
concentration kinetic results for the monomer, only Ab7 has multiple single concentration 
experiment measurements, which are reproducible for all measures. The addition of the kinetic 
experiment shows larger values across each metric, suggesting the need for additional experiments 
to verify the kinetic experimental results. When comparing Ab5 results, one of the two kinetic 
experiments is in good agreement with the single concentration experimental results. The second 
kinetic experiment yields a lower kd from the 𝛾 plot which leads to a much lower KD, but the KD 
calculated from the directly determined kd is more consistent with the first two experiments. 
Capture Ab3 shows consistent results for all metrics, particularly when considering the 𝛾 plot 
generated KD for the single experiment (459.6 nM) and the independently calculated (directly 
determined ka and kd) KD for the kinetic experiment (479.8 nM). Though the additional KD values 
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suggest this result may still require additional verification. Finally, Ab8 shows exceptionally good 
agreement for directly measured kd across all three experiments and similar KD values, however 
the ka for the single concentration experiment is much smaller than those from the kinetic 
experiments. Taken together, there is little compelling evidence of inconsistencies between the 
two experiment types.21  However, the initial study still requires additional experiments to 
confidently evaluate the kinetic metrics for all capture antibodies.  
Monomer and dimer single concentration comparison. Evaluating differences in binding at the 
surface of the sensor can be completed by initially determining the differences in the magnitude 
of the resonance wavelength shift. To compare the monomer and dimer species, each were 
measured at 140 nM for four capture antibodies (Ab6 omitted) and shown in Figure 5.7. For these 
measurements, the monomeric antibody concentration is equivalent; therefore, the monomer 
species is twice as concentrated as the dimer species, but equivalent in moles of monomeric 
antibody. However, because the resonance wavelength shift is proportional to the amount of 
material bound, the dimer species should elicit twice the shift of the monomer in equal 
concentrations on the surface.24  Based on the input antibody concentrations, it is reasonable to 
expect a 1:1 monomer to dimer resonance wavelength shift change during association if both 
species are similarly binding to the capture antibodies.  However, we do not observe that result for 
any capture antibody. This may be due to occluded target epitopes from dimerization, which could 
contribute to a decrease in in vivo therapeutic efficacy. Additionally, it is unclear if the monomer 
and dimer species travel to and interact with the functionalized sensor surface in similar ways. If 
such discrepancies exist, the assumed dimer concentration at the sensor surface may be inaccurate. 
A sandwich assay using the capture antibodies as both captures and secondary tracer antibodies 
may provide a secondary validation of the surface bound dimer concentration (Figure 5.8). Similar 
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to sandwich immunoassays to characterize neurodegenerative protein aggregation, the presence of 
an additional epitope on a dimer species yields an additional binding site for a tracer antibody.10,25 
For this application, the secondary antibody would not discriminate the dimer from the monomer, 
but rather quantify overall dimer presence and reveal potential structural variation in dimer species.  
The secondary antibody would presumably travel to and interact near the sensor surface similarly 
to the monomer allowing for a more direct kinetic comparison, if the results in fact differ from the 
direct dimer measurement.  
5.5 Conclusions and Future Directions  
Therapeutic monoclonal antibodies present a unique challenge for quality assurance relative to 
traditional small molecule therapies. Chemical structure alone is insufficient with efficacy better 
characterized by binding affinity and epitope specificity. Both parameters are affected by the 
formation of aggregates, commonly occurring with changes to handling or environment. We have 
developed a multiplexed immunoassay targeting specific regions of the IgG structure to better 
characterize the aggregate population and the resulting binding changes relative to the monomeric 
therapeutic antibody. This silicon photonic microring resonator based assay precisely monitors 
association and dissociation in near real time resulting in determination of the related kinetic and 
equilibrium binding constants. A representative therapeutic antibody has been initially 
characterized using two different assay approaches resulting in internally consistent results and 
notable differences in binding for the monomer and dimer species. Future experiments seek to 
repeat the kinetic titration screening of monomer and match this with a kinetic titration of the dimer 
species. Additionally, a sandwich immunoassay of the dimer will more clearly elucidate the dimer 
concentration on the sensor surface and additional structural detail to better understand the major 




Table 5.1 Capture antibody vendor and IgG target information 
Capture 
Antibody 
Supplier Catalog # Target 
Ab3 Thermo-Fisher MA1-90268 CH3 Domain 
Ab5 abcam ab72528 κ Chain 
Ab6 abcam ab7500 CH1 Domain 
Ab7 Thermo-Fisher MA1-34883 Fab Region 















Table 5.2 List of kinetic and equilibrium binding parameters for IgG regional capture 





ka (s-1 M-1) kd (s-1)a kd (s-1)b KD (nM)a KD (nM)b 
Ab3 
Single 1.4E+6 3.2E-6 5.1E-3 459.6 1631.3 
Kinetic 1.6E+6 6.0E-6 2.9E-3 275.3 479.8 
Ab5 
Single 9.3E+4 3.2E-3 - 34.6 - 
Kinetic 4.6E+4 1.6E-3 8.4E-3 35.5 182.5 
Kinetic 7.1E+4 2.0E-4 4.3E-3 2.8 61.0 
Ab6 
Kinetic 3.9E+4 1.4E-3 3.5E-3 36.6 89.7 
Kinetic 1.3E+4 1.4E-4 2.0E-3 10.9 155.8 
Ab7 
Single 1.8E+5 8.2E-4 1.9E-3 4.5 10.5 
Single 1.7E+5 7.7E-4 - 4.7 - 
Kinetic 2.6E+4 1.1E-3 2.5E-3 40.7 98.1 
Ab8 
Single 1.1E+5 1.1E-2 4.5E-3 104.2 41.7 
Kinetic 5.8E+4 - 4.8E-3 - 83.0 
Kinetic 6.9E+4 5.8E-3 4.2E-3 84.9 61.1 
Single experiment type: single concentration analysis; Kinetic experiment type: kinetic 
titration analysis; ka: association rate constant; kd: dissociation rate constant; KD: 
equilibrium dissociation constant; avalues determined from ɣ plot values; bvalues 
























Table 5.3 List of kinetic and equilibrium binding parameters for IgG regional capture 
antibodies interacting with dimer antibody 
Capture 
Antibody 
ka (s-1 M-1) kd (s-1)a kd (s-1)b KD (nM)a KD (nM)b 
Ab5 3.1E+4 3.9E-4 - 12.7 - 
Ab7 2.6E+4 2.8E-4 - 10.8 - 
Ab8 3.9E+4 4.0E-4 1.3E-3 10.1 33.7 
All experiments were single experiment type; ka: association rate constant; kd: 
dissociation rate constant; KD: equilibrium dissociation constant; avalues determined from 





































Figure 5.1 Monomeric monoclonal antibody structure and potential dimerized structures. Arrays 
of capture antibodies targeting specific structural regions will reveal structural characteristics of 















Figure 5.2 Assay and data analysis workflow. (a) Size exclusion chromatography separates dimer 
(inset) and monomer populations which are collected as fractions. (b) The pure therapeutic 
antibody population is flowed over a multiplexed sensor array at multiple concentrations followed 
by a buffer rinse, yielding a kinetic titration. (c) Each concentration step (specific step from 
highlighted region in part b) is fitted with a 1:1 Langmuir binding model to determine association 
and dissociation rate constants. The association began with the arrow and terminated with a buffer 
rinse at the asterisk (*). (d) The ɣ parameter from the association function yields a linear 
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Figure 5.3 Averaged kinetic titration traces for each capture antibody highlighting the specific 
monomer concentration ranges used for determining the association binding constant (n≥4 
sensors). (a) Ab3 targeting the CH3 region, (b) Ab5 targeting the κ chain, (c) Ab7 targeting the Fab 
region, (d) Ab6 targeting the CH1 region, (e) Ab8 targeting the CH2 region.  
151 
 




























































































Figure 5.4 Plots of γ values as a function of monomer concentration obtained from the association 
curves of microrings modified with IgG region specific capture antibodies. (a) Ab3 targeting the 
CH3 region, (b) Ab5 targeting the κ chain, (c) Ab7 targeting the Fab region, (d) Ab6 targeting the 
CH1 region, (e) Ab8 targeting the CH2 region. Error bars represent ±standard deviation of γ values 
determined from n≥4 microrings simultaneously measured at each concentration.  
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Figure 5.5 Antibody monomer kinetic binding analysis. (a) representative time resolved detection 
of dimer antibody using microrings modified with Ab8. Plots of γ values as a function of dimer 
concentration obtained from the association curves of microrings modified with IgG region 
specific capture antibodies: (b) Ab8 targeting the CH2 region, (c) Ab5 targeting the κ chain, (d) 
Ab7 targeting the Fab region. Error bars represent ±standard deviation of γ values determined from 







































































































Figure 5.6 Time-resolved detection of monomer and dimer antibody at 140 nM overlaid for each 
capture antibody. (a) Ab3 targeting the CH3 region, (b) Ab5 targeting the κ chain, (c) Ab7 targeting 










Figure 5.7 Proposed sandwich immunoassay for secondary quantification and structural 
determination of the dimer population. Antibody dimer is flowed over the multiplexed arrayed 
sensor chip followed by sequential addition of each capture antibody as tracers. Binding will occur 
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6.1 Introduction: Next Generation LTBI Assay Development 
The developments made toward diagnosing latent tuberculosis infection (LTBI) and stratifying 
subjects based on reactivation risk (Chapter 3) demonstrated significant promise for continuation. 
The primary goals for the next study are expanding the biomarker panel to include additional 
immune proteins implicated in tuberculosis (TB), enrolling a broader subject pool, and 
transforming the data analysis scheme from initial feature selection to a sophisticated diagnostic 
model.  
Mayo clinic will enroll 150 subjects representing healthy subjects and those representing diverse 
LTBI status. Peripheral blood mononuclear cells (PBMCs) will be isolated and stimulated with the 
exact protocol used in Chapter 3 including an additional TB relevant stimulation, MTB300 peptide. 
In collaboration with Dr. Elitza Theel, Director of the Mayo Clinic Infectious Diseases Serology 
Laboratory, we will also receive waste plasma supernatant from QuantiFERON TB Gold In-
Tube® interferon-ɣ release assays (QFT). While the QFT assay yields a poor predictive value for 
LTBI status, it is the most common commercial TB assay and is well-integrated into the clinical 
workflow at Mayo Clinic. Similar to the PBMC stimulation protocol, white blood cells in plasma 
are stimulated with a TB-specific antigen mixture [CFP-10, ESAT-6, and TB7.7(p4)], mitogen, 
and a negative control condition.1-3 We will perform side-by-side comparisons of the expanded 
biomarker panel performance with the three stimulation conditions of plasma relative to the six 
stimulation conditions of the PBMCs to determine the predictive capabilities of the resulting 
biomarker signatures.  
The rigorous development of a clinically translatable diagnostic signature requires extensive 
characterization and clinical evaluation to prioritize those biomarkers most relevant to the disease 
state. With the completion of this study, we aim to have demonstrated that we can reveal predictive 
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biomarker signatures using both sample types, with QFT supernatants offering advantages in terms 
of their broad availability owing to the existing TB diagnostic workflow. 
6.2 New Biomarker Analytical Characterization 
The expanded biomarker panel (Table 6.1) includes the following markers IFN-ɣ4, TNF-α5, IL-
26, IP-107, CCL38, CCL49, IL-2310, IL-1β11, IL-612, IL-1013, IL-1514, IL-1715, MCP-116, and MCP-
217. Each of these markers were selected because of their individual or combined role in the 
immune system’s response to TB infection and long-term latency.18-20 The incorporation and 
validation of each target required careful antibody selection, cross-reactivity evaluation and 
calibration, the results of which are shown in Table 6.1. Two targets, CCL3 and CCL4 require 
additional validation due to changes in the sandwich antibody pairs from the first generation of the 
panel, therefore were omitted from the current studies.  
Potential matrix effects were evaluated due to the possible signal suppression or interfering protein 
content accompanying the addition of human serum (10%) in the PBMC stimulated supernatant 
or from the stimulated human plasma. Saturating concentrations of each biomarker were prepared 
as a cocktail and spiked pooled health human serum (Figure 6.1). The results revealed signal 
changes with the addition of serum requiring future calibrations to be completed in 10% pooled 
human serum. The matrix effects of plasma were also evaluated, with the spiked pooled healthy 
human plasma concentration ranging from 0-100% (Figure 6.2).  
The multiplexed calibration of 12 biomarkers was completed using pre-functionalized sensor chip 
arrays, with each target’s capture antibodies functionalized on n=4 sensors plus a negative control 
(anti-mouse IgG capture antibody). The calibrations shown in Figure 6.3 were from 10% pooled 
human serum spiked recombinant protein solutions serially diluted for n=7 concentrations plus a 
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baseline (running buffer, 10% human serum). The assay proceeded similar to the first LTBI assay 
protocol and resulted in concentration dependent responses for each target. While most calibrations 
were well-within expected performance metrics based on company provided literature or previous 
individual validation experiments, IL-17, IL-1β, and IL-2 require additional evaluation to improve 
the quality of the calibration and linear working range. Assay optimization is often an iterative 
process (as outlined in Chapter 2) so it is reasonable to expect additional analytical improvements 
despite successful individual assay performance.  
6.3 Feature Selection and Model Development 
The initial feature selection analysis was completed with the machine learning based Boruta 
algorithm. While this provided insightful features for LTBI related signature development, the 
results were considered unranked giving little dimensionality to the relative importance of a 
predictive feature. As an important step towards the creation of a predictive model, we will utilize 
a full suite of feature selection and model building tools including extended random forest (ERF). 
This machine learning approach ranks both the relevance and significance of the input features 
(normalized biomarker response). While this approach has not been extensively applied to our 
proof-of-principle data from Chapter 3, a preliminary example of the output of the ERF analysis 
is shown in Figure 6.4. The results from this more detailed feature selection analysis shows good 
agreement with the Boruta algorithm results and reveals a more nuanced biomarker signature to 
evaluate the relevance of each biomarker within the signature. Combining this powerful analysis 
with the precision normalized response from the expanded biomarker panel will aid in the 






The development of a precision-medicine based diagnostic strategy for LTBI requires significant 
analytical, clinically, and informatic contributions for clinical translation. Each stage of 
development requires careful consideration to prioritize those biological features most relevant to 
a clinically robust assay. This is true for any successful assay implementation and should be the 
central tenants guiding all future assay development. 
6.5 Tables 
Table 6.1 Expanded biomarker panel including stage of development for each biomarker 
assay and relationship to LTBI 
Biomarker 
Development Status 






IL-23* X X X Protective immunity, IL-17 
IL-2* X X X T-cell differentiation 
IFN-ɣ* X X X Antigen-specific T-cells 
TNF-α* X X X Innate cytokine/chemokine response 
CCL3* X     granuloma formation 
CCL4* X     granuloma formation 
IP-10* X X X Early T-cell recruitment 
IL-1β X X X pro-inflammatory, Induction of IL-17 
IL-6 X X X Type 1 IFN signaling 
IL-10 X X X Anti-inflammatory 
IL-15 X X X CD8+ T-cells 
IL-17 X X X Chemotaxis for inflammation  
MCP-1 X X X Chemoattractive to granulocytes 
MCP-2 X X X Enhances cell-mediated immunity 












































































































































Figure 6.1 Matrix effects for the 12-plex expanded biomarker panel in pooled healthy human 
serum. The 12 biomarkers were prepared as a cocktail at signal saturating concentrations. Both 
figures represent data from the same set of experiments with the left figure showing only the effects 
of spiked human serum (omitted 0% serum results). Error bars represent the standard deviation of 






































































































































Figure 6.2 Matrix effects for the 12-plex expanded biomarker panel in pooled healthy human 
plasma. The 12 biomarkers were prepared as a cocktail at signal saturating concentrations. Both 
figures represent data from the same set of experiments with the left figure comparing only the 
effects of 10% and 100% spiked human plasma relative to buffer diluted proteins (0% plasma). 







































Equation y = A2 + (A1-A2)/(1 + (x/x0)^p)
Plot Avg. Net Shift
A1 595.17427 ± 126.47647
A2 10242.29836 ± 2701.70228
x0 13495.21389 ± 22014.49581




























Equation y = A2 + (A1-A2)/(1 + (x/x0)^p)
Plot Avg. Net Shift
A1 697.33494 ± 82.81302
A2 1.40384E7 ± 2.25781E10
x0 8.97283E11 ± 3.01923E15









































































































































































































































Figure 6.3 Calibration curves for 12 biomarkers. The calibration curves were collected as a 12-
plex assay in which all 12 recombinant proteins were prepared as a cocktail and spiked with 10% 
pooled healthy human serum. Each calibration curve was constructed using a logistic fit as outlined 






Figure 6.4 Preliminary ERF feature selection applied to LTBI diagnostics. This method ranks 
biomarkers in terms of “likelihood of relevance” and a “variable importance metric.” The data 
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Endogenous fatty acid synthesis is up regulated in breast cancer. Phospholipids are implicated in 
many cellular processes including signaling, proliferation, and apoptosis, but their role in cancer 
is largely unknown. In an effort to understand how lipid expression correlates to tumor progression 
and oncogene expression, intact human breast cancer cells were interrogated by desorption 
electrospray ionization mass spectrometry (DESI-MS). This in vitro cell-based workflow provides 
rapid and detailed analysis with little sample preparation compared to traditional lipid 
chromatographic methods.  Principal component analyses of cellular lipid profiles supported 
classification of cell lines based on differential expression of both Her2 and p53 genes. Breast 
cancer cell lines of differing metastatic potential and grade were also easily distinguished within a 
single assay. Tandem MS analyses identified of over 200 lipid species in negative ion mode, which 
is currently one of the most comprehensive phospholipid composition of breast cancer cells. These 
results demonstrate that DESI-MS assays are powerful tools for rapidly classifying cancer cells 
according to their geno- and phenotypes, while simultaneously providing extensive lipid 
compositions which may be relevant to elucidating important biochemical mechanisms in cancer 
progression.  
A.2 Introduction 
Breast cancer is one of the most common cancers with over 200,000 diagnoses a year and over 
40,000 resulting deaths.1  Mechanistic understanding of its onset and progression is pivotal to 
diagnostic and therapeutic success.  A hallmark of cancer is the increase in de novo fatty acid (FA) 
synthesis, which is associated with increased consume glucose metabolism (Warburg effect).2,3 
Fatty acid synthase (FASN), a key enzyme upregulated in this pathway, produces palmitate which 
acts as a fundamental building block for further complex lipid synthesis. Those synthetic products, 
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particularly glycerophospholipids (PL) are integral to fundamental cellular processes including 
proliferation, signaling, and apoptosis.4 However, the role of PLs in cancer is largely unknown, 
but pathogenesis involves gene mutations that influence lipid composition. Examining the 
connection of those mutations most prevalent in breast cancer and the resulting lipid compositions 
may reveal a clearer picture of the dynamic relationship of genetic changes and PL levels.  
Tumor suppressor p53, the most prevalent genetic alteration in breast cancer, and the human 
epidermal receptor protein 2 (Her2/neu) are critical mutations in breast cancer.5,6 The metabolic 
effects of tumor suppressor p53 are demonstrated through the regulation of glycolysis and 
mitochondrial oxidative phosphorylation. Alternatively, Her2/neu can modulate the 
phosphatidylinositol-3 kinase (PI3K) pathway that requires tri-phosphorylated 
phosphatidylinositols (PI) to act as signaling molecules.8  Downstream signaling from Her2/neu 
can also lead to the stimulation of FASN through the transcription factor sterol regulatory element-
binding protein 1c (SREBP1c).4  Mutations of Her2/neu or p53, as often seen in breast cancer, lead 
to metabolic changes that contribute to cancer progression.   
The relationship between oncogene expression and PL levels can be evaluated by measuring the 
levels of the lipid classes most prevalent in the cell. For example, phosphatidylcholines (PC) and 
phosphatidylethanolamines (PE) are among the most abundant PLs in the lipid bilayer and are 
therefore often upregulated during rapid cell proliferation.9  Phosphatidylglycerols (PG) and 
phosphatidylserines (PS) act either as a precursor or in the initiation of apoptosis respectively.10,11   
These PL species are detectable by numerous analytical methods including nuclear magnetic 
resonance (NMR) spectroscopy,12 Raman spectroscopy,13 and high performance liquid 
chromatography coupled to mass spectrometry (HPLC-MS).14  While NMR and Raman fall short 
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of providing individual species identification, all three have demanding sample requirements and 
laborious methods.   
Recently, ambient (ionization) mass spectrometry including desorption electrospray ionization 
(DESI) has been developed as a platform to efficiently interrogate samples with minimal sample 
pretreatment. In DESI-MS a stream of charged microdroplets are directed at the sample surface 
and through the generation of analyte-containing secondary droplets proceed toward the mass 
spectrometer and ionize via an electrospray ionization like mechanism.16  To date, DESI-MS has 
been used to interrogate intact bacteria,17 mouse fibroblasts,18 and mouse oocytes19 proving it an 
important tool for native biochemical studies.  DESI-MS based analysis of cancer lipidomes has 
been limited to mass spectrometry imaging (MSI) of tissue sections from tumors.20 Identifying the 
intrinsic lipid signals from specific cancer cell types is imperative to understanding their 
biochemical relevance and elucidating the role of specific lipids in cancer progression. 
Herein, we have applied power of lipidomic based DESI-MS and MSI to in vitro analysis of intact 
human breast cancer cells. By interrogating a panel of breast cancer cells described by Her2/neu 
and p53 expression level changes, we can separate each cell line based on its lipid profile and 
identify unique features that may correlate to oncogene expression level changes. In the same 
experiment, we also distinguished those breast cancer cell lines that differ by metastatic potential 
and cancer grade. This label-free DESI-MS analysis of human breast cancer cells provides an 
efficient method to explore the relationship between lipid levels and genetic changes related to 






DESI-MS of intact human mammary cell lines. The cell-based DESI-MS assay requires very 
few steps including little sample manipulation for an in-depth lipid analysis. The workflow 
(Figure A.1) begins after the trypsinization process with a simple washing step with ammonium 
formate to remove excess salts. Resuspended cells are then deposition onto diagnostic Teflon-
coated glass slides and DESI-MS interrogation is completed by either manual acquisition or in a 
profiling-based mode. DESI-MS manual acquisition was used to acquire lipid compositions of all 
cell lines in Table 1 in negative ion mode (Figure A.2). High-resolution single stage mass spectra 
of MCF10A and T47D (Figure A.2a-b) were acquired by Orbitrap-MS (FT-MS). Tandem mass 
spectra for fragmentation analysis (Figures A.2c-d) were acquired by ion trap MS (IT-MS). The 
identification of m/z 700.5292 as 34:1 plasmenyl PE and its exact lipid species is straightforward 
due to the predictive nature of lipid fragmentation and the LIPIDMAPS database.23  The resulting 
PL compositions from DESI-MS manual acquisition describes over 200 PL species per cell line 
(Supplementary Tables A.1-10).  The total compositions can be more succinctly described using 
characteristics like PL class representation (Table A.2, Supplementary Figure A.1). The values 
represent the PL class percentage from the absolute intensities of the FT-MS identified intact lipid 
peaks. The percent PL class composition of MCF10A representing variable time and passage 
number show acceptable range for this analysis (Supplementary Table A.1).  
Using only the manually acquired DESI-MS data, unique lipid profiles are apparent from the intact 
breast cancer cell lines. However, utilizing DESI-MS profiling capabilities can provide a more 
rapid analysis to determine the most relevant signal differences. The imaging workflow utilizes 
the same sample preparation as manual acquisition, but initially proceeds without tandem MS 
collection, which can be completed post- imaging analysis targeting specific peaks of interest. 
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Different cell lines deposited on the diagnostic slides are interrogated at set intervals using point-
to-point profiling mode, scanning only five rows scanning over the largest part of the spot for rapid 
data collection. The data collection results in high-resolution single stage mass spectra of each cell 
line, including replicate spots, for multivariate analysis.  
The multivariate analysis approach, principle component analysis (PCA) is an unsupervised 
statistical method that transforms the data set into linearly independent space of principal 
components (PC) that describe some amount of variance for the data set.24 This statistical tool is 
typically used for data reduction, identifying those features contributing to the greatest variance in 
the data set. PCA has been used for predictive model development with related MS approaches.25 
Using this analysis, the lipid profiles of each breast cancer cell line were evaluated to discriminate 
unique signals as well as determine those lipids most important to differentiating cell lines based 
on the greatest variance.   
Analysis of changes in oncogene expression levels. Of the human breast cancer cells analyzed 
by DESI-MS, those that differed by expression levels of Her2/neu and p53 provided a select panel 
to observe the relationship between lipid and oncogene expression level changes. Because the cell 
lines were defined by the combination of two mutated targets, typically at different expression 
levels, cell lines were evaluated iteratively in an attempt to reveal possible trends related to lipid 
levels and expression changes.  The score plot illustrate the data of breast cancer cell lines that 
have exclusively variable Her2/neu expression (no documented p53 mutation) along the first and 
second principle components (Figure A.3a).22  The score plot along PC1 reveals the separation of 
HCC 1419 (Her2/neu+++), relative to HCC 1599 (Her2/neu-) and HCC 202 (Her2/neu+).  The 
related loading plot (Figure 3b) shows m/z values contributing to separation along PC1 and can 
help identify lipids correlated to the separation of these populations. Additional cell lines were 
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then incorporated into the analysis (Supplementary Figure A.2a, Figure A.3c) resulting in a 
similar separation of overexpressing Her2/neu cell lines HCC 1419 (Her2/neu+++) and HCC 2218 
(Her2/neu+++) from those with moderate to low expression levels [HCC 1599 (Her2/neu-), HCC 
70 (Her2/neu-), and HCC 202 (Her2/neu+)] in PC1. The separation of the two types of subgroups 
of Her2/neu expression in PC1 may closely correlate to lipidomic features of Her2/neu expression 
changes. Changes in p53 expression are indistinguishable in the first two PCs, but when viewing 
PC2 and PC3 (Figure A.3c-d), there is p53 expression level correlated separation along PC3. The 
lipids related to this variance may be correlated to changes in p53 expression and were identified 
by PCA of the two populations (Supplementary Figures A.3a-c, Supplementary Tables A.2-4). 
The resulting loading plots for each oncogene related separation were compared to the original 
manual data to identify the m/z values and lipid species most relevant to distinguishing the two 
populations. The resulting 18 PL peaks were comprised of 10 unique PL peaks and their intensities 
alone were used to generate the final score plots (Figures A.3e-3f). Using this initial dataset, the 
additional two cell lines [HCC 202 (Her2/neu+) and HCC 70 (Her2/neu-)] were projected into PC 
space and group similarly to HCC 1599 (Her2/neu-) as seen in the original score plot (Figure 
A.3c). Revealing this lipid mediated oncogene correlated separation and testing the critical 
identified lipids with additional cell-lines demonstrates that this DESI-MSI workflow can 
discriminate breast cancer cells, based on expression level changes, and highlight the lipid species 
contributing to those separations.  
Analysis of changes in metastatic potential. The human breast cancer cells in the panel that 
differed by metastatic potential were analyzed in a similar manner to oncogene expression to 
identify critical lipid expression changes. The panel included three cell lines that shared a major 
oncogene, WNT7B, but are described in literature as either low (T-47D, MCF7) or high (MDA-
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MB-231) metastatic potential.26  Additionally, a non-metastatic (normal) breast tissue cell line, 
MCF10A, was included to evaluate the potential to distinguish a non-cancerous cell line.  The 
initial PCA score plot of MCF10A (normal), T-47D (low), and MDA-MB-231 (high) (Figure 
A.4a) clearly separates the three cell lines with the first two PC. The loading plot describes the 
critical data for separation along PC1 which separates the cancerous cell lines from the normal 
breast tissue line (Figure A.4b). Interestingly, PC2 separates the two cell lines that differ by 
metastatic potential. Further analysis followed the same analysis protocol as described for 
oncogene expression. By performing pair-wise PCA of those cell lines connected by the lines of 
the plane (Figure A.4c), the critical lipids for each separation were identified (Supplementary 
Figures A.3d-f, Supplementary Tables A.5-7). This resulted in 12 unique intact PL peaks, 
including lipids only correlated to separation by metastatic potential (Figure A.4c). Using only 
data from those 12 intact PL peaks, MCF7 (low) was then incorporated into the score plot (Figure 
A.4d) to determine the possible predictive value of the separation. MCF7 (low) was most closely 
related to T-47D (low) which is consistent with both manual acquisition data. Like the oncogene 
expression level analysis, this metastatic potential analysis by DESI-MS and MSI provides those 
lipid species most relevant to the separation of cell lines that differ by the presence of cancer and 
increasing metastatic potential. 
Analysis of changes in cancer grade. Finally, those cell lines that differed by the breast cancer 
grade were analyzed from a subset of the panel. HCC 1419 (grade 3), HCC 2218 (grade 3), HCC 
2157 (grade 2) share similar oncogene expression levels but vary by grade.22  The PCA analysis 
of all three cell lines revealed separation of HCC 1419 and HCC 2218 from HCC 2157 along PC1 
(Figure A.5a-b).  To identify only those lipids most relevant to preserving the separation by grade, 
pair-wise PCA was performed along the plane of PC1 (Supplementary Figures A.3g-h, 
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Supplementary Tables A.8-9).  The resulting score plot shown (Figure A.5c) was created by 
using only the data from four unique PL intact peaks with the highest loading, including m/z 776.5 
(32:1 PC), m/z 788.5 (36:1 PS), m/z 885.5 (38:4 PI), and m/z 835.5 (34:1 PI). The contribution 
from PIs were from the lipid profile of HCC 2157 (grade 2) which was separated by a group of 
these lipids seen in the loading plot (Figure A.5b) around m/z 885 as well as in the manual profile 
of HCC 2157 (grade 2). The presence of primarily PI species critical to separating cell lines by 
cancer grade may indicate of changes in the PI3K pathway with cancer severity for this cell line 
panel.27  Further analysis of this data set was limited by cell line accessibility and therefore was 
not tested for predictive capabilities.  However, the manual acquisition data supported the 
separation seen in the score plots due to HCC 2157 (grade 2) having both a unique high resolution 
single stage mass spectrum and PL class composition.  
A.4 Discussion 
Metabolic changes related to lipid expression are a key characteristic of breast cancer progression. 
However, the relationship between the genetic changes related to cancer and lipid expression is 
not well understood. This DESI-MS assay provides a label free platform for in vitro cellular 
analysis of lipid signals.  Manual acquisition of the lipid profiles of each cell line were visually 
distinct without statistical analysis and yielded identification of hundreds of exact lipid species. 
This information unearthed trends including the distinct absence of ether-linked PLs in MCF7 and 
T-47D, both low metastatic potential breast cancer cell lines, while MCF10A and MDA-MB-231, 
classified as normal breast tissue cells and high metastatic potential cancer respectively, expressed 
high ether-linked PL levels. This characteristic change in ether linked PLs from normal, low, and 
high metastatic potential breast cancer has been correlated to hormone sensitivity and breast cancer 
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onset.28  This DESI-MS workflow is well suited for exploratory profiling such as this due to its 
detailed lipid detection capabilities.  
The streamlined imaging based DESI-MS assay more efficiently profiles breast cancer cells by 
collecting high-resolution lipid profiles of multiple cell types in a single experiment.  These spectra 
provide sufficient information for statistical discrimination of each cell line based solely on the 
negative ion mode lipid profile. Using this profile, the relationship between oncogene expression 
level, metastatic potential, and cancer grade to lipid expression was also explored.  The select panel 
of cell lines describing varying expression levels of Her2/neu and p53 proved DESI-MS capable 
of discerning lipid profiles of cells with different genetic expression levels.  This distinction is 
powerful because changes in expression particularly with Her2/neu affect the cancer subtype 
diagnosis and treatment plan.6,29  When identifying those lipids critical to the discrimination of 
those cell lines via PCA, each major PL class was represented, even in the subset of PLs 
representing the minimum number of lipids required for regenerating the original score plot.  Using 
only those species to classify the remaining two cell lines, there is reasonable agreement to the 
original score plot with all five cell lines included in the analysis. This process illustrates the ability 
of the workflow to both identify signals relevant to unsupervised analysis, and identify the species 
related to those signals. Furthermore, by successfully limiting the variables needed for statistical 
analysis of additional cell lines, we have shown the predictive nature of lipid profiles correlated to 
gene expression changes.  
The panel representing metastatic potential yielded similar encouraging results with the same 
analysis particularly in the classification of the additional cell line, MCF7. Ether-linked PLs in 
particular were well represented in the loadings which underlines the correlation between ether 
linked PL expression and metastatic potential.   
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The final analysis from a small subset of breast cancer cell lines demonstrated in vitro 
discrimination of the lipid profiles of those cells that differed by cancer grade. This was particularly 
important because grade is often evaluated in tumor tissues by mass spectrometry and is a measure 
of the breast cancer’s progression.21  The PCA of the three cell lines showed a minimum of four 
unique lipids necessary for discrimination.  Based on the loading plot and manual lipid profiles, 
the stark differences seem to originate from specific PI species represented in the four unique lipids 
as well as the additional species identified from the loadings.  
The lipid species relevant to each characteristic of breast cancer in this panel do overlap.  This is 
unsurprising due to the extensive roles of PLs in cellular processes. However, this workflow does 
not necessitate that the data set be limited to few lipid species as there is biochemical merit to 
utilizing the entire lipid profile. It does however demonstrate this assay’s ability to explore entire 
lipid compositions or rapidly target specific characteristics in a single experiment. Furthermore, in 
vitro systems, including those presented herein, are quite complex with multiple processes and 
mutations that may affect lipid expression.  However, this select panel still establishes these DESI-
MSI assays as powerful tools for rapidly classifying cancer cells based on their physical, genetic, 
and functional features, while simultaneously providing comprehensive lipid compositions that 
may be relevant to the mechanisms of cancer progression. 
A.5 Materials and Methods 
Cell lines and culture conditions. All cell lines were acquired through American Type Culture 
Collection (ATCC, Manassas, VA) and maintained according to ATCC recommended procedures 
at 37 °C and 5% CO2 in a Forma Series II water jacket CO2 incubator (Thermo Fisher Scientific, 
San Jose, CA).  
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MCF10A cells were grown in DMEM/F-12, 15 mM HEPES, EGF, insulin, CT, hydrocortisone, 
5% horse serum, penicillin, and streptomycin. MDA-MB-231 cells cultured in DMEM containing 
4.5 g/L glucose, NEAA, sodium pyruvate, 10% fetal bovine serum (FBS), penicillin, and 
streptomycin.  T-47D, HCC 2218, HCC 1599, HCC 202, HCC 1419, and HCC 70 cells were 
cultured in RMPI 1640, 10% FBS, penicillin, and streptomycin. MCF7 cells were grown in MEM 
supplemented with 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 10% FBS, penicillin, and 
streptomycin. HCC 2157 cells were cultured in DMEM supplemented with 0.02 mg/ml insulin, 
0.01 mg/ml transferrin, 25 nM sodium selenite, 50 nM hydrocortisone, 1 ng/ml epidermal growth 
factor, 0.01 nM ethanolamine, 0.01 nM phosphorylethanolamine, 100 pM triiodothyronine, 0.5% 
(w/v) bovine serum albumin, 10 mM HEPES, 0.5 mM sodium pyruvate, 2 mM L-glutamine, and 
10% FBS.  
Sample Preparation. Adherent cell lines (MCF10A, T-47D, MCF7, HCC 202, HCC 1419, HCC 
70, MDA-MB-231) were rinsed with 5 mL of phosphate buffered saline (PBS), detached with 
trypsin, and isolated via centrifugation. Cells were washed twice in excess 50 mM ammonium 
formate buffer (pH 6.6) and suspended in minimal 50 mM ammonium formate buffer (pH 6.6) to 
facilitate deposition onto diagnostic Teflon coated glass slides. Suspension cell lines (HCC 2218, 
HCC 2157, and HCC 1599) were directly isolated via centrifugation and washed twice in excess 
ammonium formate buffer. Cells were spotted via single channel pipet (Eppendorf, Hamburg, 
Germany) onto a clean glass Teflon coated diagnostic slide (2 mm spot, 30 total spots) and rapidly 
dried under nitrogen.  
DESI-MS Analysis. An LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, San 
Jose, CA, USA) was used for all cell characterization experiments. The instrument parameters 
were as follow: Ion injection time = 500 ms (for full MS data); m/z range = 600-1000; spray 
183 
 
voltage= 5 kV; capillary voltage = ±35 V; tube lens voltage = ±100 V. AGC was turned off for all 
experiments. 
The DESI solvent spray composition was chloroform and methanol 1:1 (v/v). A 10 mL syringe 
(Hamilton Company, Reno, NA) delivered solvent at a flow rate of 5.0 µL/min (Harvard 
Apparatus, Road Holliston, MA) with a nebulizing gas pressure of 240 PSI ultra-high purity 
nitrogen.  Prior to data acquisition, the DESI parameters were optimized to obtain the highest 
possible signal from rat brain tissue and intact cells. 
Profiling was completed using the point-to-point motion profile in Prosolia omni-spray 2D.  This 
mode interrogated the sample spot by collecting scans every 200 µm for a total of 20 scans per 
row. The stage proceeded to each of the following samples, skipping the blank Teflon between.  A 
total of five rows were sampled through the center of each spot for a total of 100 scans per sample. 
Mass spectral data were reduced and aligned using the algorithm presented by Xiong, et al. 
implemented in house with C#.30  Spectra over the entire spot were averaged for a single high 
resolution mass spectrum for further analysis. 
Lipid Characterization. The identity of each lipid observed in the sample was confirmed by high-
resolution mass measurements acquired using an Orbitrap mass spectrometer (FT-MS). High 
resolution single stage mass spectra and tandem MS measurements were acquired in negative ion 
mode with the previously described DESI and instrument parameters.  
Using the high-resolution measurements from the Orbitrap mass spectrometer, calculated 
molecular formulae were obtained from LIPIDMAPS database. Exact species determination was 
made based on literature precedence of the consistent fragmentation of PL species. These lipid 
attributions are listed in the supplementary materials.  
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Manual Data Acquisition Technical Evaluation. All cell lines were acquired at least three times 
by DESI-MS. MCF10A data from three different experiments of different passage numbers and 
collected on different days were analyzed manually and the absolute intensities of each PL class 
was calculated as well as the mean and standard deviation (Supplementary Table A.11).  
Principal Component Analysis. After data reduction and alignment, mass spectra were output as 
a list of m/z values above the cutoff for noise and several files containing intensities of each m/z 
value for each scan. The matrices of intensities for each scan were imported into MATLAB for 
further analysis. PCA was performed using the built-in ‘pca’ function to determine the loadings, 
score plots, and described variance. To determine the minimum set of m/z to replicate score plots 
of the entire profile, a subset of m/z intensities with the highest loadings were included in PCA 
analysis and manually compared. Projection of additional cell lines into score space is performed 













Table A.1 Human breast cancer cell line panel 
Cell Line Disease Origin Oncogene* 
MCF10A Normal Epithelial NA 
T-47D Ductal carcinoma Pleural effusion WNT7B 
MDA-MB-231 Adenocarcinoma Pleural effusion WNT7B 
MCF7 Adenocarcinoma Epithelial WNT7B 
HCC 1599 Ductal carcinoma Epithelial Her2/neu-;p53- 
HCC 70 Ductal carcinoma Epithelial Her2/neu-;p53+++ 
HCC 2218 Ductal carcinoma Epithelial Her2/neu+++;p53+ 
HCC 202 Ductal carcinoma Epithelial Her2/neu+;p53- 
HCC 1419 Ductal carcinoma Epithelial Her2/neu+++;p53- 
HCC 2157 Ductal carcinoma Epithelial Her2/neu++;p53+ 















Table A.2 Percent compositions from absolute intact PL peak intensities from DESI-MS 
manual acquisition  
Cell Line PI* PC PS PG PE SM EL# 
MCF10A‡ 24 20 8 22 22 2 17 
T-47D 37 10 12 28 13 0 0 
MDA-MB-231 18 21 14 20 26 1 20 
MCF7+ 22 14 7 4 48 0 0 
HCC 1599 28 31 14 9 17 1 20 
HCC 70 33 24 21 1 20 1 10 
HCC 202 36 21 13 2 27 1 13 
HCC 1419‡ 33 13 20 8 24 1 6 
HCC 2218 22 35 7 2 32 2 3 
HCC 2157 46 14 14 2 24 0 8 
*Abbreviations: PC: phosphatidylcholine; PS: phosphatidylserine; PI: phosphatidylinositol; PE: 
phosphatidylethanolamine; PG: phosphatidylglycerol; SM: sphingomyelin; EL: ether lipid 
#calculated as a percentage of the total lipid composition (represented in other classes of lipids as 
well) 
+contains 5% phosphatidylthreonine (not listed in table) 















Figure A.1 DESI-MS assay for in vitro analysis of intact human breast cancer cells. The pathway 
to the left of the single stage MS depicts manual DESI-MS acquisition for lipid species 
identification. The pathway to the right of the single stage MS depicts the DESI-MSI acquisition 


























































































Figure A.2 DESI-MS manual acquisition data including high resolution single stage MS of the 
normal breast cell line MCF10A (a), breast cancer cell line T-47D (b), and the MS/MS spectra of 
34:1 plasmenyl phosphatidylethanolamine showing fatty acids (18:1) (c) and the MS3 showing 

















































































































































































Figure A.3 PCA of DESI-MSI data of breast cancer cell lines with varying Her2/neu and p53 
expression. The score plots of PC1 and PC2 of cell lines with negative p53 expression (a) and the 
resulting loading plot from PC1 (b); the score plot of PC1 and PC2 for all five Her2/neu, p53 breast 
cancer cell lines (c) and the score plot of PC2 and PC3 (d); the score plot of PC1 and PC2 generated 
using only 10 lipid species with highest loading valuesdetermined by pair-wise PCA for the three 































































































































































Figure A.4 PCA of DESI-MSI data of breast cancer cell lines with increasing metastatic 
potential. The score plots of PC1 and PC2 of MCF10A (normal), T-47D (low metastatic 
potential), and MDA-MB-231 (high metastatic potential) (a) and the resulting loading plot from 
PC1 (b); the score plot of PC1 and PC2 generated using only 12 lipid species with highest 
loading values determined by pair-wise PCA for the three cell lines (c) and the projection of 























































































a b c Decreasing Cancer Grade
 
Figure A.5 PCA of DESI-MSI data of breast cancer cell lines with different cancer grades. The 
score plots of PC1 and PC2 of HCC 2218 (grade 3), HCC 1419 (grade 3), and HCC 2157 (grade 
2) (a) and the resulting loading plot from PC1 (b); the score plot of PC1 and PC2 generated using 
only 4 lipid species with highest loading values determined by pair-wise PCA for the three cell 














A.8 Supplementary Tables 
Supplementary Table A.1 MCF10A technical replicate data for manually collected lipid 
composition 
PL Composition (%) 
PI 19 ± 4 
PC 26 ± 5 
PS 10 ± 4 
PG 18 ± 2 
PE 22 ± 9 
EL 19 ± 4 
Standard deviations represent n=3 replicates collected from different days and passage numbers. 











All tables describing the loadings from each PCA represent species identified from manual 
acquisition data. The tables include only those peaks that were greater than 5% of the base peak in 
the loading plot.  
Supplementary Table A.2 Top lipids from the PCA generated loadings for HCC 1599/HCC 2218 
HCC 1599 HCC 2218 
m/z ID m/z ID 
885.544 38:4 PI 776.541 32:1 PC 
788.541 36:1 PS 766.526 32:1 PC 
773.523 36:2 PG 714.504 34:2 PE 
700.524 34:1 P-PE 809.513 32:0 PI 
747.529 34:1 PG 716.519 34:1 PE 
863.56 36:1 PI 835.529 34:1 PI 
746.507 38:6 P-PE* 807.503 32:1 PI 
861.545 36:2 PI 760.509 34:1 PS 
750.537 38:4 P-PE 738.539 36:4 PE 
722.509 36:4 P-PE 764.522 38:5 PE 
830.586 36:2 PC 802.555 34:2 PC 
790.555 34:1 P-PC 794.542 34:1 PC 
744.55 36:1 PE 881.513 38:6 PI 
804.571 34:1 PC 762.52 34:0 PS 
775.526 36:1 PG   
832.601 36:1 PC   
887.559 36:3 PI   











Supplementary Table A.3 Top lipids from the PCA generated loadings for HCC 1599/HCC 
1419 
HCC 1599 HCC 1419 
m/z ID m/z ID 
804.571 34:1 PC 835.529 34:1 PI 
885.544 38:4 PI 760.509 34:1 PS 
747.529 34:1 PG 714.504 34:2 PE 
722.509 36:4 P-PE 807.503 32:1 PI 
746.507 38:6 P-PE* 833.545 34:2 PI 
830.586 36:2 PC 786.524 36:2 PS 
744.55 36:1 PE 742.535 36:2 PE 
832.601 36:1 PC 734.53 33:0 O-PS* 
788.541 36:1 PS 776.541 32:1 PC 
700.524 34:1 P-PE 766.526 32:1 PC 
887.559 38:3 PI 716.519 34:1 PE 
863.56 36:1 PI 849.571 35:1 PI 
750.537 38:4 P-PE 758.493 34:2 PS 
790.555 34:1 P-PC 732.478 32:1 PS 
773.523 36:2 PG 774.531 32:2 PC 
794.542 34:1 PC 809.513 32:0 PI 
775.526 36:1 PG 861.545 36:2 PI 
  802.555 34:2 PC 
  823.55 33:0 PI 
  745.532 34:2 PG 
  702.505 33:1 PE 















Supplementary Table A.4 Top lipids from the PCA generated loadings for HCC 2218/HCC 
1419 
HCC 2218 HCC 1419 
m/z ID m/z ID 
776.541 32:1 PC 788.541 36:1 PS 
804.571 34:1 PC 835.529 34:1 PI 
766.526 32:1 PC 760.509 34:1 PS 
809.513 32:0 PI 773.523 36:2 PG 
716.519 34:1 PE 861.545 36:2 PI 
794.542 34:1 PC 786.524 36:2 PS 
764.522 38:5 PE 863.56 36:1 PI 
881.513 38:6 PI 742.535 36:2 PE 
802.555 34:2 PC 774.531 32:2 PC 
832.601 36:1 PC 734.53 33:0 O-PS* 
  700.524 34:1 P-PE 
  758.493 34:2 PS 
  807.503 32:1 PI 
  750.537 30:0 PC 
  732.478 32:1 PS 
  885.544 38:4 PI 
  747.529 34:1 PG 
  702.505 33:1 PE 
  730.535 35:1 PE 
















Supplementary Table A.5 Top lipids from the PCA generated loadings for MCF10A and T47D 
MCF10A T-47D 
m/z ID m/z ID 
802.555 36:1 PT 804.571 34:1 PC 
861.545 36:2 PI 885.544 38:4 PI 
863.56 36:1 PI 742.535 36:2 PE 
887.559 38:3 PI 776.541 32:1 PC 
773.523 36:2 PG 794.542 34:1 PC 
700.524 34:1 P-PE 766.526 32:1 PC 
726.54 36:2 P-PE 716.519 34:1 PE 
800.54 36:2 PT 883.528 38:5 PI 
788.541 36:1 PS 835.529 34:1 PI 
786.524 36:2 PS 714.504 34:2 PE 
771.507 36:3 PG 764.522 38:5 PE 
728.548 36:1 P-PE 857.535 36:4 PI 
828.57 36:3 PC 744.55 36:1 PE 
832.601 36:1 PC 913.574 40:4 PI 
724.524 36:3 P-PE 911.559 40:5 PI 













Supplementary Table A.6 Top lipids from the PCA generated loadings for MCF10A and 
MDA-MB-231 
MCF10A MDA-MB-231 
m/z ID m/z ID 
802.555 36:1 PT 885.544 38:4 PI 
861.545 36:2 PI 750.537 38:4 P-PE 
773.523 36:2 PG 766.526 32:1 PC 
887.559 38:3 PI 832.601 36:1 PC 
863.56 36:1 PI 804.571 34:1 PC 
700.524 34:1 P-PE 788.541 36:1 PS 
726.54 36:2 P-PE 911.559 40:5 PI 
800.54 36:2 PT 748.525 38:5 P-PE 
747.529 34:1PG 764.522 38:5 PE 
786.524 36:2 PS 909.544 40:6 PI 
835.529 34:1 PI 854.586 38:4 PC 
820.566 36:2 PC 744.55 36:1 PE 
771.507 36:3 PG 722.509 36:4 P-PE 
859.549 36:3 PI 812.54 38:3 PS 
760.509 34:1 PG 822.563 38:1 PC 
742.535 36:2 PE 913.574 40:4 PI 
830.586 36:2 PC 883.528 38:5 PI 
716.519 34:1 PE 775.526 36:1 PG 
724.524 36:3 P-PE 746.507 38:6 P-PE 















Supplementary Table A.7 Top lipids from the PCA generated loadings for T47D and MDA-
MB-231 
T-47D MDA-MB-231 
m/z ID m/z ID 
742.535 36:2 PE 750.537 38:4 P-PE 
804.571 34:1 PC 788.541 36:1 PS 
716.519 34:1 PE 832.601 36:1 PC 
861.545 36:2 PI 748.525 38:5 P-PE 
835.529 34:1 PI 722.509 36:4 P-PE 
773.523 36:2 PG 775.526 36:1 PG 
794.542 34:1 PC 812.54 38:3 PS 
776.541 32:1 PC 911.559 40:5 PI 
714.504 34:2 PE 909.544 40:6 PI 
883.528 38:5 PI 822.563 38:1 PC 
747.529 34:1 PG 728.548 36:1 P-PE 
857.535 36:4 PI 746.507 38:6 P-PE 
760.509 34:1 PS 752.55 38:3 P-PE 
859.549 36:3 PI 766.526 38:4 PE 
887.559 38:3 PI 828.57 36:3 PC 
764.522 38:5 PE 885.544 38:4 PI 
889.578 38:2 PI   
















Supplementary Table A.8 Top lipids from the PCA generated loadings for HCC 2218 /HCC 
2157 
HCC 2157 HCC 2218 
m/z ID m/z ID 
885.544 38:4 PI 776.541 32:1 PC 
887.559 38:3 PI 714.504 34:2 PE 
788.541 36:1 PS 835.529 34:1 PI 
883.528 38:5 PI 804.571 34:1 PC 
911.559 40:5 PI 716.519 34:1 PE 
863.56 36:1 PI 809.513 32:0 PI 
861.545 36:2 PI 766.526 32:1 PC 
750.537 38:4 P-PE 807.503 32:1 PI 
748.525 38:5 P-PE* 760.509 34:1 PS 
775.526 36:1 PG 794.542 34:1 PC 
812.54 38:3 PS 802.555 34:2 PC 
744.55 36:1 PE   
834.523 40:6 PS   
830.586 36:2 PC   
764.522 38:5 PE   
742.535 36:2 PE   
786.524 36:2 PS   















Supplementary Table A.9 Top lipids from the PCA generated loadings for HCC 1419 /HCC 
2157 
HCC 2157 HCC 1419 
m/z ID m/z ID 
885.544 38:4 PI 835.529 34:1 PI 
887.559 38:3 PI 760.509 34:1 PS 
788.541 36:1 PS 714.504 34:2 PE 
883.528 38:5 PI 807.503 32:1 PI 
911.559 40:5 PI 773.523 36:2 PG 
863.56 36:1 PI 774.531 32:2 PC 
861.545 36:2 PI 776.541 32:1 PC 
750.537 38:4 P-PE 700.524 34:1 P-PE 
748.525 38:5 P-PE* 734.53 33:0 O-PS* 
775.526 36:1 PG 716.519 34:1 PE 
812.54 38:3 PS 786.524 36:2 PS 
744.55 36:1 PE 849.571 35:1 PI 
834.523 40:6 PS 758.493 34:2 PS 
830.586 36:2 PC 742.535 36:2 PE 
764.522 38:5 PE 745.532 34:2 PG 
742.535 36:2 PE 732.478 32:1 PS 
786.524 36:2 PS 861.545 36:2 PI 












A.9 Supplementary Figures 
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Supplementary Figure A.1 High resolution single stage mass spectra of each cell line: MDA-
MB-231 (a), HCC 1599 (b), HCC 70 (c), HCC 202 (d), HCC 1419 (e), HCC 2218 (f), HCC 2157 








Supplementary Figure A.2 Loading plot of each paired PCA analysis: HCC 1599/HCC 2218 (a), 
HCC 1599/HCC 1419 (b), HCC 2218/HCC 1419 (c), MCF10A/T47D (d), MCF10A/MDA-MB-
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The upregulation of fatty acid (FA) synthesis is characterized as a hallmark in cancer.1 As such, 
this pathway has been a target for therapeutics including small molecule inhibitors of the enzyme 
fatty acid synthase (FASN).1,2,3,4 This complex enzyme is an important regulator of de novo fatty 
acid synthesis and key to the production of palmitic acid (16:0 FA).1  The increased activity of this 
enzyme has been studied in a number of cancer types, including breast cancer.5  Targeting this 
enzyme for therapeutic response has led to the development of the FASN inhibitors cerulenin and 
orlistat.6,7  These drugs have been known to disable FASN by selectively targeting the ketoacyl 
synthase domain or the thioesterase domain respectively.6  The biochemical action of these drugs 
has led to promising studies on their anti-tumorigenic effects as well as the metabolic effects on 
cancer cells.  Orlistat has been described to arrest FASN in as little as 30 min and show markedly 
decreased lipid production demonstrated by [14C] acetate NMR studies specifically in cancer 
cells.4,8,9 However, the detailed effect of these drugs on the specific lipids synthesized by the cell 
is unknown.  Describing such information is significant due to the importance of complex lipids 
to cell communication, proliferation, and apoptosis. Specific lipid classes are often implicated in 
distinct biochemical pathways and the lipid profile can be unique to the genotype of the cell.  
By using ambient mass spectrometry,10 specifically desorption electrospray ionization (DESI-
MS)11 coupled to high resolution mass spectrometry, the phospholipid (PL) profile as well as the 
identities of individual lipids can be acquired.  This information can then be used to assess the 
effect of FASN inhibitors on intact human cancer cells in a label free cell based assay that 
necessitates little sample preparation while providing detailed molecular information. This assay 
looks to describe the effects of orlistat and other potential FASN inhibitors on four breast cancer 
cell lines representing the major breast cancer subtypes as well as a normal breast tissue cell line.  
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The initial experiments were developed as an adaptation of literature experiments combined with 
an assay developed for characterizing the lipid profile of these cell lines. Immediately, the 
experiment was scaled down to 24-well plates from T-75 flasks to keep the cell count low enough 
for the drug to affect the cells. This was then streamlined to a 12-well plate for increased sample 
access and finally to a chamber well slide for minimal sample preparation. The subsequent 
experiments were repeated with variable success for MCF7 and MCF10A yielding promising 
results and necessary assay improvements.  
B.2 Experimental Methods 
Human Breast Cancer Cell Culture. All cell lines were acquired through American Type Culture 
Collection (ATCC, Manassas, VA) and maintained according to ATCC recommended procedures 
at 37 °C and 5% CO2 in a Forma Series II water jacket CO2 incubator (Thermo Fisher Scientific, 
San Jose, CA).  
MCF10A cells were grown in DMEM/F-12, 15 mM HEPES, EGF, insulin, CT, hydrocortisone, 
5% horse serum, penicillin, and streptomycin. MCF7 cells were grown in MEM supplemented 
with 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 10% fetal bovine serum (FBS), 
penicillin, and streptomycin. MDA-MB-231 cells cultured in DMEM containing 4.5 g/L glucose, 
NEAA, sodium pyruvate, 10% fetal bovine serum FBS, penicillin, and streptomycin. 
Inhibition of fatty acid synthesis by Orlistat. Cells (1.3 X 105 cells/well in 24-well plates; 3.0 X 
105 cells/well in 12-well plates) were seeded and incubated at 37 °C and 5% CO2 for 3 h (or 
overnight for 12-well plate). Orlistat dissolved in DMSO (0.025 M stock) was added to the media 
at various concentrations and the cells incubated for 30 min-4 h.  The media was then removed, 
and the cells washed with PBS and trypsin added. The cells were removed and isolated by 
210 
 
centrifugation using a Sorvall ST 16R centrifuge (Thermo Fisher Scientific, San Jose, CA) at 1600 
rpm for 3 min.  The cells were washed twice in excess ammonium formate buffer (pH 6.6) and 
suspended in minimal ammonium formate to facilitate deposition onto Teflon coated glass slides. 
For profiling of MCF7 and MCF10A the cells were spotted onto a clean glass Teflon coated 
diagnostic slide with 30 2 mm spots dried under nitrogen.  
Chamber well slide preparation. Cells (1.0 X 105 cells in 0.3 mL media/well) were seeded into 
8-well chamber slides and incubated at 37 °C and 5% CO2 overnight. Prior to drug addition, fresh 
media was added to each chamber. Orlistat, dissolved in DMSO (0.025 M stock) was then added 
to the media at various concentrations (25 µM-250 µM) for 30-60 min. The cells were then washed 
with 0.5 mL of 50 mM ammonium formate buffer for several seconds. Following the wash, the 
chamber was removed, and the slide was dried under N2.  
Desorption Electrospray Ionization Mass Spectrometry Analysis. An LTQ-Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) was used for all cell characterization 
experiments. The instrument parameters were as follow: Ion injection time = 500 ms (for full MS 
data); m/z range = 600-1000; spray voltage= 5 kV; capillary voltage = ±35 V; tube lens voltage = 
±100 V. AGC was turned off for all experiments. 
The DESI solvent spray composition was chloroform and methanol 1:1 (v/v). A 10-mL syringe 
(Hamilton Company, Reno, NA) delivered solvent at a flow rate of 5.0 µL/min (Harvard 
Apparatus, Road Holliston, MA) with a nebulizing gas pressure of 240 PSI ultra-high purity 
nitrogen. Prior to data acquisition, the DESI parameters were optimized to obtain the highest 
possible signal from rat brain tissue and intact cells. 
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Profiling was completed using the continuous motion profile, or manual acquisition in Prosolia 
omni-spray 2D. Continuous scanning motion profiling interrogated the sample spot by collected 
scans every 200 µm for a total of 15 rows per set of 10 spots on the diagnostic slide.  
Mass spectral data were reduced and aligned using the algorithm presented by Xiong, et al. 
implemented in house with C#.12  Spectra over the entire spot were averaged for a single high 
resolution mass spectrum for further 
Lipid Characterization. The identity of each lipid observed in the sample was confirmed by high-
resolution mass measurements acquired using an Orbitrap mass spectrometer. High resolution 
single stage mass spectra and tandem MS measurements were acquired in negative ion mode with 
the previously described DESI and instrument parameters.  
Using the high-resolution measurements from the Orbitrap mass spectrometer, calculated 
molecular formulae were obtained from LIPID MAPS database. Exact species determination was 
made based on literature precedence of the consistent fragmentation of PL species. 
Principal Component Analysis. After data reduction and alignment, mass spectra were output as 
a list of m/z values above the cutoff for noise and several files containing intensities of each m/z 
value for each scan. The matrices of intensities for each scan were imported into MATLAB for 
further analysis. PCA was performed using the built-in ‘pca’ function to determine the loadings, 
score plots, and described variance. To determine the minimum set of m/z to replicate score plots 
of the entire profile, a subset of m/z intensities with the highest loadings were included in PCA 





B.3 Results and Discussion 
The lipid profile of the intact human breast cancer cell line MCF7 has been fully characterized in 
negative ion mode with DESI-MS. As such, it was a suitable candidate for the development of the 
FASN inhibitor label free cell based assay of lipid changes in cancer cells. The dose, time points, 
and cell concentration were adapted and modified from literature to create a preparation procedure 
that would allow for unique lipid characterization of cancer cells when exposed to FASN 
inhibitors, specifically orlistat.4, 13,14  The first experiment (not shown in figures) did not illustrate 
any changes due to a significantly high cell count relative to the previous literature experiments.  
The experiments were then adapted to 24-well plates with a cell count of about 1.0 X 105 cells/well. 
The initial 24 well plate experiment required the contents of multiple wells be combined for 
sufficient sample. Figure 1 shows the resulting MCF7 lipid profiles after 1 h of dosing with DMSO 
at (a) 30 µM and (b) 50 µM and with orlistat at (c) 30 µM and (d) 50 µM. The control samples 
were quite similar, as expected, with only slight intensity deviations. However, with the addition 
of orlistat at either dose, the profile changes both in intensity of peaks shared with the control as 
well as the distinct presence of new or otherwise low intensity peaks as seen with m/z 750.62, 
960.69, and 608.38 (tandem MS yielded no identification). Furthermore, intensity changes and 
profile intensity changes were desirable markers for the success of orlistat dosing, however 
combining samples for increased signal intensity was undesirable so the cell preparation was 
altered to 12-well plates.  
The preparation of the 12-well plate proceeded similarly, but resulted in a slightly altered lipid 
profile for MCF7. This may be due to a number of factors including growth conditions, which can 
certainly alter the biochemistry of the cells. The study shown in Figure 2 is over three different 
orlistat doses from 50 µM to 150 µM for 1 h. This experiment aided in establishing the 12-well 
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plate method and for observing any dose related responses. The three DMSO control spectra for 
50 µM (a), 100 µM (b), and 150 µM (c) suffered from inconsistencies, but this is unsurprising as 
increasing DMSO content can slow cell growth (as a major component of freezing media). When 
comparing the control spectra to the orlistat dosed spectra for 50 µM (d), 100 µM (e), 150 µM (f), 
there are clear spectral differences. Most notably are the peaks at m/z 608.37 and 906.69, which 
were both considered indicators of drug response in the previous study. The final new peak from 
the previous study, m/z 750.62, was not at as high of a relative intensity, but is visible particularly 
in the highest dosed sample.  
To continue considering dose related responses, a similar 12-well plate study was completed to 
probe changes in the lipid profile at significantly increased orlistat doses. The resulting lipid 
profiles are shown in Figure 3 with additions of 0.5 mM DMSO (a), 1.0 mM DMSO (b), 0.5 mM 
orlistat (c), and 1.0 mM orlistat. Because the dose was increased an order of magnitude, the time 
of dosing was decreased to 30 min to minimize cell death. The control spectra share many of the 
same major peaks despite such a high DMSO dose, while the spectra representing orlistat addition 
show clear differences between the controls and each other. Most notably was the presence of the 
three peaks previously discussed and the increase in m/z 760.5394 in the 1.0 mM orlistat sample. 
There are a number of peaks that have changed intensity, contributing to overall profile change for 
both doses. However, this dose likely surpassed reasonable levels for consistent viable samples as 
seen with the 12-well plate study with MCF10A. Literature has described orlistat’s effect on 
normal tissue and cells to be negligent, therefore a lipid profile change is unlikely.6  Figure 4 shows 
the results of MCF10A dosed at 0.5 mM DMSO (a), 1.0 mM DMSO (b), 0.5 mM Orlistat (c), and 
1.0 mM orlistat (d).  There are significant profile changes upon dosing with orlistat that may 
suggest that this dose is out of a reasonable therapeutic range. Upon further testing with MCF10A 
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with 100 uM DMSO (Figure 5a) and 100 µM orlistat (Figure 5b), there was no evidence of profile 
changes. This has been a consistent result and is supported by the literature.  
With this 12-well plate protocol, the issue of sample amount was addressed. However, manual 
acquisition and visual inspection were still inefficient for data analysis. Therefore, a 12-well plate 
orlistat study with MCF7 was completed using DESI-MS imaging (MSI) and principle component 
analysis (PCA) to better understand if samples were different and which signals were relevant to 
those differences. Figure 6 shows the spectra for the addition of 250 µM DMSO (a) and 250 µM 
orlistat (b) which show clear intensity differences. However, those peaks that were once indicative 
of changes in the presence of orlistat were more difficult to see, therefore the chromatograms 
showing signal from m/z 750.6-750.7 (Figure 6c) and m/z 960.6-790.75 (Figure 6d) helped to 
visualize the orlistat dosed samples from the controls. The images generated from this experiment 
show a single sample for conditions 250 and 500 µM DMSO and Orlistat as labeled (Figure 7). 
The image of the four samples can be viewed as the total ion current (TIC) normalized image 
(Figure 7a) or correlated to specific m/z values such as 744.5 (b). Principle component analysis 
can also be visualized in this manner or graphically via the score plot. The first principle 
component describing over 50% of the variance is shown in Figure 7c distinguishing those samples 
exposed to orlistat and DMSO. The score plot shown in Figure 7d is a similar representation 
underlining the same conclusion, but was used to further generate a loading plot of those signals 
crucial to the separation of the samples along principle component 1 (Figure 7e). These modes of 
analysis provide a statistical means to view differences between samples that otherwise show few 
changes, as well as help to identify those signals with the highest loadings for a given separation. 
This is imperative for correlating lipid profile changes to single variable changes like the addition 
of orlistat and dose. This study was repeated at lower doses with similar results.  
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The most recent change to the MCF7-orlistat study was removing the extensive 12-well plate 
preparation in favor of a chamber well slide (CWS) set up which allows the cells to be directly 
grown on a slide that can be used for DESI-MS interrogation. The first CWS experiment showed 
lipid profile differences in the control prompting the comparison experiment outlined in the 
additional experiments section. A representative of more successful CWS drug studies is shown 
in Figure 8, with doses at 250 µM DMSO (a), 50 µM orlistat (b), 150 µM orlistat (c), and 250 µM 
orlistat (d). The lipid profile of MCF7 is more consistent to previous experiments in the control 
and some peak changes are evident in those dosed with orlistat (m/z 960.69). However, the PCA 
data did not support that these samples were different as seen in the score plot in Figure 8e. The 
number of data points per sample, as this is displaying ever pixel individually, may be variable 
enough to mask relevant spectral differences. This analysis issue can possibly be rectified by 
collecting fewer points or averaging (with replicate samples). This study has been repeated 
numerous times with various doses with some success. Most notably were issues with drug 
response and non-drug related lipid profile changes. Figure 9 shows a similar MCF7 and orlistat 
CWS experiment with doses of 200 µM DMSO (a) and 200 µM orlistat (b) with little drug-induced 
change. The same study was repeated with MDA-MB-231 with a 1 h dose time showing little 
drug-induced change and significant profile differences with the control compared to previous 
work with this cell line. The lack of profile changes in the presence of orlistat may be due to drug 
inactivation in the DMSO storage. However, a CWS performed within a week of the previous 
study shown in Figure 10 seemed to show some spectral differences (m/z 960.69) with the addition 
of orlistat, but the lipid profile was significantly different from what was expected for MCF7. This 
is more consistent to those issues with MDA-MB-231 and suggests that there may changes 
216 
 
occurring with the cells during growth and necessitates biological controls that are more rigorous 
prior to the actual drug study.  
B.4 Additional Experiments 
Other parameters that were of interest based on the variation of the protocol in literature was the 
length of time the sample was dosed as well as media contents (serum versus serum free).8  Both 
of these were addressed in two experiments shown in Figures 11 and 12.  First, the time points 
were tested by increasing the dose time from 30 min-1h to 2 h and 4 h for a 50 µM dose of orlistat 
or DSMO.  Figure 11 shows exposure of DMSO for 2h (a) and 4h (b) as well as orlistat for 2h (c) 
and 4h (d). There is consistency within the controls and drugged lipid profiles, however the 
drugged lipid profiles do distinguish themselves with the characteristic peaks previously described. 
Otherwise, there was little change to be attributed to an extended dosing effect. The second 
parameter, the presence of serum in the media, was explored by serum starving cells overnight 
prior to drug exposure supporting the logic that animal serum provides additional free fatty acids 
that could mask the effect of a FASN inhibitor. All cells were exposed to fresh serum enriched 
media during the dosing period. The results shown in Figure 12 are for 100 µM DMSO without 
serum (a), 100 µM orlistat without serum (b), 100 µM DMSO with serum (c), and 100 µM orlistat 
with serum (d). Aside from indications that orlistat has had some effect on the lipid profile, there 
are no remarkable differences between the two conditions. All subsequent experiments were 
completed with serum-supplemented media. 
As a quick validation of the CWS data and subsequent analysis goals, two exploratory experiments 
were completed. First, the lipid profile of MCF7 cells grown in a flask and prepared according to 
a standard protocol (i.e. trypsinized, washed with ammonium formate) were compared to those 
grown on a chamber well slide. Figure 13 shows the lipid profile of the traditionally grown cells 
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(a) and those from the chamber well slide (b) with little variation. Despite this consistent result, 
there has been some variability in the lipid profile of MCF7 throughout this study. The second 
exploratory experiment was testing the data dependent scanning mode for acquiring MS/MS in a 
continuous fashion on chamber well slides. This was completed with MDA-MB-231 cells which 
would eventually be introduced into the study. Figure 14 shows the single stage spectrum (a) and 
the subsequent MS/MS of m/z 750.55, 788.55, and 885.55.  The signal of each scan deems this a 
successful protocol for collecting tandem mass spectra in a single experiment. The future goal of 
this is to implement a program that can identify the spectral differences between samples in real 
time and collect tandem mass spectral data for those peaks that differed the most.  
Two additional FASN inhibitors have been introduced into this study, cerulenin and 
epigallocatechin gallate (ECGC). Both have had initial experiments performed with MCF7 cells, 
with minimal success. Cerulenin dosing was based on literature protocols suggesting a longer time 
point than orlistat.3  The representative experiment shown in Figure 15 were at doses of 200 µM 
DMSO for 90 min (a), 100 µM of cerulenin for 90 min (b), 200 µM of cerulenin for 90 min (c), 
and 200 µM of cerulenin for 30 min.  The spectra show very few if any profile differences, which 
indicated that the drug likely had little effect on the cells. This is unsurprising as a major drawback 
of cerulenin as a FASN inhibitor is the reactive epoxide group pivotal to its biochemical action. If 
this epoxide reacts prior to its reaction with FASN, the drug will be inactive. This drug was deemed 
too difficult to continue studies due to its reactivity, clinical relevance, and cost. Initial studies 
with ECGC were more difficult owing to it being a natural product extract and therefore not 
tailored for potent FASN interaction.15   Figure 16 shows the results of an initial study with MCF7 
and ECGC dosed at 250 µM DMSO (a), 250 µM ECGC (b), 150 µM ECGC (c), and 50 µM ECGC 
for 6 h.  The spectra show some minor differences including the more prominent m/z 794.54.  
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However, it may be that the cells were not drugged for a long enough period to see changes that 
are more significant. Future work with this drug will require exploring high doses and time points 
up to 24 h.  
B.5 Conclusions 
The analysis of MCF7 with the addition of orlistat, a FASN inhibitor, yields significant changes 
in the lipid profile. This experiment was completed with a label free cell based assay that utilizes 
DESI-MS as an analytical technique that can provide detailed molecular information about a 
complex sample with little sample preparation. At this point, the assay requires a more rigorous 
set of biochemical controls. The lipid profile of MCF7 is more dynamic than is to be expected 
within a single preparation protocol. It is expected that the profile would change from 12-well plate 
to CWS, but consistency throughout a specific type of experiment is needed for reproducibility 
and evaluation of the drug effects. Initial studies with additional drugs and cell lines have begun 
and will continue with ECGC and those cell lines deemed most stable after completed control 
experiments. The goal of this assay is to streamline screening the effects of FASN inhibitors on 
the lipid profiles of intact human cells from preparation to analysis. Accomplishing this would 






































































































































Figure B.1 Single stage high resolution mass spectra of a 24-well plate study with MCF7 and 
orlistat dosed at 30 uM DMSO (a), 50 uM DMSO (b), 30 uM orlistat (c), and 50 uM orlistat (d) 










































































































































































































Figure B.2 Single stage high resolution mass spectra of a 12-well plate drug study with MCF7 and 
orlistat at doses of 50 uM DMSO (a), 100 uM DMSO (b), 150 uM DMSO (c), 50 uM orlistat (d), 
100 uM orlistat (e), 150 uM orlistat (f) for 1 h. The peaks in this region represent the intact PL 











































































































































Figure B.3 Single stage high resolution mass spectra of a 12-well plate drug study with MCF7 and 
orlistat at doses of 0.5 mM DMSO (a), 1.0 mM DMSO (b), 0.5 mM orlistat (c), and 1.0 mM orlistat 













































































































































Figure B.4 Single stage high resolution mass spectra of a 12-well plate drug study with MCF10A 
and orlistat at doses of 0.5 mM DMSO (a), 1.0 mM DMSO (b), 0.5 mM orlistat (c), 1.0 mM orlistat 















































































Figure B.5 Single stage high resolution mass spectra of a 12-well plate drug study with MCF10A 
and orlistat at doses of 100 uM DMSO (a) and 100 uM orlistat (b) for 1 h. The peaks in this region 












































































































































Figure B.6 Single stage high resolution mass spectra of a 12-well plate drug study with MCF7 and 
orlistat at doses of 250 uM DMSO (a) and 250 uM orlistat (b) for 30 min. The chromatograms for 
m/z 750.6-750.7 (c) and m/z 960.6-960.75 (d) show the presence of peaks in those ranges over the 
sampling time. This has distinguished four samples, two of which were dosed with orlistat and 
should have these peaks present at a greater intensity.  
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Figure B.7 False color image of a 12-well drug study with MCF7 with orlistat at doses of 500 uM 
and 250 uM DMSO and Orlistat. The TIC normalized image (a) shows a single sample spot for 
each sample type. The false color image of the intensity of m/z 744.5 (b) shows how the ion 
intensity changes from the control to drugged samples. The false color image of the first principle 
component (c) describing 53% of the variance distinguishes the control and drugged samples. The 
score plot (d) and loading plot (e) of the first principle component describe the same separation 
with specific peak differences seen in the mass spectra present in the loading plot.  
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Figure B.8 Single stage high resolution mass spectra from a chamber well slide drug study with 
MCF7 and orlistat at doses of 250 uM DMSO (a), 50 uM orlistat (b), 150 uM orlistat (c), and 250 
uM orlistat (d) for 30 min. The score plot (e) generated by performing PCA on the image of the 





























































































































Figure B.9 Single stage high resolution mass spectra from a chamber well slide drug study with 
the cell lines MCF7 and MDA-MB-231 and FASN inhibitor orlistat. Very few lipid profile changes 
are seen between MCF7 dosed at 200 uM DMSO (a) and 200 uM orlistat (b). Similarly, MDA-
MB-231 dosed at 200 uM DMSO (c), and 200 uM orlistat (d) show little change, but do show a 










































































Figure B.10 Single stage high resolution mass spectra of a chamber well slide drug study with 
MCF7 and orlistat dosed at 200 uM DMSO (a) and 200 uM Orlistat (b) for 30 min. The peaks in 
this region represent the intact PL profile for MCF7 with some deviations including the high 


















































































































































Figure B.11 Single stage high resolution mass spectra of a 12-well plate drug study with MCF7 
and orlistat dosed at 50 uM DMSO for 2 h (a) and 4 h (b) and 50 uM orlistat for 2 h (c) and 4 h 














































































































































Figure B.12 Single stage high resolution mass spectra of a 12-well plate drug study with MCF7 
and orlistat comparing serum starved to serum rich response to the drug. The serum starved cells 
were dosed at 100 uM DMSO (a) and 100 uM orlistat (c), while those that grew in serum rich 









































































Figure B.13 Single stage high resolution lipid profile of MCF7 grown traditionally and spotted on 
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Figure B.14 Single stage high resolution mass spectrum of MDA-MB-231 grown on a chamber 
well slide (a) and collected in a data dependent scan mode (single scan). Based on this spectrum, 











































































































































Figure B.15 Single stage high resolution mass spectra of a chamber well slide drug study with 
MCF7 and cerulenin dosed at 200 uM DMSO for 90 min (a), 100 uM cerulenin for 90 min (b), 











































































































































Figure B.16 Single stage mass spectra of a chamber well slide drug study with MCF7 and ECGC 
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